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Elemental Iodine: Relief for the Painful 
Breast?
John K. MacFarlane, MD, FACS, FRCSC
Chairman, Department o f Surgery, St. Paul’s Hospital, Vancouver, BC. Member, Editorial 
Board, Canadian Journal of Surgery
In this issue of the journal (pages 453 to 460) the subject of cystic 
mastopathy is featured in an article 
by Ghent* and associates. They de­
scribe three clinical studies of io­
dine therapy in what has tradition­
ally been called fibrocystic breast 
disease.
The findings of these studies, 
which involved almost 1400 wom­
en, appear to support the concept 
that elemental iodine (I2) rather 
than iodine-containing compounds 
such as Lugol’s solution produces a 
significant regression of both the 
symptoms and the signs of this 
common condition in the menstru­
ating woman.
The authors have produced their 
evidence from a series of studies 
with crossover from one compound
Dr. Ghent unfortunately died on July 29, 
1993, after a distinguished career in surgery 
at Queen’s University.
to another, based on the “demo­
graphic association” between in­
creased incidences of both benign 
and malignant breast disease and 
iodine deprivation in patients with 
goitre. Unfortunately, this has not 
been referenced in the article, so 
the basis of the study is not entirely 
clear. Nevertheless, the impressive 
number of volunteers in the studies 
indicates the significance of these 
symptoms and signs in the general 
population.
Dr. Ghent and his colleagues at 
the Virginia Mason Clinic in Seattle 
and at the Medical College of Penn­
sylvania in Philadelphia are to be 
congratulated on an excellent and 
meaningful study.
The results have been evaluated 
with both a subjective and an objec­
tive measuring process and seem to 
confirm the validity of the hypothe­
sis that molecular iodine can be of 
significant benefit to patients with 
fibrocystic breasts.
It would be of interest to deter­
mine the site of the iodine action 
within the breast. Although the 
mechanism is clear in the rat exper­
iments of Eskin and associates1 
techniques for tracking the effect of 
the iodine on the epithelial cell of 
the breast would be an important 
follow-up.
This study is an important one; 
however, the findings should be 
confirmed by another centre before 
elemental iodine is recommended as 
standard therapy for symptomatic 
benign breast disease.
Reference
1. Eskin BA, Krouse TB, Modhera PR et al: 
Etiology of mammary gland pathophysi­
ology induced by iodine deficiency. In 
Medeiros-Neto G, Gaitan E (eds): Fron­
tiers in Thyroidology, Proceedings o f the 
Ninth International Congress, 1985, Sao 
Paolo, Brazil, vol 2, Plenum, New York, 
1986: 1027-1031
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Medical Memories: an Aortoesophageal 
Fistula
D. Michael Grace, MD, FRCSC
Professor, Department o f  Surgery, University Hospital, The University o f Western Ontario, 
London, Ont. Member, Editorial Board, Canadian Journal of Surgery
A ortoesophageal fistulas are ex­tremely rare, “dramatic,” mem­
orable and usually fatal. The most 
common causes of such fistulas 
have been thoracic aneurysms and, 
more recently, malignant tumours 
or foreign bodies. In this issue 
(pages 480 to 482), Katyal, Jewell 
and Yakimets report such a case. A 
benign Barrett’s ulcer in an elderly 
man caused a fatal gastrointestinal 
hemorrhage; all appropriate mea­
sures were taken. The case is well 
described, and this particularly rare 
problem is reviewed. Autopsy in 
such a case of sudden death may be 
of medicolegal importance but is 
certainly critical in explaining 
events and educating the medical 
and nursing staff involved.
In every surgical practice there 
are a few cases that stand out in 
memory and that influence future 
clinical decisions. These cases pro­
vide excitement, even panic, in con­
trast to routine procedures like her­
nia repairs and appendectomies. As 
surgeons we are present at signifi­
cant times in people’s lives and have 
the opportunity to influence not 
just the life of the patient but also 
the lives of the entire family, their 
circle of friends and even future 
generations. The dramatic and in­
teresting case helps to maintain 
enthusiasm for surgical practice.
The description of an aortoeso­
phageal fistula by Katyal, Jewell 
and Yakimets led me to relive the 
events involved in a case that is 
etched clearly in my memory. The 
date was Aug. 2, 1970, and I was a 
resident on loan from the Royal 
Victoria Hospital in Montreal, 
spending 6 months at the General 
Hospital in St. John’s. It was a 
lovely summer weekend and I had a 
chance to explore the rugged New­
foundland coast with my girlfriend, 
and future wife, who had just ar­
rived from Montreal. I made what 
was planned to be a short hospital 
visit to check on a 17-year-old boy 
who, 6 days earlier, had had a 
foreign body that was eroding his 
esophagus removed by thoracoto­
my. The foreign body was a piece of 
nonopaque dental plate broken dur­
ing eating 7 weeks earlier that had 
not been identified by chest radiog­
raphy. His dysphagia had pro­
gressed until an upper gastrointesti­
nal series in a smaller centre had 
revealed the problem. Endoscopic 
removal was not possible so thora­
cotomy was necessary. The foreign 
body had been removed and a medi­
astinal abscess drained. His course 
had been smooth apart from a low- 
grade spiking fever.
Just as I arrived to see him he 
suddenly vomited and had a massive 
projectile upper gastrointestinal he­
morrhage with profound hypoten­
sion and collapse. Multiple intrave­
nous lines were inserted immediate­
ly in femoral vessels, and 0  nega­
tive blood was pumped in as he was 
being taken to the operating room. 
Blood pressure was still unobtain­
able. We quickly carried out a lapa­
rotomy and opened the stomach, 
which was massively distended with 
blood. When blood poured down 
the esophagus the left chest was 
reopened and an aortoesophageal 
fistula identified. The aorta was 
friable and difficult to suture, but 
the aorta and esophagus were re­
paired. A pleural flap was used to 
separate the two. After many hours 
of operation and resuscitation he 
returned to the ICU in reasonable 
condition. After prolonged discus­
sions with a concerned family I was 
able to resume my interrupted 
weekend. Fortunately my visiting 
friend was patient, understanding 
and supportive, and our relation­
ship was stronger for the experi­
ence.
Unfortunately, the young patient 
continued to have complications, 
which were eventually fatal. Eight 
days after the first “bleed,” he had 
another, which required 20 units of 
blood. The aorta was repaired 
again, and esophagostomy and gas­
trostomy were performed. His 
course was marked by progressive 
sepsis, pneumonia and recurrent
406 JCC, VOL. 36, N ° 5, OCTOBRE 1993
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bleeding, and he finally died 5 
weeks after the first hemorrhage 
and 6 weeks after the thoracotomy.
The memories of these tragic 
events — the struggle of a young 
man for life, the effect on his family 
and the need for sympathetic sup­
port, and the reality and responsibil­
ity for major complications after 
apparently successful surgery — 
have never left me.
It was my good fortune to have 
had the experience of working in 
another part of Canada, where 1
BOOK REVIEWS 
CRITIQUES DES LIVRES
The following books are also re­
viewed in this issue: Gastrointesti­
nal Bleeding (page 416); Endovas­
cular Surgery (2nd edition) (page 
421); Introduction to Vascular Ul­
trasonography (3rd edition), Elec­
trical Trauma: the Pathophysiolo­
gy, Manifestation and Clinical 
Management, The Knee: Form, 
Function, Pathology & Treatment 
(page 492); Advances in Cardiovas­
cular Engineering, Series A: Life 
Sciences, Volume 235, Surgery of 
the Ear and Temporal Bone (page 
493).
TOTAL KNEE ARTHROPLASTY. Ed­
ited by James A. Rand. 480 pp. Illust. 
Raven Press Ltd., New York, 1992. 
$130. (US). ISBN 0-88167-930-5
This multiauthored textbook is devoted 
exclusively to total knee arthroplasty 
and its role in the management of 
degenerative, inflammatory and post- 
traumatic conditions of the knee.
The book is well organized into 29 
chapters. The chapters flow logically, 
starting with biomechanics of the knee, 
patient selection and indications for 
surgery and preoperative planning.
learned to appreciate the hospitality 
and determination of Newfound­
landers and the rugged beauty of 
the coast and adjacent ocean in all 
its moods. Because early decisions 
regarding specialization must be 
made, it is rare that medical stu­
dents or residents have a chance to 
work under different cultural or 
medical conditions in other parts of 
Canada or elsewhere. In this respect 
they are missing an important part 
of personal and medical education.
I have related the story of one
Then specific chapters relate to the 
surgical technique and selection of 
prostheses, emphasizing constrained 
and nonconstrained prostheses. Special 
chapters are devoted to the controver­
sial questions of unicompartmental 
knee replacement, custom total knee 
replacement and cementless total knee 
arthroplasty.
Complications specific to total knee 
replacement are well covered. They in­
clude chapters on bone defects, sepsis, 
extensor mechanism complications and 
deep vein thrombosis. A special chapter 
is devoted to the rehabilitation of the 
patient who undergoes total knee re­
placement.
Despite the involvement of multiple 
authors, the editors have managed to 
maintain a uniform style in the text and 
the illustrations. The references for 
each chapter appear complete but not 
excessive.
The book will be extremely useful for 
surgeons who perform a moderate num­
ber of total knee replacements. It will be 
essential in the library of any hospital 
involved in postgraduate education in 
orthopedic surgery because it contains 
an excellent description of the basic 
science and design considerations as 
well as the basic surgical technique of 
total knee arthroplasty. Furthermore, it
case that affected my life and that 
of a young man’s family. Unfortu­
nately, treatment was unsuccessful, 
as it usually is for an aortoeso- 
phageal fistula, but many of our 
dramatic cases in surgery are suc­
cessful and encourage us to carry 
on. In these days of declining medi­
cal income and prestige we can be 
grateful for the challenge of clinical 
medicine and surgery and be aware 
of our responsibility to patients and 
their families whether the problem 
is routine or unusual.*
acts as a valuable resource for surgical 
technique for a variety of total knee 
prostheses.
James P. Waddell, MD, FRCSC
St. Michael's Orthopedic Associates
Suite 800
55 Queen St. E
Toronto, ON
M5C 1R5
RADIOSURGERY: BASELINE AND 
TRENDS. Edited by Ladislau Steiner. 
320 pp. Illust. Raven Press, New 
York. 1991. $105 (US). ISBN 0 - 
88167-847-3
This book, one of the first on radi­
osurgery, is valuable for neurosurgeons 
and neuro-oncologists because both 
need to know the capabilities and limi­
tations of the technique now that it is 
becoming an integral part of their prac­
tice. The text is intended to show the 
less common aspects of radiosurgery as 
utilized in centres around the world and 
to act as a baseline for the assessment 
of future advances. Excerpts from Lek-
continued on page 416
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w The inside story on 24 hr. inherent control
Roche researchers discovered a compound that could exert its 
effect over 24 hours on a single dose. This made extended drug 
delivery through sustained release engineering unnecessary.
More importantly, by avoiding prolonged absorption, 'Mobiflex' 
is generally less vulnerable to serum peaks and troughs that can 
be caused by normal variations in Cl transit time ana phi.1'4 With 
this approach to drug delivery, 'Mobiflex' can provide dependable 
serum levels for 24 hours of uninterrupted arthritis relief.
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24 hour 
arthritis relief 
starts with 
dependable 
serum levels.
24 hour inherent 
control instead of 
sustained release drug delivery 
helps minimize absorption-related 
serum peaks and troughs’4
Dependable serum levels/ 
dependable symptom control:
► helps reduce breakthrough pain5
► helps reduce morning stiffness6
► promotes a full nights rest07
According to a review of double-blind studies, 
'Mobiflex' is at least as well, or better tolerated 
than diclofenac, naproxen, indomethacin, and 
ketoprofen810t
t  As with all NSAIDs, caution should be used with the elderly: 
the most common adverse events are g.i. related
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0 ' ln  em piric therapy for a w ide range of infections 
0 *O f an enviable safety profile
“ After 10 years of clinical experience in hundreds of 
thousands of patients, it is evident that cefotaxime remains 
an excellent agent for a broad range of patients, from the 
neonate to the octogenarian, with a variety of infections.”
Neu HC. Third Generation Cephalosporins: 
Safety Profiles after 10 Years of Clinical Use. 
J. Clin. Pharmacol. 1990; 30:396-403.
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Carotid Endarterectomy Without 
Angiography. The Reliability of Doppler 
Ultrasonography and Duplex Scanning 
in Preoperative Assessment
Raymond Cartier, MD;* Paul Cartier, MD;t Andre Fontaine, MD$
Objective: To validate the use of Doppler ultrasonography and duplex scanning as the only means of 
preoperative assessment in carotid disease.
Design: A retrospective study performed between January 1980 and December 1989.
Patients: Of 597 carotid endarterectomies carried out by one author, 130 procedures were performed 
on 118 patients (47 women, 71 men, ranging in age from 49 to 85 years) without preoperative cerebral 
angiography. Justifications for proceeding without angiography were risk of angiography (27 
patients), iodine allergy (8 patients), renal insufficiency (5 patients), technical problems (4 patients) 
and surgeon’s preference (74 patients).
Interventions: Doppler ultrasonography and duplex scanning were the only means of preoperative 
assessment on 130 occasions. The studies were done by fully trained radiologists. Until 1982 carotid 
stenosis was assessed with a continuous wave bidirectional Doppler flowmeter and gray-scale 
ultrasonography in equivocal cases. Thereafter, a real-time spectrum analyser connected on-line to a 
Doppler flowmeter was used. Duplex scanning was introduced in 1985.
Main Outcome Measures: Surgical observations confirmed the preoperative assessment on 124 
occasions (96%).
Results: Six patients had occlusion of the internal carotid artery (ICA); five patients had recent 
thrombosis that had occurred between the noninvasive assessment and the endarterectomy. 
Revascularization was successful in all. In one patient, the ICA was chronically occluded. In 63 
patients, the mean pressure in the ICA stump and the mean gradient across the stenosis, measured 
intraoperatively, were 40 ± 3 mm Hg (95% confidence interval: 34 to 48 mm Hg) and 55 ±  3 mm Hg 
(95% confidence interval: 46 to 58 mm Hg), respectively, which confirmed the severity of the stenosis. 
Conclusion: The authors conclude that in their institution, carotid endarterectomy based on Doppler 
ultrasonography and duplex scanning only is reliable and safe.
Objectif: Valider l’usage du Doppler et du duplex carotidien comme unique moyen d’investigation 
preoperatoire d’une chirurgie carotidienne.
Conception : Etude retrospective effectuee au cours de la periode s’echelonnant de janvier 1980 a 
decembre 1989.
Patients : Des 597 endarteriectomies carotidiennes partiquees par l’un des auteurs, 130 procedures ont 
ete effectuees chez 118 patients (47 femmes et 71 hommes dont l’age a varie de 49 a 85 ans). Les 
raisons qui ont motive cette pratique ont ete les suivants : le risque potentiel de l’angiographie (27 
patients), l’allergie a l’iode (8 patients), l’insuffisance renale chronique (5 patients), problemes 
techniques (4 patients) et la preference du chirurgien chez 74 patients.
Interventions : Le Doppler et le duplex carotidien ont ete les seuls moyens devaluation en 130
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occasions. Tous les examens ont ete faits par un radiologiste certifie. Jusqu’en 1982, revaluation 
carotidienne etait faite a 1 aide d’un Doppler continu bidirectionnel et i’echographie avec echelle de gris 
dans les cas douteux. Plus tard, un analyseur spectral en temps reel tut couple au Doppler. Enfin, le 
duplex fut introduit en 1985.
Principaux effets mesures : L’exploration chirurgicale a continue le diagnostic preoperatoire en 124 
occasions (96 %).
Resultats : Six patients ont presente une occlusion de la carotide interne (Cl). Cinq etaient des cas de 
thrombose recente de la Cl survenue entre le moment de F evaluation non invasive et 
l’endarteriectomie. Ils furent tous revascularises avec succes. Un patient avait une occlusion chronique 
de la Cl. Chez 63 patients, la pression carotidienne residuelle et le gradient transstenotique mesures en 
periode peroperatoire, se situaient, respectivement, a 40 ±  3 mm Hg (intervalle de confiance de 95 % 
[Cl] : 34 a 48 mm Hg) et 55 ±  3 mm Hg (Cl 95 % : 46 a 58 mm Hg) confirmant la severite de la stenose. 
Conclusion : Les auteurs conduent que dans leur etablissement, la chirurgie carotidienne basee 
uniquement sur 1 investigation au Doppler et au duplex s’est averee une pratique fiable et securitaire.
The modem era in carotid artery assessment began in 1937 
when Moniz, Lima and de Lacerda1 
publicized the value of cerebral an­
giography for the evaluation of ca­
rotid artery disease. Since then an­
giography has remained the stan­
dard method of investigating extra­
cranial carotid disease. In the 
mid-1960s Doppler scanning gave 
the vascular surgeon a broader 
spectrum of methods for assessing 
cerebral blood flow.2 Nevertheless, 
it was only a decade ago that 
surgeons started performing inter­
nal carotid endarterectomy on pa­
tients assessed solely by Doppler 
scanning.3 Although the accuracy 
of noninvasive evaluation of he­
modynamics and tissue character­
ization in carotid disease have been 
documented in many reports,4-10 
routine carotid endarterectomy 
based only on Doppler ultrasonog­
raphy or duplex scanning is still 
seriously questioned.1112
The purpose of this study is to 
present our initial experience with 
patients who had carotid endar­
terectomy based on the preoperative
findings of Doppler ultrasonogra­
phy and duplex scanning without 
the use of cerebral angiography.
Patients and Methods
Patients
Between January 1980 and De­
cember 1990, 597 carotid endar­
terectomies were performed by one 
of us (P.C.) for internal carotid 
artery (ICA) stenosis causing a re­
duction of more than 75% of the 
surface area of the artery. During 
this period, 130 (22%) procedures 
were performed on 118 patients 
without the use of cerebral angiog­
raphy. The majority were performed 
after 1986 (Fig. 1). There were 47 
women and 71 men, ranging in age 
from 49 to 85 years (mean 66 ± 7 
years). The preoperative risk factors 
are documented in Table I. Before 
endarterectomy, the contralateral 
ICA was occluded in 14 (12%) pa­
tients or had 50% or greater steno­
sis in 41 (35%) patients. Six (5%)
Table I. Carotid Endarterectomy: 
Preoperative Risk Factors (/V =  118)
Patients, no.
Risk factor (%)
Ischemic heart disease 1 ( 1)
Hypertension 25 (19)
Diabetes 36 (28)
Smoking habit 26 (20)
Hyperlipidemia 23 (18)
Peripheral vascular disease 22(17)
FIG. 1. Number of patients who underwent carotid endarterectomy without cerebral 
angiography (black portion of bars) compared with total number who underwent 
carotid endarterectomy (white bars).
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patients had previously undergone 
carotid surgery and were reoperated 
on for symptomatic recurrence.
Hemispheric symptoms were 
present in 65 (55%) patients and 
nonhemispheric symptoms in 45 
(38%) patients. Twenty-two (19%) 
patients were asymptomatic and 1 
patient presented with tinnitus re­
lated to carotid stenosis.
Justifications for proceeding 
without angiography were as fol­
lows: angiographic technical failure 
related to severe peripheral vascular 
disease in 4 patients (3%), chronic 
renal insufficiency in 5 patients 
(4%), dye allergy in 8 patients (7%) 
and potential neurologic complica­
tion during angiography (especially 
in patients with symptomatic criti­
cal stenosis) in 27 patients (23%). 
In 74 (63%) patients, the decision 
to proceed without angiography 
was related to the surgeon’s prefer­
ence.
Doppler Ultrasonography and 
Duplex Scanning
Doppler and duplex examinations 
were performed by fully trained, 
certified radiologists. Over 80% of 
the procedures were performed by 
one of us (A.F.). Our criteria for 
Doppler evaluation of carotid ste­
noses have evolved with the devel­
opment of the Doppler and duplex 
technologic advances that took 
place between 1980 and 1990. Ac­
quisition of more sophisticated 
equipment has allowed the tech­
niques to be refined and the results 
improved. In the early 1980s only a 
continuous-wave bidirectional Dop­
pler flowmeter (D800; Delalande, 
Tours, France) was available. It dis­
played an analogue time-frequency 
tracing that became distorted in 
turbulent flow situations. During 
those years, the severity of carotid 
stenosis was assessed mainly on the 
acoustic analysis of audio Doppler 
signal frequencies, by listening to
the degree of acceleration and tur­
bulence. Increased resistance index 
and signs of collateralization 
through the ophthalmic artery from 
branches of the external carotid 
artery (ECA) were also sought to 
reinforce previous findings. Occa­
sional gray-scale ultrasonography 
was done in equivocal cases.
In 1982, the availability of a 
real-time spectrum analyser (Vas- 
culab D 10SP25; Medasonics, 
Mountainview. Calif.) connected on­
line to a Doppler flowmeter allowed 
display of the full Doppler spec­
trum. On the assumption of a 
8-MHz frequency and 45° angle to 
the skin, increased peak systolic 
frequencies in the range of 10 to 
14 kHz were considered tight ste­
nosis (75% to 90% reduction of the 
vessel’s surface area); frequencies 
over 14 kHz were considered very 
tight stenosis (more than 90% re­
duction in vessel surface area). De­
grees of spectral broadening, in­
creased resistance index and ECA 
collateral flow complemented the 
overall Doppler picture. Duplex 
technology (Ultramark-8; Advanced 
Technology Laboratory, Bothell, 
Wash.) was introduced in our insti­
tution in 1985 and was used con­
currently with continuous wave 
Doppler ultrasonography preopera- 
tively in 73 cases. Morphologic in­
formation with Doppler data can be 
acquired with duplex scanning. The 
carotid artery wall can be imaged, 
plaque can be characterized (surface 
irregularities, intraplaque, hemorrh­
age and ulceration) and, mostly, 
absolute flow velocity instead of 
relative frequencies can be ex­
pressed. Since then, our estimation 
of significant extracranial carotid 
arterial stenosis (a reduction in ar­
terial surface area greater than 
75%) has been based on three crit­
eria:
•  The assessment of cross-sec­
tional area reduction on transverse 
scan
•  A threefold or fourfold in­
crease of peak systolic velocity into 
or immediately beyond the stenotic 
zone compared with the peak sys­
tolic velocity in the areas of laminar 
flow, either downstream or up­
stream, within the same carotid 
artery (ICA versus ICA and common 
carotid artery versus common carot­
id artery)
•  An absolute peak systolic ve­
locity of 250 cm /s or more.
Degrees of turbulence, elevated 
resistance index and plaque charac­
terization are also used to confirm 
duplex findings.
Study Endpoints
Surgical findings and the accura­
cy of the preoperative assessment 
were noted in particular as were 
surgery-related neurologic events 
(transient and permanent) and the 
operative death rate.
Results
Surgical Findings
Surgical exploration confirmed 
the presence of a significant steno­
sis in 124 occasions. The ICA was 
occluded in six patients. A fresh 
thrombus, which could have formed 
between the time of investigation 
and surgical exploration was found 
in five patients. They all underwent 
successful revascularization without 
complication. One patient had 
chronic ICA occlusion and severe 
ECA disease. This patient initially 
presented with an ipsilateral tran­
sient ischemic accident (TIA). A 
successful external carotid endar­
terectomy was done, and the patient 
remained asymptomatic. This was 
our only case of misdiagnosis.
Anatomic Features
Surgical exploration revealed an
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atherosclerotic plaque in all but 
three patients who presented with 
intimal hyperplasia. These three 
were operated on for recurrent ca­
rotid stenosis. The atherosclerotic 
plaque was associated with loose 
debris in 17%, subintimal hemorrh­
age in 33% and ulcer in 55% of 
patients.
In 63 procedures, pressure gradi­
ents across the stenosis and the 
stump pressure were measured. The 
mean carotid stump pressure was 
40 ±  3 mm Hg (95% confidence 
interval [Cl]: 34 to 48 mm Hg) and 
the mean pressure gradient was 55 
± 3 mm Hg (95% Cl: 46 to 58 
mm Hg).
Morbidity and M ortality (Table II)
Two patients died during the 
early postoperative period. Both 
were over 80 years old and had 
multiple risk factors. The first pa­
tient presented with crescendo 
hemispheric TIA. Investigation re­
vealed an ipsilateral ICA stenosis 
greater than 80% and a contralater­
al ICA occlusion. At surgery, exten­
sive atheromatous debris was 
found. The patient sustained a mas­
sive cerebrovascular accident (CVA) 
postoperatively and died 48 hours 
later. Either multiple embolism or 
subarachnoid hemorrhage second­
ary to a reperfusion syndrome was 
incriminated as the cause of death.
The second patient had nonhem- 
ispheric symptoms. Significant, bi­
lateral, carotid stenosis was found 
(left side more than 80%, right side 
more than 50%). An uncomplicated 
left carotid endarterectomy was per­
formed, and the patient was dis­
charged 5 days later with no sign of 
cardiac ischemia. Unfortunately 6 
days later he was readmitted for 
chest pain and died of a myocardial 
infarction. Two patients sustained a 
TIA in the recovery room but fully 
recovered. The postoperative course 
was complicated by reperfusion syn­
drome in two other patients. Both 
responded successfully to medical 
management. Unfortunately two 
(1.7%) patients, who had hemisphe­
ric symptoms preoperatively, sus­
tained perioperative strokes (mono­
plegia) and recovered only partially. 
None of the asymptomatic patients 
sustained transient or permanent 
deficit related to the operation.
Discussion
Cerebral angiography is a well- 
established invasive diagnostic pro­
cedure. Renal insufficiency has been 
reported up to 10% in high-risk 
populations, with a 2.5% incidence 
of patients requiring permanent 
renal dialysis.13 Contrast allergic 
reaction is unusual and is asso­
ciated with cerebral angiography in 
about 2% of cases.14 A neurologic 
event is the most feared complica­
tion of the procedure. Overall, cere­
bral angiography carries a 0.1% 
risk of permanent neurologic defi­
cit. However, in an atherosclerotic 
population, the combined risk of 
transient or fixed deficit has been 
reported to range from 0.4% to 
4%.13-18
Even though carotid angiography 
has been considered the gold stan­
dard in extracranial carotid disease, 
it has been supplanted by duplex
Table II. Morbidity and Mortality of Carotid Endarterectomy According to Preoperative Indications
Preoperative indications TIA, no. CVA, no.
Operative 
death, no.
Hemispheric symptoms 2 3 1
Nonhemispheric symptoms 0 0 1
Asymptomatic 0 0 0
TIA =  transient ischemic attack, CVA =  cerebrovascular accident
scanning in the morphologic char­
acterization of arteriosclerotic 
plaque.19
Since Von Reuten, Ortega- 
Schkramp and Spiiner3 reported 15 
cases of carotid endarterectomy di­
agnosed on spectral analysis, many 
authors have reported good results 
with this practice.459 The conclu­
sions of these authors were that 
patients with hemispheric symp­
toms, especially crescendo TIA or 
preocclusive lesions, patients with 
allergy or other medical contrain­
dications and patients previously 
investigated by angiography but 
found to have progressive disease 
on follow-up ultrasonography could 
be operated upon safely without 
angiography.
However, others have not been so 
optimistic. Geuder and associates,11 
in a study of 100 patients assessed 
preoperatively by angiography and 
duplex scanning, reported an 8% 
incidence of wrong or missed diag­
noses. Some wrong diagnoses were 
linked to nonhemispheric symp­
toms, and some of the missing 
information was related to arch­
vessel stenosis, which could have 
been detected on physical examina­
tion or continuous Doppler scan­
ning. Furthermore, in their study, 
two patients sustained permanent 
neurologic damage during the angi­
ographic procedure. This could 
have been avoided by limiting the 
assessment to duplex scanning 
alone.
In our study, the only incorrect 
diagnosis was made on a symptom­
atic patient with ICA occlusion and 
severe ECA stenosis. An external 
carotid endarterectomy was carried 
out successfully and the patient was 
cured. This misinterpretation oc­
curred before duplex scanning was 
introduced to our institution and 
when continuous spectral Doppler 
scanning was the only alternative 
technique available.
Asymptomatic patients in this se-
414 JCC, VOL. 36, N° 5, OCTOBRE 1993
DOPPLER AND DUPLEX FOR CAROTID ENDARTERECTOMY
ries underwent surgery without 
deaths or neurologic complications. 
The First Phase Report of the Co­
operative Veterans Administration 
Asymptomatic Carotid Study has 
reported a 0.4% incidence of neuro­
logic deficit related to cerebral angi­
ography.18 Since all the patients 
were asymptomatic, these results 
are troublesome. The necessity of 
routinely performing angiography 
on patients suffering asymptomatic 
carotid disease is questionable. The 
purpose of angiography becomes 
that of detecting any associated 
lesions that could compromise the 
success of surgery. These lesions 
are mainly tandem vascular lesions 
(siphon stenosis or arch disease) or 
intracerebral lesions like berry an­
eurysms or brain tumours.
Carotid siphon disease has a 
slower natural evolution than extra­
cranial carotid disease but should 
not preclude the correction of the 
latter.20 The influence of carotid 
siphon disease on carotid endar­
terectomy is not clear, and, lately, 
clinical series have denied any dele­
terious effect on the procedure.21-22 
The concomitant occurrence of 
asymptomatic berry aneurysms has 
not been found to jeopardize the 
issue of carotid endarterectomy 
when that procedure is justified.23 
Proximal tandem lesions can be 
detected by the use of continuous 
Doppler scanning and can be con­
firmed by arch angiography.
There is an unquestionable ad­
vantage in managing asymptomatic 
patients without the use of routine 
angiography since the incidence of 
neurologic complications must be 
kept as low as possible. Concerns 
may be expressed when the surgeon 
has to deal with nonhemispheric 
symptoms. In our study, patients 
with nonhemispheric symptoms 
were operated upon without any 
further investigation. The outcome 
has been successful for all but one 
patient who died 11 days after
operation of a myocardial infarc­
tion. Nevertheless, we agree with 
the necessity of performing routine 
cerebral computed tomography (CT) 
in this subset of patients to exclude 
other brain-related diseases that 
could be responsible for nonhemis­
pheric symptoms.10 Furthermore, in 
patients presenting with unilateral 
carotid stenosis, carotid angiogra­
phy should be performed to visual­
ize the intracerebral and posterior 
circulation and to determine if the 
vertebrobasilar circulation is defi­
cient.
We do not believe that routine 
use of cerebral CT is necessary in 
patients with hemispheric symp­
toms. Akers, Bell and Kerstein,23 in 
a retrospective study of 1000 con­
secutive cerebral angiograms, in­
cluding 784 intracranial views ob­
tained for evaluation of carotid ar­
tery disease, found just one case of 
brain tumour. They concluded that 
intracranial studies did not alter the 
management of their patients and 
questioned the cost-effectiveness of 
the procedure.23 Others have come 
to the same conclusion in patients 
presenting with focal symptoms.7-24 
In this context, the place of routine 
cerebral CT before the operative CT 
is not clear. Nevertheless, a major 
drawback to this practice is the 
reliability of professionals carrying 
out the duplex scanning. Their 
technical skill must be appraised 
and challenged with carotid angiog­
raphy done in their own institution. 
Their expertise will count on case 
load and referral. Therefore, duplex 
scanning should be limited to major 
centres where professionals can 
reach this level of expertise.
In conclusion, we believe that 
carotid endarterectomy performed 
with preoperative duplex imaging 
only is an acceptable alternative to 
standard cerebral angiography in 
patients with carotid artery steno­
sis. Patients presenting with non­
hemispheric symptoms should un­
dergo brain CT to rule out any 
other cerebral disease. We strongly 
recommend the use of carotid angi­
ography when the findings on du­
plex scanning are inconclusive, 
when the stenosis is located distally 
on the 1CA, in patients who have 
vertebrobasilar symptoms with uni­
lateral carotid stenosis, when there 
is evidence of carotid high resist­
ance index without carotid stenosis, 
suggesting intracerebral disease, 
and when arch vessels are involved.
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sell’s Brain Fragments are also included 
as a tribute.
The first three parts of the book are 
offered without editorial comment. 
They cover radiobiology, radiosurgical 
technique and experimental studies. 
The radiobiologic basis for the response 
of nervous tissue to large single frac­
tions of radiation is described, and an 
attempt is made to predict complica­
tions and the biologic effect of the 
radiation, depending on a number of 
variable factors. The chapter on graph­
ics and computer technology is complex 
and hard to follow unless one is already 
an expert in this field, although these 
developments are fundamental to radi­
osurgery. Subsequent chapters describe 
the practical techniques of radiosurgery 
with the gamma knife, linear accelera­
tor (LINAC), stereotactic heavy-charged 
particles and a method for stereotactic 
fractionated radiotherapy for extracrani­
al targets (although no data on 
reproducibility in practice are offered). 
The third part describes a number of 
experimental radiosurgery studies in 
sphenoid and animal models — these 
experiments are among the first of their 
kind, and much more work is needed 
here.
The fourth part of the book describes 
the treatment of patients by gamma-
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knife radiosurgery for acoustic neuro­
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charged-particle radiosurgery for pitu­
itary tumours and by LINAC radiosurg­
ery for malignant intracranial tumours. 
The series reported are small. Clearly 
more experience with longer follow-up 
is required before the place of radi­
osurgery in the treatment of tumours is 
established. In the editor’s comments, 
other series are discussed, adding 
weight to the use of radiosurgery in 
acoustic neuromas, pituitary adenomas 
and solitary brain metastases. Further 
experience is needed in the treatment of 
meningiomas and glial tumours.
The fifth section of the book de­
scribes radiosurgery in the treatment of 
arteriovenous malformations (AVMs). 
The technique is already established for 
the use of the gamma knife and heavy- 
charged particles, so the chapters in 
this section are more specific. They deal 
with AVMs of the posterior fossa, com­
bined embolization and radiosurgery, 
the LINAC technique and results and 
evaluation of sequelae of treatment. 
There is also a chapter on heavy- 
charged-particle radiosurgery for intra­
cranial, angiographically occult AVMs, 
containing the editor’s comments based 
on a round-table discussion.
The final part of the book discusses
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radiosurgery in functional diseases.
Overall, this text achieves its aim to 
act as a baseline for radiosurgery and is 
useful as an introduction to the subject 
for those contemplating this modality of 
treatment.
Anthony C. Whitton, MB, BS, FRCR, 
FRCPC
Deputy head of radiation oncology 
Ontario Cancer Treatment and Research 
Foundation
Hamilton Regional Cancer Centre 
699 Concession St.
Hamilton, ON 
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GASTROINTESTINAL BLEEDING. 
Edited by Choichi Sugawa, Bernard M. 
Schuman and Charles E. Lucas. 564 
pp. Illust. Igaku-Shoin, New York. 
1992. $173. ISBN 0-89640-221-5
This comprehensive, multiauthored 
book is intended as a reference text for 
physicians who are interested in the 
diagnosis and treatment of gastrointes-
continued on page 421
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T h e  Influence of Intermittent 
Positive-Pressure Ventilation on the 
Cardiorespiratory Dynamics 
of Diaphragmatic Rupture With Gastric 
Herniation
Jameel Ali, MD, FRCSC, FACS; Wan Qi, MSc
To determine the effect of intermittent positive-pressure ventilation (IPPV) on gastric herniation in 
diaphragmatic rupture, 16 piglets underwent laceration of the left hemidiaphragm. Arterial blood gas 
levels, pulmonary artery wedge pressure, cardiac output and arterial blood pressure were measured. 
The stomach was then placed above the diaphragm. The initial measurements were repeated, and 
displacement of the stomach above the diaphragm (S/D) was measured. The animals were divided into 
two groups: group 1, eight animals breathing 80% oxygen spontaneously and group 2, eight animals 
receiving IPPV. Initially in group 2 there was only a small decrease in mean (± SD) arterial oxygen 
tension from 484 ± 34 mm Hg to 424 ± 20 mm Hg (other parameters were unchanged). In group 1, 
gastric herniation produced a further fall in arterial oxygen tension to 308 ± 1 0  mm Hg at 1 hour, a 
rise in arterial carbon dioxide tension to 49 ± 4 mm Hg and a decrease in pH to 7.32 ±  0.04. In group 
2 similar changes in arterial blood gas levels occurred with gastric herniation, but there was a return 
to baseline values of 490 ± 28 mm Hg for arterial oxygen tension, 37 ± 4 mm Hg for carbon dioxide 
tension and 7.38 ± 0.05 for pH after IPPV. Similar changes were seen in blood pressure, cardiac 
output and pulmonary artery wedge pressure. S /D  remained at 6.3 ± 0.2 cm in group 1 but decreased 
from 6.0 ± 0.2 cm to 1.1 ± 0.5 cm after 1 hour in group 2.
The authors conclude that diaphragmatic rupture produces cardiorespiratory changes, but these are 
small in the absence of gastric herniation. IPPV effectively reduces gastric herniation and corrects the 
cardiorespiratory abnormalities and is therefore a valuable temporary treatment until a definitive 
operation can be done.
Dans le but de mesurer l’effet de la ventilation a pression positive intermittente (VPPI) sur l’hernie 
gastrique dans les cas de rupture diaphragmatique, on a fait subir a 16 porcelets, une laceration de 
l’hemidiaphragme gauche. Initialement, on a mesure les gaz arteriels, la pression capillaire 
pulmonaire, le debit cardiaque et la tension arterielle. L’estomac fut ensuite place au dessus du 
diaphragme. Les mesures initiales furent repetees et on mesura le deplacement de l’estomac au dessus 
du diaphragme (E/D). Les animaux furent separes en deux groupes : le groupe 1, constitue de huit 
animaux respirant de l’oxygene a 80 % de fa?on spontanee, et le groupe 2, forme de huit animaux qui 
eurent une VPPI. Au debut, dans le groupe 2, on n’a enregistre qu’une petite diminution de la tension 
d’oxygene arterielle moyenne (± ET), celle-ci passant de 484 ± 34 mm Hg a 424 ± 20 mm Hg (les 
autres parametres demeurant inchanges). Dans le groupe 1, l’hernie gastrique a provoque une baisse 
supplementaire de la tension d’oxygene arterielle a 308 ± 10 mm Hg apres une heure, une 
augmentation de la tension de bioxyde de carbone arterielle a 49 ± 4 mm Hg et une diminution du pH a 
7,32 ± 0,04. Dans le groupe 2, des modifications similaires des gaz arteriels ont suivi l’hernie
From the Department o f Surgery, University o f  Toronto, Toronto, Ont.
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gastrique mais, apres la VPPI, on a assiste a un retour aux valeurs de depart de 490 ±  28 mm Hg pour 
la tension d’oxygene arterielle, de 37 ±  4 mm Hg pour la tension de bioxyde de carbone et de 7,38 ±  
0,05 pour le pH. Des changements similaires furent observes pour la tension arterielle, le debit 
cardiaque et la pression capillaire pulmonaire : une baisse initiale des valeurs mesurees et une chute 
accrue apres l’hernie gastrique, suivies d’un retour aux valeurs de depart dans le groupe 2. Le E/D est 
reste a 6,3 ± 0,2 cm dans le groupe 1 mais il a diminue de 6,0 ±  0,2 a 1,1 ± 0,5 cm apres 1 heure dans 
le groupe 2.
Les auteurs concluent qu’une rupture diaphragmatique provoque des changements 
cardiorespiratoires mais que ces changements sont minimes en l’absence d’une hernie gastrique. La 
VPPI est efficace pour reduire l’hernie gastrique et corriger les anomalies cardiorespiratoires. Elle est 
done utile comme traitement temporaire en attendant qu’on puisse proceder a une operation definitive.
Diaphragmatic rupture may occur after blunt or penetrat­
ing injury to the torso. In the 
absence of increased intra-abdomi­
nal pressure, visceral herniation 
does not uniformly occur during 
spontaneous breathing when there 
is diaphragmatic rupture.1 When it 
does, it may be associated with only 
mild cardiopulmonary dysfunction.2 
We have shown previously that in­
creased intra-abdominal pressure in 
the presence of diaphragmatic rup­
ture not only precipitates visceral 
herniation but also is responsible 
for severe cardiopulmonary compro­
mise and death; we have further 
shown that intermittent positive- 
pressure ventilation (IPPV) partially 
reverses the cardiopulmonary ef­
fects and improves the chances of 
survival.2
The present study was designed 
to determine the cardiopulmonary 
effects of IPPV on diaphragmatic 
rupture with gastric herniation in 
the absence of increased intra­
abdominal pressure. We used pigs 
because their anatomic chest struc­
ture is similar to that in humans in 
that the hemithoraces are separated 
by an intact mediastinum.
Methods
Sixteen, healthy, New Hampshire 
piglets, weighing between 30 and 
32 kg, were anesthetized with sodi­
um thiopental and ketamine hydro­
chloride. The animals were intubat­
ed and maintained on spontaneous
ventilation with 1% halothane and 
80% oxygen. A solution of normal 
saline was administered intrave­
nously and continuously at an 
hourly rate of 2 mL/kg. Carotid 
artery and pulmonary artery pres­
sures were measured by a multi­
channel recorder and by pressure 
transducers connected to catheters 
in the appropriate vessels. A Swan- 
Ganz thermodilution catheter was 
introduced into the pulmonary ar­
tery through an external jugular 
vein. Cardiac output obtained from 
thermodilution was measured in 
triplicate and an average taken.3
An ABL2 blood gas analyser 
(Radiometer, Copenhagen, Den­
mark) was used for measuring tem­
perature-corrected blood gas levels 
from carotid artery blood. All mea­
surements were made at the end of 
expiration.
After the animal’s condition had 
been stabilized, a surgical laceration 
of the left hemidiaphragm, 12 cm 
long, was made through a small left 
lateral thoracotomy. Metallic mark­
ers were then placed on the edge of 
the diaphragm, and the stomach 
was manually positioned exactly in 
the centre of the diaphragmatic 
laceration at the level of the dia­
phragm. The position of the stom­
ach was identified fluoroscopically 
by means of a safety pin secured to 
the uppermost surface of the stom­
ach.12 A 16-French catheter was 
placed in the pleural space, the 
thoracotomy closed and the cathe­
ter removed after all the residual 
gas had been aspirated. Baseline
measurements were then made in 
all animals. The thoracotomy was 
reopened, and the stomach was 
placed 6 cm above the lacerated 
diaphragmatic edge, as determined 
by the fluoroscopic markers. The 
thoracotomy was again closed after 
aspiration of residual gas from the 
pleural space.
The position of the stomach rela­
tive to the diaphragm was moni­
tored by means of fluoroscopy at a 
fixed magnification and distance 
from the chest wall. The vertical 
distance between the safety pin and 
the diaphragmatic fluoroscopic 
marker was measured on the fluo- 
roscope screen (Fig. 1). The base­
line cardiopulmonary measurements 
made before displacement of the 
stomach above the diaphragm were 
repeated at 15 minutes, 30 minutes, 
45 minutes and 1 hour after dis­
placement. In group 1, eight ani-
FIG. 1: Fluoroscopic appearance of 
diaphragmatic marker (bottom) and 
gastric marker (safety-pin). Vertical 
distance between diaphragmatic and 
gastric markers was used as index of 
gastric herniation.
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mals remained intubated and spon­
taneously breathed 80% oxygen; in 
group 2, the other eight animals 
were ventilated with IPPV of 20 
cm H20  and 80% oxygen after the 
15-minute measurement. The mea­
surements were then repeated at 
the same times as for the animals in 
group 1. The animals maintained 
their own respiratory rate.
At the end of the experiments the 
animals were sacrificed by intracar­
diac instillation of potassium chlo­
ride solution.
Paired f-tests were used for com­
parisons of the data within the 
groups. Analysis of variance fol­
lowed by Tukey’s multiple range 
test was used for multiple compari­
sons among the groups. A p value 
of 0.05 was accepted as statistically 
significant. The data are presented 
as means plus or minus the stan­
dard deviation.
Results
All the animals survived the 
1-hour period of the study.
Arterial Blood Gas Levels (Table I)
Arterial blood gas levels were 
similar in both groups before dia­
phragmatic laceration and during 
spontaneous breathing. Baseline 
measurements taken after diaphrag­
matic laceration with the stomach 
located at the level of the dia­
phragm showed a slight but statisti­
cally significant decrease in arterial 
oxygen tension (Pa02), with no sig­
nificant changes in pH or arterial 
carbon dioxide tension (PaC02). 
There were no significant differ­
ences in Pa02 between the groups.
At 15 minutes after gastric her­
niation, both groups showed a simi­
lar statistically significant (p < 
0.05) decrease in Pa02, with a small 
but statistically significant rise in 
PaC02 and no change in pH. At 30 
minutes after gastric herniation the 
Pa02 in group 1 fell further, there 
was another rise in PaC02 and a 
slight but statistically significant 
fall in pH. At 45 minutes and 1 
hour after herniation there had 
again been decreases in Pa02, in­
creases in PaC02 and decreases in 
pH in group 1. By 30 minutes after 
gastric herniation and 15 minutes 
after IPPV, group 2 showed a sta­
tistically significant rise in Pa02, 
and the increase was progressive 
back to baseline levels of fti02 at 1 
hour after herniation. Although 
there was a trend for the PaC02 to 
decrease this did not reach statisti­
cal significance in group 2 after the 
30-minute measurement. Similarly 
the pH remained relatively constant 
in this group.
Blood Pressure (Table II)
The arterial blood pressure was 
similar in the two groups of animals 
before diaphragmatic laceration,
and it did not change after lacera­
tion but before gastric herniation. 
After displacement of the stomach 
above the diaphragm, however, 
there was a statistically significant 
(p < 0.05) decrease in arterial blood 
pressure to the same extent in both 
groups. The animals in group 1 
maintained this arterial blood pres­
sure at 1 hour after gastric hernia­
tion. The animals in group 2 
showed a return to baseline arterial 
blood pressure at 1 hour after 
gastric herniation, once IPPV had 
been instituted.
Cardiac Output (Table II)
Baseline cardiac output measure­
ments in the two groups of animals 
were similar both before diaphrag­
matic laceration and after laceration 
but without gastric herniation. At 
15 minutes after gastric displace­
ment, the cardiac output fell slight­
ly and was 3.6 ± 0.2 L/min at 1 
hour in group 1. In group 2 there 
was a similar decrease at 15 min­
utes after herniation and a return to 
baseline levels by 1 hour with the 
institution of IPPV.
Pulmonary Artery Wedge Pressure 
(Table II)
Baseline measurements of the 
pulmonary artery wedge pressure 
were similar in the two groups 
before diaphragmatic laceration and 
did not change significantly after
T a b le  1. A rte r ia l B lo o d  Gas L e v e ls
Group 1 Group 2
M e a su re m e n t
tim e Pao2, mm Hg Paco2, mm Hg pH flao2, mm Hg Paco2, mm Hg PH
P re -tho raco tom y 4 80  ±  36 39  ± 4 7 .39  ±  0 .05 4 8 4  ±  34 3 8  ± 3 7 .3 8  ±  0 .0 5
Base line 4 30  ±  19 39  ± 5 7 .39  ±  0 .05 4 2 4  ±  20 3 9  ±  5 7 .3 9  ±  0 .0 5
15 m in 4 00  ±  14* 41 ±  5* 7 .3 9  ±  0 .05 3 96  ±  12* 4 0  ±  4 7 .3 8  ±  0 .0 6
30  m in 3 56  ± 4* 46  ±  3 * t 7 .3 6  ± 0 .02* 4 2 0  ± 14* 3 9  ± 2 7 .3 9  ± 0 .0 5
45  m in 3 20  ± 8* 48 ± 2 t 7 .3 4  ± 0 .0 2 f 4 7 0  ± 30* 3 8  ±  3 7 .3 8  ± 0 .0 5
60 m in 3 08  ± 10* 49  ± 4 + 7 .3 2  ± 0 .0 4 t 4 9 0  ± 28 3 7  ± 4 7 .3 8  ± 0 .0 5
' p < 0 .05  com pared  w ith  p re v iou s  value
t p < 0.05  com pared  w ith  g roup  2
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diaphragmatic laceration without 
gastric herniation. There was a very 
small but significant increase in 
pressure after gastric herniation in 
group 1 but no further statistically 
significant change in this measure­
ment throughout the experiment. 
In group 2 the pulmonary artery 
wedge pressure increased slightly at 
15 minutes after herniation, and 
there was a small but statistically 
significant fall by 1 hour after 
gastric herniation.
Displacement o f the Stomach Above 
the Diaphragm (Table III)
By design, the distance of the 
stomach above the diaphragm 
(S/D) was similar in the two groups 
before and after diaphragmatic lac­
eration until the stomach was man­
ually displaced above the dia­
phragm. At 15 minutes after dis­
placement, the S /D  was similar in 
the two groups. At 30 minutes 
there was a trend for the S /D  to 
decrease in group 2, although this 
was not significant. The S/D  of 
group 1 animals was unchanged at 
45 minutes and 1 hour, but the 
S/D  of group 2 animals was 
markedly decreased at these times.
Discussion
In this study we have demon­
strated that diaphragmatic lacera­
tion during spontaneous breathing 
is associated with only minor he­
modynamic and respiratory dys­
function in the absence of visceral 
herniation. Gastric herniation re­
sults in moderate changes in blood 
pressure, cardiac output, pulmo­
nary artery wedge pressure and ar­
terial blood gas levels. These 
changes are, however, all compati­
ble with short-term survival.
We have shown that the displace­
ment of the stomach above the 
diaphragm during spontaneous 
breathing is maintained (for at least 
1 hour) and that this displacement 
can be decreased with the institu­
tion of IPPV. We have also shown 
that after gastric herniation the use 
of IPPV improves arterial blood gas 
levels, pulmonary artery wedge 
pressure and blood pressure. This 
improvement in cardiorespiratory 
function occurs even before there is 
any detectable decrease in the de­
gree of gastric herniation. Our re­
sults demonstrate that diaphrag­
matic laceration during spontane­
ous breathing without visceral her­
niation is well tolerated and that 
even with gastric herniation the
hemodynamic changes are compati­
ble with short-term survival. Our 
study may explain the observation 
that diaphragmatic rupture is a fre­
quently missed or delayed diag­
nosis,4-6 particularly in patients 
with multiple injuries whose minor 
hemodynamic changes (such as oc­
curred in these animal studies) may 
be easily explained by other, associ­
ated injuries. Thus, it seems that 
the monitoring of hemodynamic 
and pulmonary parameters alone 
may not lead to the diagnosis of 
diaphragmatic rupture with or with­
out visceral herniation and that 
other investigative modalities may 
be required.7
Our study also suggests that in 
patients with cardiopulmonary dys­
function after diaphragmatic rup­
ture and visceral herniation, IPPV 
is a useful therapeutic modality: it 
not only improves hemodynamic 
and respiratory function before re­
ducing the visceral herniation, but 
also effectively decreases the her­
niation; thus, it can be used as a 
temporizing measure, particularly 
in cases of multiple trauma, until 
definitive surgery is possible.
Table III. Stomach Displacement Above Diaphragm
Measurement time, min Group 1 Group 2
15 6.0 ±  0.1 6.0 ±  0.2
30 6.0 ± 0.2 5.5 ±  0.3
45 6.0 ± 0 .1 * 3.2 ± 0 .2 t
60 6.3 ± 0.2* 1.1 ± 0 .5 t
*p < 0.05 compared with group 2
t P < 0.05 compared with previous value
Table II. Hemodynamic Data
Group 1 Group 2
Measurement
time BP, mm Hg CO, L/min PAWP, mm Hg BP, mm Hg CO, L/min PAWP, mm Hg
Pre-thoracotomy 120 ± 8 3.9 ± 0 .1 7.9 ± 0.1 118 ±  8 4.0 ±  0.1 7.8 ±  0.2Baseline 118 ± 10 3.8 ± 0.1 8.0 ± 0.1 119 ± 10 3.9 ± 0 .1 7.9 ± 0.215 min 100 ± 6* 3.6 ± 0 .1 * 8.4 ± 0.2* 99 ± 8* 3.5 ±  0.2* 8.6 ± 0.2*30 min 98 ± 6* 3.5 ± 0.1t 8.6 ± 0 .2 t 114 ± 4* 4.0 ± 0 .1 * 8.0 ± 0 .1 *45 min 99 ± 4 t 3.5 ± 0 .2 f 8.4 ± 0 .2 t 116 ± 4 4.1 ± 0.1 7.9 ± 0.260 min 99 ± 6 t 3.6 ± 0 .2 t 8.4 ± 0 .3 t 118 ± 9 4.0 ±  0.2 7.9 ± 0.2
'p < 0.05 compared with previous value 
t P < 0.05 compared with group 2
BP =  blood pressure, CO =  cardiac output, PAWP =  pulmonary artery wedge pressure
420 JCC, VOL. 36. No 5, OCTOBRE 1993
IPPV IN DIAPHRAGMATIC RUPTURE
References
1. Ali J, Qi W: The effects of positive airway 
pressure and intra-abdominal pressure in 
diaphragmatic rupture. World J Surg 
1992; 16:1120-1125
2. Idem: The cardiorespiratory effects of 
increased intra-abdominal pressure in dia­
phragmatic rupture. J Trauma 1992; 33:
BOOK REVIEWS
continued from page 416
tinal hemorrhage. Emergency room 
physicians, internists, gastroenterolo­
gists, family physicians and surgeons 
will “find relevant guidance” from rec­
ognized experts in the “day to day 
encounters with bleeding from the gas­
trointestinal tract.”
The book is organized into six sec­
tions. The first section deals with the 
general aspects of upper and lower 
gastrointestinal bleeding: the magni­
tude of the clinical problem; the pathol­
ogy of bleeding lesions; liver disease in 
gastrointestinal bleeding; drug-induced 
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the current management of gastrointes­
tinal bleeding and should be useful to 
all physicians who have to treat patients 
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ENDOVASCULAR SURGERY. 2nd 
edition. Edited by S.S. Ahn and W.S. 
Moore. 612 pp. Illust. W.B. Saunders 
Co., Philadelphia. 1992. $182. ISBN 
0-7216-4370-1
This is a large and impressive second 
edition, edited by two vascular surgeons 
from the UCLA Centre for Health Sci­
ences. The editors are part of a mul­
tidisciplinary team of cardiac and vascu-
continued on page 430
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ORIGINAL ARTICLES
Effect of Cardiac Stabbing on Ventricular 
Function: Evaluation by Radionuclide 
Angiography
Erik D. Skarsgard, MD, MSc(Surg), FRCSC;* P. Terry Phang, MD;*§ Allan S. Belzberg, MD, FRCPC;t 
James A. Russell, MD, FCCP, FRCPC$
Objective: To determine whether cardiac stab wounds cause early ventricular dysfunction.
Design: Retrospective case series over 7 years.
Setting: University-affiliated teaching hospital.
Patients: Nine consecutive survivors of cardiac stab wounds.
Interventions: Postoperative radionuclide angiography performed in all patients between 1 and 13 days 
after injury and repeated in two patients 2 months and 7 months respectively after injury.
Main Outcome Measures: Information on the patient’s clinical presentation and hospital course was 
obtained from the patient’s charts and correlated with ventricular function as measured by the right 
and left ventricular ejection fractions (RVEF and LVEF).
Results: Cardiac injuries consisted of isolated right (five) and left (three) ventricular lacerations, and 
one biventricular laceration. Three patients had perioperative dysrhythmias (two ventricular, one 
atrial), and nonspecific electrocardiographic changes occurred in seven patients. Six patients had 
postoperative complications: pericarditis in three and pneumonia, pulmonary thromboembolism and 
abdominal wound dehiscence in one each. The LVEF was normal in all patients. Although none had 
clinically apparent cardiac dysfunction at the time of radionuclide angiography, six patients had a 
reduced RVEF (less than 0.45). All patients remained asymptomatic at the time of discharge from 
hospital (median 12 days postoperatively). In two of the six patients who had a reduced RVEF, one had 
a normal RVEF 2 months later; the other had a near-normal RVEF (0.43) but had persistent right 
ventricular enlargement 7 months later. Both were asymptomatic.
Conclusions: Although a reduced RVEF is common in survivors of cardiac stab wounds, the reduction 
is small and is not associated with clinically apparent cardiac dysfunction.
Objectif: Determiner si les blessures cardiaques par couteau causent un dysfonctionnement 
ventriculaire immediat.
Conception : L’examen retrospectif des cas vus pendant une periode de 7 ans.
Contexte : Un hopital universitaire.
Patients : Neuf survivants consecutifs a des blessures cardiaques par couteau.
Interventions : Une angiographie isotopique postoperatoire pratiquee chez tous les patients, de 1 a 13 
jours apres la blessure, et repetee chez deux patients, respectivement, 2 et 7 mois apres la blessure. 
Principaux effets mesures : Le tableau clinique du patient a 1’arrivee et son evolution a l’hopital furent 
extrait du dossier d’hopital et mis en parallele avec le fonctionnement ventriculaire mesure par les 
fractions d’ejection ventriculaire droite et gauche (FEVD et FEVG).
Resultats : Les lesions cardiaques etaient constitutes de cinq lacerations ventriculaires droites isolees,
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de trois laceration ventriculaires gauches et d’une laceration des deux ventricules. Trois patients ont 
developpe des dysrythmies peroperatoires (deux ventriculaires, une auriculaire) et des changements 
non specifiques du trace electrocardiographique sont survenus chez sept patients. Six patients ont 
souffert de complications postoperatoires : trois pericardites et, un cas chacun de pneumonie, d’embolie 
pulmonaire et de desunion des sutures d’une plaie abdominale. La FEVG etait normale chez tous les 
patients. Bien qu’aucun n'ait manifesto de dysfonctionnement cardiaque cliniquement apparent au 
moment de l’angiographie isotopique, six patients montraient une reduction de la FEVD (moins de 
0,45). Tous les patients etaient asymptomatiques au moment de recevoir leur conge de I’hopital 
(mediane de 12 jours postoperatoires). De deux des six patients qui avaient montre une diminution de 
la FEVD, un s’etait normalise 2 mois plus tard; l’autre avait une FEVD presque normale (0,43) apres 7 
mois mais conservait une hypertrophie ventriculaire droite. Les deux etaient asymptomatiques. 
Conclusions : Meme si une diminution de la FEVD est frequente chez les survivants d’une blessure 
cardiaque par couteau, cette diminution est petite et n’est pas reliee a un dysfonctionnement cardiaque 
cliniquement apparent.
P enetrating injuries of the heart represent one of the most ur­
gent conditions facing those in­
volved in trauma care. The pro­
found physiologic derangement im­
posed by penetrating injury compli­
cated by pericardial tamponade 
mandates immediate intervention to 
restore cardiac function. Although 
prompt thoracotomy and cardior- 
rhaphy can restore a physiologic 
hemodynamic state in the short 
term, there have been no studies of 
early postoperative right and left 
ventricular function in survivors of 
cardiac stab wounds. Therefore, we 
carried out this study first to deter­
mine whether severe penetrating 
cardiac injury decreases the right 
and left ventricular ejection frac­
tions (RVEF and LVEF) as mea­
sured by radionuclide angiography 
and second to correlate ventricular 
ejection fractions with clinical pre­
sentation and outcome.
Patients and Methods
Over a 7-year period ending in 
July 1990, nine survivors of cardiac 
stab wounds were treated at St 
Paul’s Hospital, Vancouver, and un­
derwent radionuclide angiography 
at least once before discharge. In­
formation on the nature of the 
weapon and injury, clinical cardio­
vascular status on admission, treat­
ment, response to treatment and
complications were obtained from 
the hospital charts.
Radionuclide Data Acquisition and 
Processing
All radionuclide angiograms were 
obtained with a portable gamma 
scintillation camera (Picker Dyna­
mo, Northford, Conn.), positioned 
so that there was maximal separa­
tion between the right and left 
ventricular images (40° to 50° left 
anterior oblique). Electrodes were 
placed on the chest, and a gating 
device was connected to a mobile 
minicomputer (DPS 2800; ADAC 
Laboratories, Sunnyvale, Calif.). 
The patient’s red blood cells were 
labelled by injecting stannous chlo­
ride (0.03 mg/kg) 10 to 30 min­
utes before the injection of 20 to 
25 mCi of technetium 99m ( 99mTc) 
through a central venous catheter.1 
Multigated scintigraphy was done 
using 16-frame images obtained 
over 80% of the cardiac cycle. Each 
frame contained 2 000 000 counts. 
All data were acquired with hard­
ware zooming to expand the data 
1.5 times and were recorded in a 
byte mode 64 X 64 matrix.
After nine-point smoothing, com­
puter-generated (DPS 2800; ADAC 
Laboratories) regions of interest 
were assigned around the right and 
left ventricle. All frames were re­
viewed manually, and changes were 
made when necessary to ensure
correct placement of the region of 
interest. A left paraventricular back­
ground region was assigned on the 
end-systolic frame. Background- 
subtracted time-activity curves were 
generated, and the computer select­
ed the end-diastolic and end-systolic 
points on the basis of maximal and 
minimal counts, respectively. Ejec­
tion fraction (EF) was calculated 
by means of the formula EF = 
(EDC-ESC) -r EDC, where EDC = 
end-diastolic counts and ESC = 
end-systolic counts. In our depart­
ment, the lower limits of normal 
RVEF and LVEF are 0.45 and 0.50 
respectively.
Reproducibility o f LV EF  and RVEF
We have previously determined 
the reproducibility of equilibrium 
LVEF and thermodilution cardiac 
output in seven ventilated, critically 
ill patients.2 LVEF was measured by 
three observers who were blind as 
to the study. LVEF and cardiac 
output were measured three times 
at 15-minute intervals for 30 min­
utes without change of any sup­
port. When the three measurements 
over 30 minutes were compared, 
the correlation coefficient and stan­
dard deviation of LVEF were calcu­
lated to be 0.94 and 0.02 respec­
tively.
Measurement of RVEF requires 
separation of right atrial activity 
from right ventricular activity. We
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performed two manoeuvres to maxi­
mize this separation. First, the 
gamma camera was carefully posi­
tioned in the left anterior oblique 
position with cranial angulation as 
necessary to minimize right atrial 
and right ventricular overlap. Sec­
ond, end-systolic and end-diastolic 
regions of interest were defined sep­
arately by computer and independ­
ent observers. Maddahi and col­
leagues3 have shown that measure­
ment of the RVEF by this technique 
correlates well with first-pass ra­
dionuclide cineangiography (r = 
0.95). In our hands the correlation 
coefficient between two observers 
(interobserver variation) for equilib­
rium RVEF was 0.91 and for repeat 
equilibrium studies (intraobserver 
variation) it was 0.98.
For a qualitative description of 
regional abnormalities in ventricular 
wall motion, the blood-pool ra­
dionuclide cineangiograms were 
routinely supplemented by regional 
EF images and were defined as 
abnormal if localized areas of hypo­
kinesia, akinesia or dyskinesia were 
observed.
Statistical Analysis
Associations between abnormal 
radionuclide angiograms and clini­
cal variables were assessed using 
Fisher’s exact test.
Findings
Eight of nine patients were men, 
with a median age of 30 years 
(range from 19 to 51 years). A 
single anterior thoracic stab wound 
was the source of injury in seven 
patients; the other two had multiple 
thoracic stab wounds (Table I). As­
sociated injuries were confined to 
the thorax in four patients, (hemo- 
pneumothorax or open chest 
wound), and one patient had a stab 
wound in the left flank with he-
moperitoneum. None of the patients 
had a history of significant pre- 
morbid cardiopulmonary disease.
Four patients underwent urgent 
thoracotomy and pericardiotomy in 
the emergency department for re­
lease of severely compromising peri­
cardial tamponade a median of 10 
minutes after admission (range from 
6 to 23 minutes). Of the patients 
who underwent thoracotomy in the 
emergency department, two pre­
sented with absent vital signs, and 
three remained in profound shock 
from tamponade despite aggressive 
cardiopulmonary resuscitation (en­
dotracheal intubation, intravenous 
volume loading). The other four 
patients maintained a systolic blood 
pressure of at least 80 mm Hg after 
aggressive volume resuscitation and 
underwent either median sternoto­
my or left lateral thoracotomy in 
the operating room, a median of 55 
minutes (range from 35 to 67 min­
utes) after admission. One patient 
underwent pericardiocentesis for re­
suscitation before thoracotomy.
All patients had hemopericardi- 
um. Five patients had isolated right 
ventricular lacerations, three had
isolated left ventricular lacerations 
and one had biventricular lacera­
tions with injury to the acute mar­
ginal branch of the right coronary 
artery, requiring ligation. Cardiac 
lacerations were repaired with inter­
rupted sutures, with or without 
Teflon pledgets. One patient with 
hemoperitoneum also underwent 
exploratory laparotomy, which re­
vealed a lacerated left hemidia- 
phragm without injury to an intra­
abdominal viscus.
Three of the patients experienced 
nonrecurrent perioperative dys­
rhythmias (Table II). Ventricular 
dysrhythmias occurred in two pa­
tients (intraoperative ventricular fi­
brillation and postoperative ventric­
ular tachycardia), and one patient 
experienced postoperative paroxys­
mal atrial tachycardia. Nonspecific 
ST segment changes developed in 
seven patients postoperatively. 
These changes returned to normal 
in four patients during hospitaliza­
tion (8 to 19 days).
Postoperative complications de­
veloped in six patients. Three pa­
tients suffered from pericarditis as 
determined by chest pain, pericardi-
T a b le 1. C lin ic a l F ea tu res o f N ine  S u rv iv o rs  o f  C a rd ia c  S ta b  W o u n d s
S y s to lic  B P T im e  to S ite  o f
P a t ie n t A g e . E x te rn a l on a d m is s io n , th o ra c o to m y , c a r d ia c
no. S e x y r w o u n d m m  H g m in in ju ry
1 M 3 2 R, L p a ra s te rn a l 50 3 5 , OR R V, L V  a cu te
ICS 6 m a rg in a l
a r te ry
2 M 19 L p a ra s te rn a l 0 6 , ER RV
ICS 7
3 M 2 9 L m id c la v ic u la r 60 10 , ER LV
ICS 6
4 M 3 0 L m id c la v ic u la r 80 6 5 , ER LV
ICS 2, 5
5 F 3 8 L m id c la v ic u la r 80 6 7 , OR* RV
ICS 6
6 M 21 S u b x ip h o id 60 6 5 , OR RV
7 M 2 2 L m id c la v ic u la r 0 8 , ER RV
ICS 5
8 M 51 L m id c la v ic u la r 50 4 5 , OR RV
ICS 5
9 M 2 6 L a n te r io r a x illa ry  lin e 130 2 3 , ER LV
ICS 6
‘ P receded  b y  p e r ic a rd io c e n te s is
ICS = in te rc o s ta l sp a ce , BP =  b lo o d  p re ss u re , OR =  o p e ra tin g  ro o m , ER =  e m e rg e n c y  ro o m , K V
=  r ig h t v e n tr ic le , LV =  le f t  ven tric le
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al friction rub and ST elevation on 
the electrocardiogram. One patient 
had postanoxic encephalopathy and 
paraplegia as a result of prolonged 
prehospital hemodynamic compro­
mise from pericardial tamponade, 
despite undergoing thoracotomy 
within minutes of arrival in the 
emergency department. Other com­
plications included pneumonia (one 
patient), pulmonary thromboembo­
lism (one patient) and dehisence of 
the abdominal incision (one pa­
tient).
Periods of hospitalization ranged 
from 4 days in one patient who left 
against medical advice, to 105 days 
in the patient with anoxic encepha­
lopathy (Table II). The median hos­
pitalization was 12 days.
At the time of discharge, none of
the patients had evidence of cardi­
opulmonary dysfunction detectable 
by either clinical examination or 
chest radiography.
Radionuclide Angiography
Radionuclide angiography was 
performed in all patients a median 
of 4 days after injury (range from 1 
to 13 days). At the time of the 
examination none of the patients 
had clinical evidence of left or right 
ventricular failure or dysrhythmia.
Decreased RVEF (< 0.45) was 
present at initial study in six pa­
tients (Table III), including two who 
had an isolated left ventricular (LV) 
laceration. One patient had right 
ventricular (RV) enlargement and 
hypokinesis in association with re­
Table II. D y s rh y th m ia s , C o m p lic a tio n s  and D ura tion  o f H o sp ita liz a tio n
Patient
no. Dysrhythmia
ST-T segment 
change
Peri­
carditis Complication
Hospital 
stay, d
1 V e n tr ic u la r
ta c h y c a rd ia
E le va tion Y es N one 12
2 None E le va tion No P ne u m o n ia 12
3 None E leva tion No N one 10
4 None F la tte n ing No N one 8
5 None N one No N one 4 *
6 P a ro x ys m a l
a tr ia l
ta c h y c a rd ia
E le va tion Yes N one 9
7 V e n tr icu la r
f ib r i l la t io n
E leva tion Y es C erebra l anox ia 105
8 None N one No A b d o m in a l w o u n d  
d e h isc e n ce
17
9 None E leva tion No P u lm o n a ry
e m b o lis m
19
'P a t ie n t  d ischarged  h im s e lf  a g a in s t m e d ica l advice .
Table III. F ind in g s  o f P o s to p e ra tive  R ad ionuc lide  A n g io g ra p h y *
Patient Postop day of Ventricular wall
no. study LVEF RVEF motion
1 4 0 .6 5 0 .35 N o rm a l
2 4 0 .7 6 0.51 N o rm a l
3 6 0 .6 9 0.37 N o rm a l
4 1 0 .7 5 0 .38 N o rm a l
60 0 .6 7 0 .45 N o rm a l
5 1 0 .5 7 0.42 N o rm a l
6 13 0 .5 5 0.33 N o rm a l
7 2 0 .6 2 0.45 N o rm a l
8 7 0 .5 3 0.37 RV e n la rg e d , h yp o k in e tic
2 2 5 0 .4 7 0.43 RV en la rged
9 2 0 .5 9 0 .45 N o rm a l
'P a t ie n ts  4  and 8 had fo llo w -u p  ra d io n u c lid e  a n g io g ra p h y  at 60  and 2 2 5  d a ys  re s p e c tiv e ly .
LVtr =
v e n tr ic le
le ft ve n tr icu la r e je c tio n  fra c tio n , RVEF =  r ig h t ve n tr icu la r e je c tio n  fra c tio n , RV =  rig h t
duced RVEF. Two patients who had 
reduced RVEF underwent follow-up 
radionuclide angiography, one at 2 
months and one at 7 months after 
injury. Both patients were asymp­
tomatic with unremarkable findings 
on physical examination, a normal 
chest radiograph and a normal elec­
trocardiogram at the time of the 
follow-up radionuclide angiography. 
Follow-up radionuclide angiography 
showed normal RVEF in one patient 
and near normal RVEF (= 0.43) in 
the other patient associated with 
persistent enlargement of the right 
ventricle. Initial studies showed that 
the LVEF was normal (> 0.50) in 
all patients.
Associations Between Radionuclide 
Angiography and Clinical Variables
Reduced RVEF occurred in iso­
lated LV lacerations as well as in 
RV lacerations. There was no asso­
ciation between reduced RVEF and 
age. There was a trend in the 
association between reduced RVEF 
after injury and time from admis­
sion to thoracotomy: only two of 
five patients who underwent thora­
cotomy within a median of 10 min­
utes of arrival in the emergency 
department had reduced RVEF, but 
all four patients who had thoracoto­
my or sternotomy in the operating 
room a median of 55 minutes after 
arrival had reduced RVEF (p < 
0.17). Dysrhythmias and pericardi­
tis occurred in the same patients, 
and occurred only in patients who 
had reduced RVEF. Dysrhythmias 
and pericarditis did not occur in 
patients who had a normal RVEF. 
LVEF was normal and independent 
of anatomic site of injury.
Discussion
The major finding of our study is 
that severe penetrating cardiac inju­
ry decreased the RVEF in the ma-
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jority of patients, but all patients 
had a normal LVEF. Second, de­
spite the decreased RVEF the clini­
cal outcome was excellent in that 
no patient had clinical symptoms of 
right heart failure or any other 
persistent complication of the cardi­
ac stab wound.
To our knowledge this is the first 
report of reduced RVEF after cardi­
ac stab wounds. In addition to de­
creased RVEF we report early se­
quelae of penetrating cardiac injury, 
including pericarditis and atrial and 
ventricular dysrhythmias similar to 
the findings of others.4-9 These 
complications were readily treated 
and did not cause major acute mor­
bidity. Others4-9 have reported more 
serious complications of penetrating 
cardiac injury, including valvular 
insufficiency, ventricular septal de­
fect, ventricular aneurysm and myo­
cardial infarction. None of these 
occurred in our small group of 
patients. We suggest that heart 
failure did not develop in our pa­
tients because there was no major 
structural injury to the heart.
Although reduced RVEF from 
penetrating cardiac wounds has not 
been documented previously, re­
duced RVEF from blunt cardiac 
injury is well documented and has a 
prevalence of 36% to 55%.10-15 As in 
our study of penetrating cardiac 
injury, the commonest abnormality 
on radionuclide angiography after 
blunt cardiac injury is reduced 
RVEF, with or without focal or 
global wall-motion abnormalities. 
Also similar to our study, there 
appears to be little correlation be­
tween reduced RVEF and clinical 
cardiopulmonary dysfunction in the 
majority of blunt cardiac trauma. 
Abnormalities in radionuclide angi­
ography resolved in the majority of 
patients who had blunt trauma 
within their period of hospitaliza­
tion so that at 1 year after injury 
there was little significant cardiac 
dysfunction after blunt traumatic
myocardial contusion.14 Therefore, 
although reduced RVEF is a com­
mon finding after cardiac injury, 
reduced RVEF is rarely associated 
with clinical evidence of cardiac 
failure in survivors of either pene­
trating or blunt traumatic cardiac 
injury.
The mechanism of decreased 
RVEF after penetrating cardiac in­
jury is not known and was not 
investigated in our study. There are 
at least three potential mechanisms 
of RV dysfunction. First, direct 
myocardial injury alone could re­
duce RVEF after penetrating cardi­
ac trauma. Second, RVEF could 
decrease because of increased RV 
afterload (increased RV afterload 
and increased pulmonary vascular 
resistance may occur after penetrat­
ing trauma because of concomitant 
pulmonary injury, hypoxia, acido­
sis, sepsis and pulmonary embo­
lism). Third, RV ischemia may 
occur first because of reduced coro­
nary perfusion pressure during 
shock and second because of in­
creased RV wall tension caused by 
increased RV afterload and volume 
following rapid intravenous fluid re­
suscitation. In our study only one 
patient had pulmonary arterial 
pressure monitoring at the time 
of radionuclide angiography. 
This patient had an increase in 
the pulmonary artery pressure 
(40/18 mm Hg) with a reduced 
RVEF. Patient no. 1 had a lacera­
tion of the right coronary artery, 
which was ligated at surgery. Oc­
clusion of the right coronary artery 
could have resulted in RV ischemia 
and decreased RVEF. We have no 
other direct evidence that increased 
RV afterload or RV ischemia con­
tributed to reduced RVEF in the 
other patients. Increased RV after­
load and RV ischemia have been 
postulated as mechanisms of re­
duced RVEF in other critically ill 
patients who had multiple traumatic 
injuries or sepsis.1516 In those
studies, nonsurvivors of trauma and 
sepsis had more marked decreases 
of RVEF (mean RVEF 0.18) than 
did the survivors of severe penetrat­
ing cardiac injury in our study 
(initial mean RVEF 0.40).
We did not routinely assess pa­
tients after hospital discharge. Two 
patients who had decreased RVEFs 
were selected for later assessment, 
one patient at 2 months and one 
patient at 7 months after injury. 
Both patients had normal clinical 
cardiac findings at that time, and 
both had recovery of the decreased 
RVEF.
In summary, survivors of cardiac 
stab wounds had reduced RVEFs, 
but LVEFs remained normal. How­
ever, the magnitude of reduction in 
the RVEF was small and was not 
associated with clinically apparent 
cardiac dysfunction. We suggest 
that isolated cardiac stabbings with­
out major cardiac structural injury 
do not cause right or left heart 
failure or clinically significant ven­
tricular dysfunction.
We thank the nuclear medicine tech­
nologists at St Paul’s Hospital, Vancou­
ver, for their assistance and cooperation 
in performing the nuclear angiography 
in these patients.
References
1. P avel DG, S immer AM, P atterson VN: 
In vivo labelling of red blood cells with 
99mTc: a new approach to blood pool 
visualization. J Nucl Med 1977; 18: 
305-308
2. Russell JA, Ronco JJ, Lockhat D et al; 
Oxygen delivery and consumption and 
ventricular preload are greater in survi­
vors than in nonsurvivors of the adult 
respiratory distress syndrome. Am Rev 
Respir Dis 1990; 141: 659-665
3. Maddahi J, Berman DS, Matsuoka DT 
et al: A new technique for assessing 
right ventricular ejection fraction using 
rapid multiple gated equilibrium cardiac 
blood pool scintigraphy. Circulation 
1979; 60: 581-589
4. Symbas PN, Diorio DA, Tyras DH et al: 
Penetrating cardiac wounds. Significant
CJS, VOL. 36, NO. 5, OCTOBER 1993 429
SKARSGARD ET AL
residual and delayed sequelae. J Thorac 
Cardiovasc Surg 1973; 66: 526-532
5. S ingh R, Nolan SP, S chrank JP: Trau­
matic left ventricular aneurysm. Two 
cases with normal coronary angiograms. 
JAMA 1975; 234: 412-414
6. Heller RF, Rahimtoola SH. Ehsani A 
et al: Cardiac complications. Results of 
penetrating chest wounds involving the 
heart. Arch Intern Med 1974; 134: 
491-496
7. Gelfand ML, Maynard AD, Cordice 
JWV et al: Follow-up electrocardio­
graphic changes in penetrating wounds 
of the heart treated surgically. Angiolo- 
gy 1957; 8: 272-276
8. Abbott JA, Cousineau M, Cheitlin M et 
al: Late sequelae of penetrating cardiac 
wounds. J Thorac Cardiovasc Surg
BOOK REVIEWS
continued from page 421
lar surgeons, cardiologists and interven­
tional radiologists who dedicate them­
selves to endovascular therapy. Such a 
unit, to the best of my knowledge, has 
no counterpart in any academic centre 
in Canada.
The editors state that their book is 
designed as an “integrated, comprehen­
sive, up-to-date textbook covering all 
aspects of this rapidly developing, ever- 
expanding and exciting new field of 
endovascular surgery.” Indeed, it pro­
vides a detailed overview of the scope of 
modern noncardiac vascular interven­
tion as practised in a well-funded and 
research-oriented academic centre in 
the United States. This should certainly 
be of interest to my surgery and radiol­
ogy colleagues in our clinically over­
loaded and woefully underfunded Cana­
dian institutions.
The list of contributing authors is 
extensive and includes staff and resi­
dents from several departments of sur­
gery, radiology, medicine and engineer­
ing as well as nonmedical experts from 
the private sector. In fact, this wide 
range of contributors allows each chap­
ter to stand on its own, but this results 
in some loss of coherence in the text.
After a short introductory section 
dealing with the organization, goals and
1978; 75: 510-518
9. Demetriades D: Cardiac wounds. Expe­
rience with 70 patients. Ann Surg 1986; 
203:315-317
10. S utherland GR, Driedger AA, Holliday 
RL et al: Frequency of myocardial injury 
after blunt chest trauma as evaluated by 
radionuclide angiography. Am J Cardiol 
1983; 52: 1099-1103
11. Rosenbaum RC, J ohnston GS: Post- 
traumatic cardiac dysfunction: assess­
ment with radionuclide angiography. 
Radiology 1986; 160: 91-94
12. Rothstein RI, French RS, Mena I et al: 
Myocardial contusion diagnosed by first- 
pass radionuclide angiography. Am J 
Emerg Med 1986; 4: 210-213
13. S champ DJ, Plotnick GD, Croteau BA 
et al: Clinical significance of radionu-
standards of the endovascular team, a 
long section dealing with angioscopy 
and intravascular ultrasonography fol­
lows. As neither of these techniques is 
yet of established clinical value, and as 
neither is routinely used in Canada, this 
particular section is only of academic 
interest and reference value.
The third section deals with balloon 
angioplasty. After a historical review 
and a basic consideration of equipment 
required, there are chapters on aor- 
toiliac, femoropopliteal, renal and mes­
enteric angioplasty. Honest comparison 
with surgical alternatives ensues. One 
benefit of the multidisciplinary ap­
proach may be a more honest and open 
comparison of competing procedures.
The fourth and fifth sections deal 
with mechanical atherectomy and laser- 
assisted angioplasty and, again, are of 
less practical import in the current 
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stents and venacaval filters. I would 
have favoured a more extensive discus­
sion of all of these topics.
A final section deals with the histo­
logic, morphologic and physiologic re­
sponses to many of the previously de­
scribed interventions. It offers a refresh­
ing and interesting perspective.
This is an attractive tome, full of 
useful radiographs and diagrams as well 
as photographs of equipment and speci­
mens. The layout is appealing and al­
lows for easy reading. I have no hesita­
tion in recommending it as a reference 
text to my academic surgery colleagues. 
It provides a timely overview of the 
wide range of endovascular therapies, 
many unproven, available today in large 
US centres.
Andrew A. Common, MD, CM, FRCPC
Head, Division of Vascular Radiology 
University of Toronto.
Director, Angiography 
and Interventional Radiology 
St. Michael's Hospital 
30 Bond St.
Toronto, ON 
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Recycling of Cardiopulmonary Bypass 
Cannulae: a Risk-Benefit Analysis
Richard J. Novick, MD, MSc, FRCSC, FACS
Objective: To determine whether recycling of arterial and venous cannulae for cardiopulmonary bypass 
is associated with an increased risk of infectious complications after open heart surgery.
Design: A prospective, risk-benefit analysis.
Setting: A university teaching hospital.
Patients: Five hundred and forty patients underwent a variety of non-transplant cardiac operations, 
which were performed by one surgeon between October 1988 and July 1993.
Interventions: Standard techniques of open heart surgery were used. Ascending aortic and vena caval 
cannulae and the multiple perfusion device for administering cardioplegia down saphenous vein bypass 
grafts were reused an average of 10 to 15 times after sterilization with ethylene oxide after each use. 
Main Outcome Measures: The postoperative morbidity and mortality and the estimated savings 
achieved by recycling the cannulae.
Results: The operative mortality (total in hospital plus within 30 days of operation) was 2.8% (15 
patients). There were no cases of endocarditis; there was only one case of superficial presternal 
infection and one case of mediastinitis. Gram-negative organisms were cultured from the blood of two 
patients and gram-positive organisms from the blood of one patient. Only one patient died of an 
infectious complication. The estimated cost saving during the study period was more than $50 000. 
Conclusions: The risk of wound and hematogenous infection after open heart surgery in which recycled 
cannulae are used is less than 1%. This rate is lower than that quoted in most recent reports. Reuse of 
heart-lung bypass cannulae may realize substantial cost savings without detriment to the patient.
Objectif: Determiner si le recyclage des canules arterielles et veineuses utilisees pour la circulation 
extracorporelle est relie a une augmentation du risque infectieux lors d’une operation a coeur ouvert. 
Conception : Une analyse couts-benefices prospective.
Contexte : Un hopital universitaire.
Patients : Cinq cent quarante patients qui ont subi diverses operations cardiaques (autres que des 
greffes) pratiquees par un chirurgien entre octobre 1988 et juillet 1993.
Interventions : Les techniques standards de chirurgie a coeur ouvert on ete utilisees. Les canules de 
l’aorte ascendante et de la veine cave, ainsi que les multiples instruments de perfusion utilises pour 
administrer la solution de la cardioplegie dans les greffons de saphene ont ete reutilises, de 10 a 15 
fois en moyenne, apres sterilisation a l’oxyde d’ethylene entre chaque usage.
Principaux effets mesures : La morbidity postoperatoire et la mortality, de meme que l’estimation des 
economies resultant du recyclage des canules.
Resultats : La mortalite operatoire (totale hospitaliere plus dans les 30 jours suivant l’intervention) fut 
de 2,8 % (15 patients). II n’y a eu aucun cas d’endocardite et seulement un cas d’infection presternale 
superficielle, et un cas de mediastinite. Des bacteries Gram negatif ont ete cultivees a partir du sang de 
deux patients et des organismes gram-positif a partir du sang d’un patient. Un seul patient est decede 
d’une complication infectieuse. Les economies realisees pendant la periode de l’etude sont estimees a 
plus de 50 000 $.
Conclusions : Le risque d’infection de plaie ou d’infection hematogene apres une chirurgie a coeur 
ouvert oil on utilise des canules recyclees est de moins de 1%. Ce taux est inferieur a ceux qui ont ete 
signales dans les publications les plus recentes. La reutilisation des canules de circulation 
extracorporelle peut permettre des economies substantielles, sans nuire au bien-etre des patients.
From the Division o f  Cardiovascular-Thoracic Surgery, University Hospital, London, Ont.
Accepted for publication Feb. 16, 1993
Reprint requests to: Dr. Richard J. Novick, Division o f  Cardiovascular-Thoracic Surgery, University Hospital, PO Box 5339, London, ON N6A 5A5
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Quality assurance and cost effec­tiveness have become increas­
ingly important concepts in health 
care practice and research.1' 4 In 
Canada, the recent failure of hospi­
tal budgets to increase beyond the 
rate of inflation has made cost 
reductions in many surgical sub­
specialities, including cardiac sur­
gery, mandatory. At University Hos­
pital, in London, Ont., recycling of 
cardiopulmonary bypass (CPB) can- 
nulae has been used as a method of 
cost saving for many years. A pro­
spective cost-benefit analysis of this 
practice was therefore undertaken 
to determine the risk of infection 
and the cost reduction that may be 
achieved by recycling these can- 
nulae.
Patients and Methods
From October 1988 to July 
1993, 599 patients underwent oper­
ations that required median ster­
notomy and CPB. All procedures 
were performed by a single surgeon 
at University Hospital. Fifty-nine of 
the operations were heart or heart- 
lung transplant procedures; these 
patients were excluded from the 
study because recycled cannulae 
were not used. Of the remaining 
540 patients, 446 underwent first­
time or repeat coronary artery by­
pass procedures, 51 underwent iso­
lated valve repair or replacement 
operations, 24 underwent combined 
coronary artery bypass grafting and 
valve replacement and 19 had mis­
cellaneous procedures (resection of 
cardiac tumours and repair of ven­
tricular septal defect, atrial septal 
defect, ascending aortic aneurysms 
and dissections). All patients were 
included regardless of their preoper­
ative clinical and hemodynamic sta­
tus.
Most patients received cefazolin, 
1 g intravenously, before the induc­
tion of anesthesia. If they were
allergic to penicillin, vancomycin, 
1 g intravenously, was given. The 
skin was prepared with povidone- 
iodine solution, and disposable 
drapes and a Vi-drape (3M Corp., 
St. Paul, Minn.) were used. Median 
sternotomy was performed, and the 
patients were placed on CPB, with a 
no. 21 French Argyle THI aortic 
perfusion cannula (Argyle Inc., St. 
Louis, Mo.) in the ascending aorta 
and no. 30 and no. 32 French Bard 
vena caval cannulae (Bard Corp., 
Tewksbury, Mass.) inserted through 
two separate right atriotomies. Car- 
dioplegic arrest was achieved with 
cold blood cardioplegic solution ad­
ministered into the aortic root and 
then sequentially into the vein 
grafts by means of the DLP 14 000 
multiple perfusion set (DLP Inc., 
Grand Rapids, Mich.). In most cases 
of coronary artery bypass grafting, 
a combination of left internal tho­
racic artery and saphenous vein 
grafts was used, although in pa­
tients under 55 years of age, both 
internal thoracic arteries were rou­
tinely employed. At the conclusion 
of the procedure, the wound was 
irrigated with 1 litre of warm sterile 
saline, and the sternal edges were 
reapproximated with nine 22-gauge 
no. 4 surgical wires. The fascia was 
closed with running 0-Ticron su­
tures, the subcutaneous tissues 
with 2-0 Vicryl sutures and the skin 
edges with running 4-0 Dexon su­
tures. Postoperative antibiotic ther­
apy consisted, in most cases, of 
cefazolin 1 g intravenously every 8 
hours for the first 48 hours. The 
mediastinal and pleural tubes were 
removed on the 2nd postoperative 
day, and antibiotic therapy was then 
discontinued.
Four types of infectious compli­
cations were defined and prospec­
tively evaluated.5
•  Superficial presternai infection 
— defined as drainage of purulent 
material from the midline incision 
or sternal wound cellulitis with or
without cultures positive for bacte­
ria.
•  Mediastinitis — defined as a 
purulent collection in the retroster­
nal tissues, with sternal dehiscence 
or instability and cultures from the 
wound that were positive for bacte­
ria.
•  Endocarditis — defined as a 
proven bloodstream infection in 
which there was clinical, echocardi- 
ographic, operative or autopsy evi­
dence of cardiac infection.
•  Septicemia — defined as two 
or more blood cultures that gave 
positive results for bacteria associ­
ated with systemic signs of infec­
tion but without intracardiac local­
ization.
Operative mortality included all 
deaths occurring during the hospi­
talization in which the operation 
was performed and all deaths occur­
ring after hospitalization but within 
30 days of the procedure.6 All pa­
tients were examined daily while in 
hospital and 4 weeks after dis­
charge. In addition, patients were 
re-evaluated clinically by the author 
at any time after discharge if the 
family doctor, cardiologist or visit­
ing nurse suspected that there was 
a wound infection.
After each operation the arterial 
and venous cannulae and the multi­
ple perfusion set were rinsed free of 
blood and placed in a washer-steril­
izer at 140°C for 30 minutes. The 
cannulae and perfusion set were 
then checked for any breaks or 
defects, wrapped in double peel- 
back bags, and sterilized in ethylene 
oxide for 3 hours. They underwent 
12 hours of aeration under sterile 
conditions before subsequent clini­
cal use. The cannulae and perfusion 
set were recycled an average of 10 
to 15 times. Cost savings were 
assessed taking the retail cost of 
the equipment as of July 1993 and 
assuming that each cannula and 
perfusion set was discarded after 10 
uses.
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Results
Operative mortality was 2.8% (15 
patients). Twelve patients died of 
low cardiac output postoperatively, 
and two patients died of periopera­
tive hemorrhage. Only one postop­
erative death was associated with 
infection. A 67-year-old woman 
with evolving renal and cardiac fail­
ure required mechanical ventilation 
and inotropic support preoperative- 
ly. She underwent emergency coro­
nary artery bypass grafting, but this 
did not improve her hemodynamic 
status, and she died of continued 
multiorgan failure and gram-nega­
tive sepsis 3 weeks postoperatively.
Clinical follow-up was complete. 
No infectious complications oc­
curred beyond 3 months postopera­
tively. One patient had a superficial 
sternal wound cellulitis without 
sternal dehiscence 2 weeks after 
discharge, but culture of the wound 
did not grow any organisms and the 
infection resolved after a 10-day 
course of antibiotics. The only 
other wound complication occurred 
in a 42-year-old obese diabetic 
woman with a long history of bron­
chitis, who had previously under­
gone saphenous vein strippings bi­
laterally. She underwent triple coro­
nary artery bypass grafting with 
both internal thoracic arteries. Ster­
nal dehiscence and mediastinitis de­
veloped, and tissue culture grew 
Staphylococcus aureus. Debride­
ment followed by sternal reclosure 
over irrigating catheters was per­
formed on the 11th postoperative 
day. Her mediastinum was irrigated 
with sterile saline for 4 weeks post­
operatively, and she received van­
comycin 1 g intravenously every 12 
hours for 6 weeks, with satisfactory 
sternal healing and no evidence of 
recurrent infection after 4 years of 
follow-up.
Three other patients (0.5%) had 
fever early postoperatively in associ­
ation with blood cultures that were
positive for gram-negative (two pa­
tients) or gram-positive (one pa­
tient) organisms. In all three cases 
the source of the offending organ­
ism was not identified. With remov­
al of central venous and urinary 
catheters and appropriate intrave­
nous antibiotic therapy, the infec­
tions resolved. There were no cases 
of endocarditis in the 75 patients 
who underwent valve repair, valve 
replacement or combined coronary 
artery bypass grafting and valve 
surgery.
Cost analysis revealed that the 
Argyle THI aortic perfusion cannula 
costs $18.00 and the no. 30 and 
no. 32 French Bard vena caval can- 
nulae cost $32.50 each. The DLP 
multiple perfusion set costs $21.40. 
If these cannulae were not recycled, 
the total cost in the 540 patients 
would have been $56 376. Since 
the cannulae were reused at least 
10 times, the cost of the three items 
during the 58 months of the study 
was, at most, $5638. There have 
been no increases in the number of 
full-time or part-time equivalent po­
sitions in the department that was 
in charge of cannula recycling, be­
fore or during the course of this 
study, and labour costs have not 
increased because of the practice of 
cannula recycling. The total cost 
saving was therefore $50 738 in the 
540 patients in this study.
Discussion
With increasing economic con­
straints on the practice of subspe­
cialty surgery in Canada has come 
an increasing emphasis on quality 
control and cost effectiveness.1-4 
Even a cursory analysis of cost 
shows the considerable economic 
impact of nosocomial infection.7 
Sternal wound infection as a com­
plication of coronary artery bypass 
grafting is associated with a more 
than twofold increase in the average
hospital stay,8 and an almost three­
fold increase in the median hospital 
charge.9 Efforts at cost containment 
should therefore rank well behind 
attempts to reduce infectious com­
plications following open heart op­
erations, unless it can be demon­
strated that cost-containment pro­
cedures do not adversely affect the 
rate of perioperative infection.
This study presents a prospective 
analysis of the risk of infection after 
cardiac surgery in nonimmunosup- 
pressed patients in whom recycled 
cannulae were routinely used dur­
ing CPB. I am unaware of any other 
report in the cardiac surgical litera­
ture that has focused on this issue. 
In this study there was less than a 
0.4% incidence of superficial or 
deep sternal wound infection, and a 
less than 1% incidence of combined 
wound and hematogenous infection. 
The risk of sternal wound infections 
in recent reports has ranged from 
1.1% to 3.4%,8-18 and the incidence 
of septicemia after open heart sur­
gery has ranged from 1.3%12 to 
3.2%.14 Clearly, the recycling of 
CPB cannulae after sterilization 
with ethylene oxide was not associ­
ated with an increased risk of 
wound or hematogenous infection 
in this study.
The only case of serious sternal 
wound infection in this series oc­
curred in a young diabetic patient 
with chronic bronchitis who re­
ceived bilateral internal thoracic ar­
tery grafts. The use of bilateral 
internal thoracic artery bypass 
grafts in diabetic patients has been 
shown to increase significantly the 
risk of sternal wound, whereas the 
use of one internal thoracic artery 
has not resulted in an increase in 
this. It would therefore seem pru­
dent to avoid bilateral internal tho­
racic artery grafting in diabetics, 
especially in the presence of addi­
tional risk factors such as chronic 
obstructive pulmonary disease and 
obesity.
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The recycling of GPB cannulae 
and multiple perfusion sets can re­
sult in substantial cost savings, es­
pecially if several surgeons in the 
same institution partake in this 
practice. There is a precedent in 
Canada for the reuse of permanent 
cardiac pacemakers19 and for the 
recycling of homograft aortic valves 
from heart transplant patients.20 In 
these times of fiscal constraint, all 
efforts to generate cost savings by 
means o f equipment or device recy­
cling should be encouraged as long 
as they do not adversely affect 
patient outcome.
I thank Heather Motloch for her assis­
tance in manuscript preparation and Dr. 
Neil McKenzie for his constructive re­
view of the paper.
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SESAP VII Question /  Question SESAP VII
Item 256
A 58-year-old man with cholelithiasis and symptoms of intermittent mild biliary colic is admitted to the hospital 
for an operation. He has had three syncopal episodes in the last several months, progressive shortness of breath, 
and occasional chest pain with exertion. He has a grade 2 / 6  murmur in the left third intercostal space.
This clinical evidence suggests
(A) mitral valve prolapse
(B) prior myocardial infarction and ventricular aneurysm
(C) mitral stenosis, atrial fibrillation, and small recurrent cerebral emboli
(D) significant aortic stenosis
(E) carotid artery disease and coronary artery disease 
For the five completions given above select the one that is best.
For the critique of Item 256 see page 482.
(Reproduced by permission from SESAP ’9 2 -’93 Syllabus; Surgical Education and Self-Assessment Program 
No. 7. For enrolment in the Surgical Education and Self-Assessment No. 7, please apply to the American College 
of Surgeons, 55 E Erie St., Chicago, IL 60611.)
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Myocardial and Circulatory Performance 
During the Ischemic Phase of Superior 
Mesenteric Artery Occlusion
William G. Jamieson, MD, FRCSC; Gaetano DeRose, MD, FRCSC; Kenneth A. Harris, MD, FRCSC;
George Pliagus, MD, FRCSC; Lou Stafford
Objective: To investigate myocardial and circulatory parameters during the acute ischemic phase of 
mesenteric artery occlusion.
Design: A prospective, randomized, control trial.
Subjects: Twelve, adult, mongrel dogs.
Interventions: In seven dogs the superior mesenteric artery was occluded with two silk ligatures 
(experimental group). In five dogs the ligatures were not tied (control group). Measurements were 
made during 7 hours of occlusion.
Main Outcome Measures: Myocardial performance and circulatory performance.
Results: There were significant (p < 0.05) reductions in arterial blood pressure, mean pulmonary 
artery pressure, diastolic pulmonary artery pressure and cardiac index in dogs exposed to intestinal 
ischemia compared with the control dogs. No differences were identified in ventricular performance, 
stroke volume index or peripheral vascular resistance index.
Conclusions: Early cardiac and central circulatory changes in massive intestinal ischemia are due to 
intravascular hypovolemia. Sepsis and myocardial depressant factors were not found to be a cause of 
death.
Objectif: Mesurer les parametres myocardiques et circulatoires durant la phase d’ischemie aigue d’une 
occlusion de l’artere mesenterique.
Conception : Un essai prospectif, controle et randomise.
Sujets : Douze chiens batards, adultes.
Interventions : Chez sept chiens, une occlusion de l’artere mesenterique superieure a ete provoquee 
par deux ligatures a l’aide de fil de soie (groupe experimental). Chez cinq chiens, les ligatures n’ont 
pas ete nouees (groupe temoin). Des mesures ont ete faites pendant une occlusion de 7 heures. 
Principaux effets mesures: Les performances myocardiques et circulatoires.
Res u I tats : On a note par rapport aux chiens temoins, une diminution significative (p < 0,05) de la 
tension arterielle, de la pression arterielle pulmonaire moyenne, de la pression arterielle pulmonaire 
diastolique et de l’index cardiaque chez les chiens soumis a une ischemie intestinale. Aucune difference 
n’a ete enregistree quant a la performance ventriculaire, a l’index de debit systolique ou a l’index de 
resistance vasculaire peripherique.
Conclusions : Lors d’une ischemie intestinale massive, les changements immediats des parametres 
cardiaques et circulatoires centraux sont dus a une hypovolemie intravasculaire. Les sepsies et les 
facteurs de depression myocardique ne paraissent pas avoir cause de mortalite.
From the Division o f  Vascular Surgery, Victoria Hospital and the University o f Western Ontario, London, Ont.
Supported in part by grant 90-35 from the Physicians ’ Services Incorporated Foundation 
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I ntestinal ischemia continues to carry a high death rate despite 
new diagnostic modalities and im­
proved surgical techniques. Patients 
in the early phases of intestinal 
ischemia present a diagnostic chal­
lenge because gross physical find­
ings are lacking until bowel infarc­
tion is established. Even those who 
undergo successful revasculariza­
tion have a high death rate. The 
underlying events leading to death 
in intestinal ischemia require fur­
ther elucidation to permit more ef­
fective treatment.
Any ischemic insult may be divid­
ed into three phases: the ischemic 
phase, the early reperfusion phase 
and the late reperfusion phase. In 
many studies the first two phases 
are not separated.
The hemodynamic consequences 
of superior mesenteric artery occlu­
sion have been attributed to in­
travascular fluid loss, circulating 
myocardial depressant factor and 
sepsis. To further understand the 
continued high mortality of intesti­
nal ischemia, the pathophysiology 
of the hemodynamic derangements 
must be determined and the stage 
at which these changes occur clari­
fied precisely. This knowledge 
would permit more specific direc­
tion of therapy in the perioperative 
period. In this study we examined 
the hemodynamic events and conse­
quences of an intestinal ischemic 
insult that results in a death rate of 
90% in our model. Only the isch­
emic phase was studied.
Materials and Methods
Twelve, adult, mongrel dogs were 
randomly assigned to a control (five 
dogs) or an experimental (seven 
dogs) group. Anesthesia was in­
duced with thiopental sodium (12.5 
mg/kg), and the dogs were intubat­
ed and ventilated. Anesthesia was 
maintained with a mixture of halo-
thane (1.0% to 2.5%) and oxygen 
(6 L/min ). A femoral arterial line 
was inserted, and a Swan-Ganz 
catheter was positioned in the pul­
monary artery for cardiac output 
measurements. Continuous record 
was kept of systemic blood pressure 
measurements, pulmonary artery 
pressure measurements and heart 
rate. Ringer’s lactate solution was 
administered at an hourly rate of 
8 mL/kg.
Our animal model of intestinal 
ischemia has been described previ­
ously.1 Briefly, the superior mesen­
teric artery was exposed at its ori­
gin from the aorta through a mid­
line abdominal incision. Two large 
silk ligatures were used to encircle 
the superior mesenteric artery. In 
the control animals these were left 
loosely around the artery, and the 
abdomen was closed. In the experi­
mental group both ligatures were 
tied before closure of the abdomen. 
Measurements were made for 7 
hours after operation. Animal care 
was in accordance with the princi­
ples of laboratory animal care,2 and 
the protocol was approved by the 
University of Western Ontario Ani­
mal Ethics Committee.
Measurements
Baseline measurements included:
length, weight, heart rate (HR), 
blood pressures (systolic, diastolic 
and mean [SBP, DBP and MBP]), 
pulmonary artery pressures (systol­
ic, diastolic and mean [SPAP, DPAP 
and MPAP]), pulmonary capillary 
wedge pressure (PCWP), central ve­
nous pressure (CVP) and cardiac 
output (CO). The body surface area 
(BSA) was calculated by means of a 
standard nomogram.3 All hemody­
namic measurements were made at 
2, 4, 6 and 7 hours after the 
baseline measurements. Left ven­
tricular ejection fractions (LVEFs) 
were obtained in a modified left 
anterior oblique projection in two 
dogs in the control group and in 
five dogs in the study group, with 
electrocardiographic-gated equilibri­
um blood pool scintigraphy (tech- 
netium-99m-tagged red blood cells). 
The measured hemodynamic varia­
bles were used to calculate the 
following physiologic parameters: 
cardiac index (Cl), stroke volume 
index (SVI), peripheral vascular re­
sistance index (PVRI), left ventricu­
lar end-diastolic volume index 
(LVEDVI), left ventricular end-sys­
tolic volume index (LVESVI), myo­
cardial performance (MP), systolic 
function (SF), diastolic compliance 
(DC) and, finally, left ventricular 
stroke work index (LVSWI) (Ta­
ble I).
Table I. Calculated Variables in an Animal Model of Intestinal Ischemia 
Parameter Formula
Cardiac index
Stroke volume index
Peripheral vascular resistance index
Left ventricular end-diastolic volume 
index
Left ventricular end-systolic volume index
Myocardial performance
Systolic function
Diastolic compliance
Left ventricular stroke work index
Cardiac output (L/m in) body surface area (m2) 
Stroke volume (mL) +  body surface area (m2)
Mean pulmonary artery pressure (mm Hg) -  
pulmonary capillary wedge pressure (mm Hg) x 
79.9 cardiac index (L/m in-nr2)
Stroke volume index (m L/m 2) left ventricular 
ejection fraction (%)
Left ventricular end-diastolic volume index (mL/m2) 
-  stroke volume index 
Cardiac index (m L/m in-nr2) ^  left ventricular 
end-diastolic volume index (mL/m2)
Systolic blood pressure (mm Hg) ^  left ventricular 
end-diastolic volume index (mL/m2)
Pulmonary capillary wedge pressure (mm Hg) -  left 
ventricular end-diastolic volume index (mL/m2) 
Stroke volume index (m L/m 2) x mean arterial 
pressure (mm Hg) x 0.0136
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Statistical Analysis
Analysis was carried out to en­
sure that there was no statistical 
difference between the two study 
groups at baseline. Student’s f-test 
and the Mann-Whitney U statistic 
were calculated to examine poten­
tial differences between groups on 
all measured baseline variables. To 
permit the use of an internal con­
trol, the relative difference for each 
hemodynamic variable was calculat­
ed by determining the difference 
between the 7-hour value and the 
baseline value divided by the base­
line value. Student’s f-test was used 
to detect statistical differences in 
the mean change of all variables 
except for LVEFs. Mann-Whitney 
U statistics were calculated for the 
LVEFs. Statistical significance was 
assumed for a p value of less than 
0.05.
Results
The measured and calculated 
baseline variables were not signifi­
cantly different between the control 
and experimental groups of dogs
Table II. Comparison of Myocardial Performance Between Dogs With Induced Intestinal Ischemia
(Study Group) and Dogs Without Intestinal Ischemia (Control Group) (Mean ± Standard Deviation)
Variable
Study group (n =  7) Control group (n =  5)
Baseline 7 h Baseline 7 h
Heart rate, beats/min 106 ± 8 114 ± 8 97 ± 8 115 ± 11
SBP, mm Hg 115 ± 25 95 ± 23 97 ± 16 124 ± 33
DBP, mm Hg 74 ± 16 66 ± 16 62 11 79 ±  19
MBP, mm Hg 89 16 77 ± 20 74 =fc 12 95 ± 24
SPAP, mm Hg 11.3 ± 3.6 10.3 ±  4.2 11.4 ± 6.4 14.2 ± 4.3
DPAP, mm Hg 4.0 ± 1.4 2.3 ± 2.0 3.8 2.3 6.0 ± 2.6
MPAP, mm Hg 7.0 2.3 5.6 ± 2.8 6.6 ± 3.4 9.4 ± 2.7
PCWP, mm Hg 2.1 ± 1.8 0.4 ± 1.7 2.0 ± 1.6 2.6 ± 2.7
Cl, L/min 3.54 rfc 0.79 2.14 ± 0.64 3.14 ± 0.71 3.12 ± 0.98
SVI, L/min • rrr2 33.5 ± 9.8 20.4 ± 7.3 33.2 ± 8.6 27.2 ± 7.0
PVRI, dyn/s • cm5 114 ± 38 237 ± 112 116 ± 44 191 ± 90
SBP =  systolic arterial blood pressure, DBP =  diastolic arterial blood pressure, MBP =  mean 
arterial blood pressure, SPAP =  systolic pulmonary artery pressure, DPAP =  diastolic pulmonary 
artery pressure, MPAP =  mean pulmonary artery pressure, PCWP =  pulmonary capillary wedge 
pressure, Cl =  cardiac index, SVI =  stroke volume index, PVRI =  peripheral vascular resistance 
index
Table III. Comparison of Relative Change in Myocardial Performance*
Variable
Study group 
(/r =  7)
Control group 
( n =  5) /rvalue
Heart rate, beats/min 0.08 ± 0.08 0.19 ± 0.14 0.092
SBP, mm Hg -0 .1 7  ± 0.15 0.30 ± 0.33 0.008t
DBP, mm Hg -0 .1 0  ± 0.17 0.31 ± 0.38 0.031 +
MBP, mm Hg -0 .1 3  ± 0.15 0.30 ± 0.35 0.016+
SPAP, mm Hg -0 .0 3  ± 0.39 0.55 ± 0.82 0.132
DPAP, mm Hg -0 .2 5  ± 0.69 0.95 ± 1.02 0.035+
MPAP, mm Hg -0 .1 2  ± 0.47 0.69 ± 0.65 0.030+
PCWP, mm Hg -1 .1 3  ± 0.77 0.48 ± 1.16 0.029+
Cl, L/min -0 .3 5  ±  0.19 0.02 ± 0.32 0.029+
SVI, mL/min • n r2 -0 .3 9  ± 0.19 -0 .1 5  ± 0.20 0.070
PVRI, dyn/s • cm5 1.19 ± 1.00 1.03 ± 1.48 0.828
'Relative change =  (value at 7 h -  baseline) 4- baseline 
tSignificant
SBP =  systolic arterial blood pressure, DBP =  diastolic arterial blood pressure, MBP =  mean 
arterial blood pressure, SPAP =  systolic pulmonary artery pressure, DPAP =  diastolic pulmonary 
artery pressure, MPAP =  mean pulmonary artery pressure, PCWP =  pulmonary capillary wedge 
pressure, Cl =  cardiac index, SVI =  stroke volume index, PVRI =  peripheral vascular resistance 
index
(Table II). The results of the mea­
surements taken at 7 hours after 
SMA occlusion are shown in Tables 
II and III. There was a significantly 
greater reduction in all components 
of systemic blood pressure in the 
experimental animals when com­
pared with those of the control 
group. Also DPAP and MPAP were 
significantly reduced in the experi­
mental group. Cardiac index was 
significantly reduced. No significant 
differences were detected in CVP 
and LVSWI. Measurements derived 
from the cardiac scintigraphy (Ta­
ble I), including LVEF, LVEDVI, 
LVESVI, MP, DC and SF, demon­
strated no difference in contractility 
between the two groups. The cardi­
ac index was reduced more in the 
experimental group than in the con­
trol group with no significant differ­
ence in the SVI or PVRI. This 
suggests that sepsis was not a 
factor in this model.
Discussion
SMA occlusion with ensuing in­
testinal gangrene is incompatible 
with life. Death rates for this condi­
tion have remained constant, pri­
marily due to delay in diagnosis. 
Patients who present soon after 
SMA occlusion with reversible in­
testinal ischemia have a paucity of 
signs and symptoms, further delay­
ing diagnosis. With knowledge of 
the underlying pathophysiology, re­
suscitation and appropriate treat­
ment can be instituted to reduce 
mortality. The focus of this study 
was the continuous ischemic phase 
only, without interference of the 
events of reperfusion. A review of 
the literature regarding the actual 
physiologic derangements during 
this early ischemic phase was incon­
clusive. The hypotheses for the 
early circulatory derangements in 
acute mesenteric ischemia are fluid 
loss,4-7 sepsis,8-13 or the presence of
CJS, VOL. 36, NO. 5, OCTOBER 1993 437
JAMIESON ET AL
a circulating myocardial depressant 
factor.14-18
Myocardial performance can sim­
ply be divided into preload, heart 
rate, contractility and afterload. We 
assessed these factors in an animal 
model of acute mesenteric ischemia 
to increase our understanding of 
the underlying pathophysiologic 
changes. We used 7 hours of acute 
ischemia because previous work4 
had demonstrated a 90% mortality 
even after reperfusion.
Systemic arterial pressures and 
pulmonary diastolic pressures as 
well as PCWP and Cl were de­
pressed after 7 hours of intestinal 
ischemia, but significantly more so 
in the study dogs than in the con­
trol dogs. The HR of the animals 
remained constant. The remaining 
hemodynamic parameters showed 
no change throughout the experi­
ment. The indicators of myocardial 
contractility, including LVEF, 
LVESVI and LVEDVI, in the experi­
mental group showed no difference 
when compared with the control 
group. There was no evidence of 
right heart failure and the PCWP 
was decreased. Our findings sug­
gest that hypovolemia is the only 
cause of myocardial depression dur­
ing the ischemic phase of superior 
mesenteric artery occlusion. The 
theory that there was underlying 
sepsis is not supported by the stable 
SVRI and PVRI despite the de­
crease in Cl. Our data support a 
mechanism of fluid loss and hypo­
volemia as being the main circulato­
ry derangement in the ischemic 
phase of SMA occlusion.
The theory of a myocardial 
depressant factor has been suggest­
ed in a number of other pathologic 
processes. The presence of such a 
factor in these conditions has been 
questioned. Altimari and associ­
ates19 concluded that in experimen­
tal pancreatitis, cardiac depression 
was related to preload reduction 
rather than intrinsic cardiac dys­
function. Cobo and associates20 also 
concluded that there was a lack of 
support for myocardial depression 
in their studies of hemodynamics 
and oxygen transport in patients 
with acute pancreatitis. Decreased 
vascular tone was attributed to flow 
redistribution in the microcircula­
tion, limiting tissue oxygenation de­
spite increased metabolic demands.
Vyden and colleagues21'22 and 
Williams and colleagues23 noted a 
decrease in Cl in patients with acute 
mesenteric ischemia, a concept sup­
ported by experimental models.23'24 
In 1965, Milliken and Nahor25 re­
ported that with 3 to 5 hours of 
acute mesenteric ischemia there 
was a decrease in CO, systemic 
blood pressure and blood volume of 
31%. Cross-transfusion experiments 
led these authors to believe that 
this decrease was secondary to a 
toxic factor. Such a finding could 
equally well be explained on the 
basis of hypovolemia. The findings 
of Liilehei, Goott and Miller26 and 
Chiu, Scott and Gurd5 support this 
concept. Our studies have not ruled 
out the presence of a toxic factor 
but have demonstrated that its ac­
tion is not directly on the myocardi­
um.
Martson6 7 indicated that massive 
fluid loss was of prime significance 
in the pathogenesis of hypotension 
with massive gut ischemia. Accu­
mulation of large volumes of fluid 
in the bowel lumen, bowel wall, 
peritoneal cavity and systemic inter­
stitial space were the probable sites 
of loss. In our 7-hour model of 
ischemia with no reperfusion it ap­
pears that the hemodynamic 
changes are due to a decrease in 
circulating intravascular volume. 
This study has failed to support 
either direct myocardial dysfunction 
or sepsis as a primary cause of 
reduced Cl. Further studies are 
under way to determine the site of 
fluid loss.
Patients who present with acute
mesenteric ischemia will usually 
have either poor myocardial func­
tion (frequently the source of mes­
enteric embolism) or generalized 
atherosclerosis (involvement of the 
SMA being a frequent cause of 
mesenteric thrombosis). These, usu­
ally elderly, patients are ill suited to 
withstand a mesenteric ischemic in­
sult with accompanying hemody­
namic changes. The coexisting and 
often long-term use of diuretics 
may exacerbate the hypovolemic ef­
fects of fluid sequestration, causing 
the cardiac dysfunction that we 
have demonstrated in the ischemic 
phase of acute mesenteric ischemia. 
Since the outcome of a mesenteric 
ischemic episode is uniformly fatal 
if not effectively treated, all patients 
with this condition warrant laparot­
omy. Once infarction is established 
there is no chance for salvage of 
the ischemic bowel. To prevent in­
farction urgent laparotomy is man­
datory. Our study suggests that the 
best preparation for operation is 
fluid replacement. Although many 
patients will have concurrent dis­
ease, the placement of the central 
hemodynamic monitoring lines in 
these patients must not delay opera­
tive treatment.
Conclusions
Clinical gut ischemia is still a 
difficult management problem. The 
vague, nonspecific symptoms often 
favour conservative management 
until frank necrosis is established. 
Only with early awareness of the 
syndrome, appropriate work-up and 
urgent surgical correction will the 
high mortality be decreased. This 
work suggests that massive fluid 
loss is the primary early physiologic 
change and vigorous fluid replace­
ment combined with treatment of 
the underlying arterial occlusion 
could lead to a reduction in the 
unacceptably high mortality .
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Reconstruction of Composite Facial Defects: 
the Combined Application of Multiple 
Reconstructive Modalities
Oleh M. Antonyshyn, MD, FRCSC;* Justin L. Paletz, MD, FRCSC;t Kenneth L. Wilson, MD, FRCSCt
Objective: To describe the combined use of craniofacial skeletal reconstruction, tissue expansion and 
microvascular free tissue transfer in the repair of major composite facial defects.
Design: Case series with an integrated team approach.
Setting: Craniofacial unit, university teaching hospital.
Patients: Three cases were selected to best illustrate the combined use of the three modalities in 
reconstruction of acute traumatic, congenital and post-traumatic facial defects. A 15-year-old boy had a 
shotgun wound to the face; a 23-year-old man had Treacher Collins syndrome; and a 55-year-old woman 
had a post-traumatic composite defect of the central midface.
Interventions: Preoperatively, complete neurologic, ophthalmologic and dental examinations, 
anthropometric analysis, prosthodontic assessment, computed tomography and computer graphics. 
Operatively, craniofacial exposure followed established surgical principles. Skeletal reconstruction was 
performed to provide accurate positioning of bony segments and three-dimensional stability. Bone 
grafting was used when necessary to restore bony continuity and increase stability. Tissue expansion 
was used to provide more locally available tissue for wound closure and resurfacing composite defects. 
Microsurgical free tissue transfer was used to provide functional replacement of deficient tissues. 
Results: The results of the modalities used for reconstruction of these composite facial defects are 
illustrated for each case described.
Conclusions: The use of multiple modalities, including craniofacial skeletal reconstruction, tissue 
expansion and free tissue transfer, allow the surgeon to address the specific functional and anatomical 
requirements associated with composite facial defects that are characterized by a combined deficiency of 
multiple tissues in the craniofacial region.
Objectif: Decrire l’utilisation combinee de la reconstruction osseuse craniofaciale, de l’expansion 
tissulaire et du transfert fibre de tissu microvascularise dans la reparation des anomalies faciales 
composees.
Conception : Une serie de cas avec une approche collaborative integree.
Contexte: Le service de soins craniofaciaux d’un hopital universitaire.
Patients : Trois cas ont ete choisis pour illustrer au mieux les resultats combines de trois modalites 
utilisees dans la reconstruction des anomalies faciales de nature traumatique immediate, congenitale ou 
post-traumatique. Un garfon de 15 ans ayant subi une blessure de fusil au visage; un homme de 23 ans 
souffrant du syndrome de Treacher Collins; une femme de 55 ans presentant une anomalie composee 
post-traumatique affectant la partie centrale moyenne du visage.
Interventions : Des examens preoperatoires neurologiques complets, ophtalmologiques et dentaires.
From the *Division o f  Plastic Surgery, Sunnybrook Health Science Centre, University o f  Toronto, Toronto, Ont., and the fD ivision o f  Plastic 
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Une analyse anthropometrique et une evaluation prothetique. Une tomographie par ordinateur 
accompagnee de graphiques sur ordinateur. A l’operation, l’exposition craniofaciale a ete faite selon 
des principes chirurgicaux etablis. La reconstruction osseuse a ete effectuee de fa^on a permettre un 
positionnement precis des segments osseux et une stability tridimensionnelle. Une greffe osseuse fut 
pratiquee quand cela etait necessaire pour restaurer la continuity osseuse ou pour ameliorer la 
stability. L expansion tissulaire fut utilisee pour fournir davantage de tissu pour refermer la plaie et 
pour refaire la surface des anomalies composees. Le transfert libre de tissu microvascularise fut utilise 
pour retablir le fonctionnement d’un tissu carence.
Resultats : Les resultats des modalites utilisees pour la recontruction de ces anomalies composees sont 
illustres pour chacun des cas decrits.
Conclusions : L’emploi de modalites multiples comprenant reconstruction osseuse craniofaciale, 
expansion tissulaire et transfert libre de tissu, permet au chirurgien de repondre aux exigences 
fonctionnelles et anatomiques specifiques aux anomalies faciales composees qui sont caracterisees par 
les carences combinees de multiples tissus de la region craniofaciale.
C omposite facial defects have unique and highly variable re­
constructive requirements. These 
deformities are characterized by a 
combined deficiency of multiple tis­
sues. Facial skin, muscle, fat, bone 
and mucosal lining are involved to 
varying degrees. The defects are 
extensive and frequently encroach 
upon adjacent anatomical sites in­
cluding the orbits, cranium, nasal 
or oral cavities. As such, the ab­
sence of tissue frequently results in 
both impaired function and aesthet­
ic problems.
In the past, the options for recon­
struction were limited. The surgeon 
repairing major composite defects 
relied upon the use of large region­
al flaps to simply obliterate or cover 
a cavity. Both form and function 
were frequently compromised.
However, facial reconstructive 
surgery has evolved and expanded 
considerably in the past decade as a 
result of recent innovations and 
modifications in surgical technique. 
Increasing sophistication of tools 
for imaging and analysis provides 
unprecedented visualization of cra­
niofacial anatomy and facilitates ac­
curate preoperative planning. The 
integration of craniofacial skeletal 
reconstruction, tissue expansion 
and microvascular tissue transfer 
have made it possible for the recon­
structive team to address deficient 
tissues specifically and to restore 
the normal anatomy more precisely.
In this paper recent developments 
in reconstructive modalities and 
their combined use in the repair of 
composite facial defects are de­
scribed. Case reports are selected to 
illustrate the benefits and the inad­
equacies of interfacing these tech­
niques.
Preoperative Assessment
Composite facial defects general­
ly result from high-velocity trauma 
or ablative procedures for head and 
neck cancer or occur in association 
with congenital craniofacial malfor­
mations featuring profound hypo­
plasia or aplasia of multiple tissues. 
The scope and complexity of these 
deformities demand a comprehen­
sive multidisciplinary assessment of 
the patient preoperatively. The inte­
grated team approach facilitates 
combined operative procedures to 
reduce the number of hospital ad­
missions and offers the best pros­
pects for rehabilitation.
The preoperative assessment 
comprises a complete neurologic 
and ophthalmologic examination, in 
addition to the specific evaluation 
of soft-tissue and skeletal compo­
nents of the defect. Many patients 
have associated upper airway prob­
lems, and a preanesthetic consulta­
tion is frequently indicated. A com­
plete dental examination, with a 
review of plaster dental models and
radiographs in selected cases, is 
required to define the occlusion and 
dental status. Anthropometric anal­
ysis provides a quantitative descrip­
tion of facial surface morphology 
and is useful in treatment planning. 
In particularly extensive defects, 
preoperative prosthodontic assess­
ment permits modification of recon­
structive procedures to accommo­
date subsequent placement of max­
illofacial prosthetic devices.
The preoperative radiographic 
evaluation of major craniofacial de­
formities relies primarily on an anal­
ysis of computed tomography (CT) 
scans. High-resolution axial CT 
scans clearly define bony elements 
and defects of the facial skeleton, 
while associated soft tissues are 
visualized with unprecedented de­
tail. An absence of geometric mag­
nification error in the generated 
images further permits accurate 
quantitation of defect size.
Most recently, computer graphics 
have been used to produce accurate 
three-dimensional images from two- 
dimensional data obtained from 
standard CT scanners. The osseous 
reconstructions resemble black-and- 
white photographs of a dry skull 
and can be displayed from any de­
sired perspective. These three- 
dimensional images are particularly 
valuable to the craniofacial sur­
geon, because of their capacity to 
reveal asymmetries and dispropor­
tions, the spatial relationships of
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critical anatomical structures, and 
the size, shape and location of 
skeletal defects.
Skeletal Reconstruction
The reconstruction of a compos­
ite facial defect relies upon initial 
restoration of a stable three-dimen­
sional bony structure that approxi­
mates normal anatomy as closely as 
possible. This provides a symmetri­
cal facial skeleton with normal di­
mensions and proportions and a 
supportive framework that main­
tains the position, projection and 
volume of all associated soft tis­
sues. Recent technical innovations 
and developments in surgical tech­
nique have enabled the craniofacial 
surgeon to realize these reconstruc­
tive goals.
Craniofacial Exposure
The field of craniofacial surgery 
emerged as a distinct subspecialty 
in the 1960s, thanks to the pioneer­
ing work of Paul Tessier. In collab­
oration with excellent neurosurgical 
and ophthalmologic groups at 
Hopital Foch in Paris, he estab­
lished the basic principles that form 
the foundation of current craniofa­
cial surgical techniques:1-3
•  Segments of the facial skele­
ton can be completely denuded of 
their periosteal blood supply, os- 
teotomized and repositioned, and 
yet survive.
•  Wide subperiosteal elevation 
through camouflaged incisions per­
mits direct exposure of the entire 
craniofacial skeleton.
•  Dissection of the periorbita 
enables all bony displacements to be 
effected without interference with 
ocular, oculomotor, palpebral or 
lacrimal functions.
•  An intracranial exposure al­
lows the cranial contents and me­
ninges to be protected through di­
rect visualization, in any procedures 
on the fronto-orbital or nasoeth- 
moid regions.
•  The orbits and eyes can be 
translocated horizontally or verti­
cally over a considerable distance 
without impairing vision.
These principles govern the sur­
gical approach to virtually any cra­
niofacial deformity. Incisions are 
planned to provide maximum expo­
sure while minimizing the apparent 
scar. Wide subperiosteal dissection 
provides direct access to the entire 
facial skeleton. The reconstruction 
is then performed under direct visu­
alization, with optimal protection of 
both intracranial and intraorbital 
contents.
Rigid Skeletal Fixation
Skeletal reconstruction relies 
upon an accurate positioning of 
bony segments, thorough adapta­
tion of adjoining bone surfaces and 
absolute three-dimensional stability. 
Failure to provide a rigidly stable 
skeletal framework may lead to de­
layed union or nonunion of bone 
segments, resorption and loss of 
volume in bone grafts, and ulti­
mately to collapse of the facial 
skeleton, dysgnathia and deforma­
tion.
Stability is based on the effect of 
frictional binding between bone seg­
ments. Internal fixation devices ap­
proximate fragments under tension, 
producing a frictional force between 
corresponding bone surfaces. Rigid 
stability is achieved as long as the 
frictional binding is greater than 
the external functional forces acting 
on the bone.4 In these circum­
stances, the mechanical properties 
of healing bone are superior,5 and 
primary bone healing occurs even in 
open, contaminated wounds or in 
the presence of infection.6 Mobiliza­
tion of the jaw can be initiated
earlier, thus minimizing the occur­
rence of temporomandibular joint 
arthropathy, yet increasing patient 
comfort and speeding rehabilitation.
Rigid internal fixation systems 
are now routinely employed in cra­
niofacial reconstruction. Miniature 
bone plates and screws are specifi­
cally designed to allow stable three- 
dimensional reconstruction. Multi­
ple osseous segments can be se­
quentially positioned and rigidly im­
mobilized to re-establish the normal 
anatomy. Gaps in bony continuity 
can be bridged with contoured 
plates, producing a stable recon­
struction that resists subsequent 
deformation.
Case Reports and Discussion
Case 1
A 15-year-old boy presented with 
a self-inflicted 12-gauge shotgun 
wound to the face. The entry 
wound was submandibular, the exit 
wound was through the nasoeth- 
moid region. There was no associat­
ed intracranial injury, and vision in 
both eyes remained intact.
Preoperative examination re­
vealed a composite defect of the 
palate and central midface, a skele­
tal defect of the central mandible 
and comminuted fractures involving 
the nasoethmoid and orbitozygo- 
matic regions bilaterally (Fig. 1).
Skeletal reconstruction was per­
formed immediately (Fig. 2). Naso­
ethmoid, zygomatic and maxillary 
fractures were sequentially reduced 
and rigidly fixed with miniplates 
and screws to provide a stable outer 
facial frame. Residual defects in the 
orbits, central midface and palate 
were then reconstructed with split 
cranial and iliac-crest bone grafts, 
which completely restored bony 
continuity. The mandibular defect 
was simply bridged with an internal 
stainless steel reconstruction plate.
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Upon completion of the skeletal 
reconstruction, the entire palate 
and central midface remained ex­
posed intraorally (Fig. 2, top right). 
Sufficient soft tissue was not avail­
able locally to permit resurfacing of 
the defect.
A radial forearm flap was there­
fore elevated from the volar radial 
surface of the patient’s forearm 
(Fig. 2, bottom left and right). This 
flap provides thin, well-perfused 
non-hair-bearing skin pedicled on 
the radial artery and vein. The flap 
was transferred and anastomosed to 
the facial artery and veins, provid­
ing well-vascularized tissue to re­
store intraoral lining. The wounds 
healed without complication (Fig. 
3).
Bone Graft Reconstruction
Bone grafting specifically ad­
dresses the skeletal deficiency asso­
ciated with composite facial defects. 
Restoration of bony continuity, re­
gardless of the extent of the defect, 
is of primary importance. Osteosyn­
thesis is increased and stability is 
significantly enhanced, minimizing 
the degree of relapse and secondary 
deformity.
Autogenous bone grafts provide 
the optimal material for the replace­
ment of skeletal defects. Cortical 
bone is capable of bearing stress 
and resisting deformation. New 
bone formation is stimulated both 
by surviving cellular elements in the 
graft7 and by the ability of the bone 
matrix to induce transformation of 
osteogenic precursors in the recipi­
ent site.8 This encourages early 
union of the graft to the margins of 
the defect and complete incorpora­
tion within the facial skeleton.
To optimize consolidation and re­
tention of bone grafts, a favourable 
environment must be furnished. A
well-perfused recipient site is re­
quired to encourage early revascu­
larization of the transplant. When 
the defect is extensive or surround­
ing tissues are scarred or irradiated, 
pedicled vascularized bone trans­
plants or circumferential coverage 
of bone grafts with revascularized 
soft-tissue flaps are necessary. 
Rigid immobilization is further re­
quired to eliminate shearing motion 
and allow rapid vascular penetra­
tion.9 Accurate apposition of the 
graft to the bony margins of the 
defect is important in ensuring a 
superior osteogenic response10 and 
maximizing the retention of volume 
in the transplant.11
Case 2
A 23-year-old man presented with 
facial features characteristic of 
Treacher Collins syndrome. Preop­
erative evaluation revealed bilateral
FIG. 1. Case 1. Man with shotgun wound to face. (Left) Intraoperative view demonstrating composite defect of midface. (Right) 
Three-dimensional computed tomography (CT) scan shows bone defect in mandible and central maxilla.
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composite deficiencies in the or- 
bitozygomatic region, with com­
plete aplasia of the zygoma and 
inferolateral orbits and hypoplasia 
of the overlying soft tissues (Fig.
4) .
Due to the magnitude of the 
skeletal deficiency, a vascularized 
bone transfer was employed in or- 
bitozygomatic reconstruction (Fig.
5) . A T-shaped cranial bone flap 
was elevated on a temporalis muscle 
and pericranial pedicle. The bone 
flap was rotated into the cheek to
reconstruct a malar prominence, zy­
gomatic arch and lateral orbital rim 
in one segment. Free bone grafts 
were then applied to the inferolater­
al orbit to restore bony continuity 
and provide support to the orbital 
contents.
After the skeletal anatomy was 
restored, the residual deformity 
comprised primarily a lateral can- 
thal dystopia and associated defi­
ciency in lower eyelid skin (Fig. 6). 
This was addressed in a second 
stage. Tissue expanders were intro­
duced into subcutaneous pockets in 
the temporal region and gradually 
inflated over 3 months to a volume 
of 50 mL; this provided a surplus of 
skin and soft tissue for eyelid recon­
struction. The expanded temporal 
skin flaps were transposed into the 
lower eyelids, providing sufficient 
tissue to resurface the lower lids 
and permit repositioning of the lat­
eral canthi (Fig. 7). The final result 
of the composite reconstruction of 
this young man’s face is shown in 
Fig. 8.
FIG. 2. Case 1. Immediate facial reconstruction. (Top left) Schematic diagram indicating position of miniplates and screws. 
Stippled segments represent bone grafts used in reconstruction of maxilla, palate, nose and orbits. (Top right) Intraoral view. 
Anterior maxillary and palatal defects have been bone grafted and rigidly fixed. (Bottom left) Radial forearm flap, comprising 
skin, subcutaneous tissue and fascia, is shown isolated on forearm. (Bottom right) Vascular pedicle to flap is demonstrated. 
Radial forearm flap resurfaces lining of reconstructed palate after free transfer and anastomosis to facial artery and vein.
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Microsurgical Free Tissue Transfer
The evolution of microsurgical 
techniques in plastic and recon­
structive surgery over the past 30 
years has most significantly poten­
tiated the goal of precise anatomical 
and functional replacement of defi­
cient tissues. Clinical research has 
resulted in accurate descriptions of 
selectively vascularized donor sites 
for numerous types of composite 
tissue, and this has facilitated re­
construction with distant tissue that 
most appropriately meets the re­
quirements of the recipient site.
Clinical microsurgical transfer of 
composite tissue was first accom­
plished by McLean and Buncke12 in 
1972. These investigators success­
fully revascularized transferred 
omentum for resurfacing of a scalp 
defect. Subsequently, Daniel and 
Taylor13 and O’Brien and col­
leagues14 independently described 
the use of vascularized free groin 
flaps for coverage of lower extremi­
ty defects.
Free transplantation of vascula­
rized cutaneous flaps, muscle and 
bone are now routinely used in
FIG. 3. Case 1. Final result, 1 year 
postoperatively. Frontal view.
clinical practice. In the reconstruc­
tion of composite facial defects, free 
tissue transfer is relied upon pri­
marily to provide lining of intraoral 
defects, obliteration of cavities and 
exposed sinuses, vascularized cover 
of the cranial base and augmenta­
tion of subcutaneous tissue defi­
ciencies.
Tissue Expansion
The cutaneous surface of the 
head and neck is composed of sev­
eral distinct anatomical areas, each 
distinguished by specific skin col­
our and texture characteristics, 
hair-bearing qualities, and thickness 
of subcutaneous tissues. Cutaneous 
defects are therefore optimally re­
surfaced by local tissue of similar 
quality. However, the size of com­
posite defects and the inadequacy of 
adjacent tissues frequently preclude 
the use of local flaps.
Tissue expansion is a means of 
generating a surplus of locally 
available tissue to enhance wound 
closure. This technique employs an 
inflatable silicone envelope, which is 
placed in a subcutaneous pocket 
adjacent to the defect. The implant 
is gradually inflated by serial percu­
taneous injections of saline into a 
remote port. Progressive enlarge­
ment of the implant results in ex­
pansion of the overlying soft tis­
sues.
Rather than simple stretching of 
the overlying tissues, an increase in 
epidermal mitotic activity15 and der­
mal collagen synthesis16 has been 
demonstrated in experimental 
studies in response to the mechani­
cal stress of expansion. A stable 
increase in skin surface area is thus 
obtained. Adnexal structures such 
as glands and hair follicles maintain 
activity and remain quantitatively 
the same.17 Tissue expansion is fur­
ther associated with an increase in 
vascularity and in skin-flap viabili­
ty.18
The concept of tissue expansion 
by gradual inflation of a prosthesis 
was first applied clinically in breast 
reconstruction.19 Subsequently, ex­
tensions of these same principles 
prompted the use of this technique 
in the reconstruction of cutaneous 
defects of the face20 and scalp.21 
The ability to generate a surplus of 
locally available tissue with the de­
sired colour, texture and hair-bear­
ing characteristics provides a supe­
rior means of resurfacing virtually 
any composite defect. Tissue expan­
sion is therefore currently used with 
increasing frequency in cheek and 
neck resurfacing, in nasal recon­
struction and in the coverage of 
craniofacial defects that might oth­
erwise have required the use of 
distant flaps.
Case 3
A 55-year-old woman presented 
with a post-traumatic composite de­
fect of the central midface. One 
year previously, she had sustained a 
gunshot wound to the face. An 
initial reconstructive effort, per­
formed elsewhere, was complicated 
by an early postoperative infection 
and further tissue loss. The result­
ing deformity consisted of a full­
thickness composite defect of the 
nose and midface, extending trans­
versely from the right to the left 
zygoma and from the cranial base 
superiorly to the palate interiorly 
(Fig. 9).
Because of the anatomical loca­
tion and magnitude of the defect, 
initial resurfacing of the cranial 
base and obliteration of the interor­
bital space with vascularized tissue 
were necessary (Fig. 10). Local 
flaps based on the margin of the 
defect were reflected medially and 
used to reconstruct an anterior pha­
ryngeal wall, completely sealing the 
nasal airways. Rib grafts were used 
in building a facial frame to support 
the orbital contents and soft-tissue
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FIG. 4. Case 2. Patient with Treacher Collins syndrome. (Top left) Frontal view. (Top right) Profile. (Bottom left) Brow-up view. 
(Bottom right) Three-dimensional, CT oblique view of skull. Note complete aplasia of zygoma and inferolateral orbital cavity 
bilaterally.
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FIG. 5. Case 2. Skeletal reconstruction. (Left) Schematic diagram showing method of temporalis muscle-one flap transfer for 
orbitozygomatic reconstruction. (Right) Right temporalis muscle-bone flap elevated.
FIG. 6. Case 2. Result, post-skeletal reconstruction. Residual soft-tissue deficiency in lower eyelids is clearly seen. (Left) Frontal 
view. (Right) Oblique view.
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reconstruction. A free gracilis mus­
cle flap, anastomosed to the facial 
artery and vein, was then draped 
over the frame and anchored to 
bone, effectively obliterating the en­
tire defect.
Inadequate local tissues preclud­
ed an immediate nasal reconstruc­
tion and cutaneous resurfacing. 
Eight months after the initial recon­
struction, five tissue expanders 
were inserted into separate subcuta­
neous pockets in the forehead, both 
cheeks and bilateral anterior neck 
regions (Fig. 11). Over 8 weeks, 
these were inflated to a total com­
bined volume of 600 mL, providing 
abundant non-hair-bearing skin. 
The expanded forehead flap was 
elevated and draped over a cantile­
ver bone graft to reconstruct the 
nose. Expanded cheek-neck flaps 
were elevated and transposed bilat­
erally to resurface the midface. The
FIG. 7. Case 2. Intraoperative views of expanded left temporal flap. (Left) Left temporal flap is marked out over tissue expander. 
(Right) Temporal skin flap has been transposed. Note that sufficient tissue has been provided to allow complete resurfacing of 
lower eyelid after correction of lateral canthal dystopia (i.e., after correction of obliquity of palpebral fissure).
FIG. 8. Case 2. Final result, 4 months postoperatively. (Left) Frontal view. (Middle) Profile. (Right) Brow-up view.
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patient’s postoperative course was 
uncomplicated. The final result is 
shown in Fig. 12.
Summary
In the reconstruction of compos­
ite craniofacial defects, consider­
ation must be given to the specific 
associated functional and anatomi­
cal requirements. An integrated 
team approach in which multiple 
modalities are used offers an opti­
mal means of craniofacial recon­
struction.
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Iodine Replacement in Fibrocystic Disease 
of the Breast
William R. Ghent, MD, FRCSC, FACS;* Bernard A. Eskin, MD, FACOG;t 
Donald A. Low, MD, FRCSC;$ Lucius P. Hill, MD, FACSJ
Objective: To determine the response of patients with fibrocystic breast disease to iodine replacement 
therapy.
Design: Review of three clinical studies beginning in 1975: an uncontrolled study with sodium iodide 
and protein-bound iodide; a prospective, control, crossover study from iodide to molecular iodine; and a 
prospective, control, double-blind study with molecular iodine.
Setting: University affiliated breast-treatment clinics.
Patients: Study 1: 233 volunteers received sodium iodide for 2 years and 588 received protein-bound 
iodide for 5 years. Study 2: the treatment of 145 patients from study 1 treated with protein-bound 
iodide for several months who still had symptoms was switched to molecular iodine 0.08 m g/kg; 108 
volunteers were treated initially with molecular iodine. Study 3: 23 patients received molecular iodine, 
0.07 to 0.09 m g/kg body weight; 33 received an aqueous mixture of brown vegetable dye and quinine. 
The numbers in study 2 increased over the review period so that 1365 volunteers were being treated 
with molecular iodine by 1989.
Interventions: All patients in study 3 had pre- and post-treatment mammography and measurement of 
serum triiodothyronine, thyroxine and thyroid-stimulating hormone levels.
Main Outcome Measures: Subjective evaluation — freedom from pain — and objective evaluation — 
resolution of fibrosis.
Results: Study 1: 70% of subjects treated with sodium iodide had clinical improvement in their breast 
disease, but the rate of side effects was high; 40% of patients treated with protein-bound iodide had 
clinical improvement. Study 2: 74% of patients in the crossover series had clinical improvement, and 
objective improvement was noted in 72% of those who received molecular iodine initially. Study 3: in 
the treatment group 65% had subjective and objective improvement; in the control group there was a 
subjective placebo effect in 33% and an objective deterioration of 3%.
Conclusions: The fibrocystic breast reacts differently to sodium iodide, protein-bound iodide and 
molecular iodine. Molecular iodine is nonthyrotropic and was the most beneficial.
Objectif: Mesurer la reponse des patientes souffrant de mastose sclerokystique a un traitement de 
suppleance a Tiode.
Conception : Une revue de trois etudes cliniques amorcees en 1975 : une etude ouverte de Tiodure de 
sodium et de Tiode lie aux proteines; une etude prospective, controlee, en chasse-croise de Tiodure et 
de Tiode moleculaire; et une etude prospective, controlee, a double insu avec de Tiode moleculaire. 
Contexte : Des cliniques de traitement des maladies du sein affiliees a une universite.
Patientes : Premiere etude : 233 volontaires qui ont re?u de Tiodure de sodium pendant 2 ans et 588 
qui ont re?u de Tiode lie aux proteines pendant 5 ans. Deuxieme etude : le traitement de 145 patientes
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qui avaient participe a la premiere etude et qui avaient re$u de l’iode lie aux proteines pendant 
plusieurs mois et qui montraient des signes residuels de mastose, fut modifie pour de l’iode moleculaire 
a 0,08 mg/kg; 108 volontaires refurent initialement de l’iode moleculaire. Troisieme etude : 23 
patientes re?urent de l’iode moleculaire, a raison de 0,07 a 0,09 mg/kg; 33 refurent une solution 
aqueuse de colorant brun vegetal et de quinine. Les nombres dans la deuxieme etude augmenterent 
pendant son deroulement de sorte qu’ils atteignirent 1365 volontaires traites a l’iode moleculaire en 
1989.
Interventions : Toutes les patientes ayant participe a la troisieme etude subirent mammographie pre et 
post-traitement ainsi que des determinations des taux seriques de triiodothyronine, de thyroxine et 
d’hormone thyreotrope.
Principaux effets mesures : Subjectif — l’absence de douleur — et objectif — la disparition de la 
fibrose.
Resultats : Premiere etude : 70 % des sujets traites a l’iodure de sodium eurent une amelioration 
clinique mais montrerent un taux eleve d’effets secondaires; 40 % des patientes recevant de l’iode lie 
aux proteines beneficierent d’une amelioration clinique. Deuxieme etude : 74 % des patientes dans la 
serie en chasse-croise eurent une amelioration clinique et une amelioration objective fut notee chez 
72 % de celles qui avaient re?u de l’iode moleculaire initialement. Troisieme etude : dans le groupe 
traite, 65 % montrerent une amelioration subjective et objective; dans le groupe temoin, on enregistra 
une amelioration subjective placebo dans 33 % des cas et une deterioration objective de 3 %.
Conclusions : La mastose sclerokystique reagit differemment a l’iodure de sodium, a l’iode lie aux 
proteines et a l’iode moleculaire. L’iode moleculaire n’est pas thyreotrope et a donne les meilleurs 
resultats.
F ibrocystic breast disease (FBD) is characterized by lumpy, pain­
ful breasts, generally in reproduc­
tive-aged women. Initially the syn­
drome occurs in the premenstrual 
phase but can progress to involve 
the whole cycle. Symptoms can also 
occur in menopause, particularly if 
estrogens are being used.
Histologically, FBD shows mi­
crocysts, epithelial hyperplasia, apo­
crine metaplasia and fibrosis. The 
fibrosis is the basic hallmark of the 
disease. Macrocysts greater than 1 
cm in diameter occur in 10% of 
patients with the syndrome. Bio­
chemical and cytologic analysis of 
macrocyst fluid shows that 55% 
contain high levels of potassium 
(more than 120 mmol/L) and low 
levels of sodium (less than 20 
mmol/L) and are associated with 
apocrine changes; the other 45% 
contain high levels of sodium (more 
than 120 mmol/L) and low levels 
of potassium (less than 5 mmol/L) 
and are associated with flat epitheli­
al cells.12 Observations indicate that 
the cyst fluid in the microcysts has 
a high potassium content with apo­
crine cells present.3 
The diagnosis of FBD is increas­
ing in frequency. In 1928 an autop­
sy series reported a 3% incidence,4 
whereas in 1973 an autopsy report 
quoted an 89% incidence.5 The lat­
est review by the American Acade­
my of Pathology gives a minimum 
incidence of 50% but suggests that 
80% of North American women are 
afflicted with the syndrome during 
their reproductive lifetime.6
The suggested etiology of the 
syndrome has included a prolonged 
luteal phase,7 an upset in the es- 
trone-estriol ratio,8 increased estro­
gen levels9 and other hormonal dys­
functions.910 A dietary theory impli­
cating coffee and tea has been pop­
ular,11 but this has been disproved 
by several studies.1213 Some au­
thors14' 17 have stated that FBD is a 
normal but exaggerated physiologic 
cycle and that it may be a “nondis­
ease.”
The term “iodine” has been mis­
used for many years to describe any 
iodine compound. Chemically the 
elemental form of iodine (I2), with 
an atomic weight of 125.9015, is 
the only substance that should be 
called iodine. However, there are 
some 130 compounds containing 
the element iodine. These have, by
common usage, been called generic 
iodine. Each compound is different 
and consists of simple bindings 
such as sodium or potassium to 
produce iodides (I~). Potassium io­
dide has been added to our salt in 
Canada since 1929 and has reduced 
the incidence of cretinism and 
goitre. The fact that sodium or 
potassium iodide, when mixed with 
water, forms a solution that is 95% 
iodide (I~) and 5% free iodine (I2) is 
of relevance to our findings in this 
study. More complex bindings of 
the iodine molecule to organic com­
pounds produce substances that are 
chemically different but again are 
called “iodine,” such as iodine ca­
seinate. In this presentation, the 
term iodine (I2) will refer to aqueous 
molecular iodine whereas all other 
iodine-containing compounds will 
be indicated as iodide (I- ) or gener­
ic iodine.
In this paper we report on three 
clinical trials of iodide (I~) and 
iodine (I2) replacement therapy to 
ascertain the response of the fi­
brocystic breast: iodide (I- ) replace­
ment therapy with (a) sodium iodide 
(Lugol’s iodine) and (b) iodine casei­
nate; a crossover study from iodide
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to iodine; and a double-blind pro­
spective study with iodine.
Patients and Methods
Study 1
Initially, 233 volunteers were 
treated with Lugol’s iodine (sodium 
iodide [I- ]) for 2 years. Compliance 
was difficult owing to the vile taste 
of this compound. Lugol’s iodine is 
95% iodide and 5% iodine. The 
dosage was 5 to 10 drops daily, on 
a body-weight basis. This study was 
an open-ended trial without con­
trols because we found it was im­
possible to create a placebo that 
was realistic.
In the second arm of this study 
588 patients were treated with io­
dine caseinate (iodized casein [I- ]). 
The study period was 5 years and 
the dosage of iodine caseinate was 
10 mg daily. This study was also 
conducted without controls.
Study 2
When it became evident in the rat 
model that there was a differential 
reaction in the breast tissue to 
iodides and to molecular iodine,18 it 
was decided that molecular iodine 
should be tried on human volun­
teers with FBD. Study 1 included 
145 subjects who had been treated 
with iodine caseinate for a number 
of months but still had residual 
symptoms and signs of FBD. Thera­
py in these patients was switched to 
aqueous molecular iodine at a dos­
age of 0.08 mg I2/kg , and the 
patients were assessed at 9.9 
months after crossover.
One hundred and eight more sub­
jects (de novo group) were treated 
initially with aqueous molecular io­
dine and were evaluated at 8.9 
months.
The original series of 233 volun­
teers was enlarged to 1365, ob­
served through 4813 women-years 
of treatment (Table I). These 
women were assessed at 4 to 6 
months (group 1), 7 to 18 months 
(group 2) and more than 18 months 
(group 3). The mean age of these 
women was 41.6 years (range from 
11 to 87 years) and the mean 
duration of symptoms was 44.6 
months (range from 1 to 360 
months).
Scoring system for study 2 sub­
jects. A precise method of recording 
our data was developed with a nu­
merical scoring system. This simple 
method numbers the quadrants of 
the breast from 1 to 4 (Fig. 1). The 
following five pathological changes 
that can occur in the fibrocystic 
syndrome were noted: micronodu­
larity, tenderness, fibrous tissue 
plaques, macrocysts and turgidity 
(hyperactivity). The presence or ab­
sence of these changes was record­
ed. For example, if the mi­
cronodularity of microcystic disease 
was present in the upper half of the 
breast, the numerical score would 
be 1 (micronodularity) + 2 (two 
breast quadrants) = 3. If all five 
changes occurred in all quadrants 
in one breast the score would be 1 
+ 2 + 3 + 4 (all four breast 
quadrants) X 5 (all five changes) = 
50, and for both breasts 100.
Subjective evaluation. The pa­
tient’s evaluation of her own symp­
tomatology was expressed numeri­
Table I. Demographic Data on Volunteers 
With Fibrocystic Disease in Study 2 — A 
Clinical Trial of Replacement Therapy With 
Molecular iodine (N = 1365)
No. (%) of
Demographic characteristic women
Premenopausal 871 (63.8)
Postmenopausal 494 (36.2)
Taking birth control pills 915 (67.0)
Taking estrogen 252 (18.5)
Parous 1081 (79.2)
Previous breast surgery
Biopsy 304 (22.3)
Mastectomy 25 (1.8)
Family history of fibrocystic
breast disease 333 (24.4)
cally: 0 — symptoms worse, 1 — 
symptoms unchanged, 2 — less 
pain, only premenstrual discomfort, 
3 — no pain, unable to predict 
menstruation.
Objective evaluation. The subjec­
tive scoring system was employed 
and graded as follows: 0 — no 
palpable abnormalities (normal), 1 
— a score of less than 7, 2 — a 
score greater than 7 but less than 
the pre-treatment score and 3 — a 
score greater than the pre-treat­
ment score.
Study 3
Fifty-six volunteers were enrolled 
in a prospective double-blind study 
at the Virginia Mason Clinic in 
Seattle, Wash. This study was su­
pervised by D.A.L. and L.D.H. The 
patients were enrolled over 2 
months and were treated for 6 
months. All had mammography be­
fore and after treatment. In addi­
tion, serum triiodothyronine, thy­
roxine and thyroid-stimulating hor­
mone levels were measured for all 
patients before and after treatment. 
The patients were randomly as­
signed by the pharmacist to the 
treatment or the placebo arm.
The patients were assessed at 
2-month intervals, with a final as­
sessment at a mean of 191 days. 
Subjective evaluation in this study
FIG. 1. Numerical designation of 
breast quadrants for fibrocystic breast 
disease.
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FIG. 2. Results of replacement therapy with iodized casein. 1 =  return to normal 
without pain, 2 =  residual premenstrual pain and fibrosis, 3 = slight reduction in 
pain and cysts and 4 =  no change.
IODIZED CASEIN 
TRANSFER TO MOLECULAR l 2
MOLECULAR l 2 
DE NOVO
IODIZED CASEIN MOLECULAR I ,
% Frequency
FIG. 3. Comparison of results of replacement therapy in patients treated first with 
iodized casein and then with molecular iodine and in patients treated with 
molecular iodine alone. 1 =  return to normal without pain, 2 =  residual 
premenstrual pain and fibrosis, 3 =  slight reduction in pain and cysts and 4 =  no 
change.
Table II. Objective Numerical Score fo r Patients in Study 2, Before and After Treatm ent*
Tim e of scoring
Group 1 Group 2 Group 3 Total
(n =  292) [n = 639) (n =  434) (n= 1365)
Before treatm ent
Mean 30.12 31.29 31.16 30.99
Range 1 - 8 0 3 - 8 0 4 - 1 0 0 1 - 1 0 0
A fte r treatm ent
Mean 3.15 1.18 1.51 1.97
Range 0 - 4 6 0 - 6 2 0 - 4 0 0 - 6 2
p va lu e t 0.0001 0.0001 0.0001
'D ura tio n  of treatment: group 1, 4 to  6 mo, 
t x z analysis
group 2, 7 to  18 mo group 3, nore than 18 mo
was in three categories: 0 — worse, 
1 — no change and 2 — less pain 
or pain free. Objective evaluation 
was carried out by two examiners, 
who used a numerical grading sys­
tem slightly modified from the one 
described earlier. They were un­
aware of the treatment status of the 
patients under study.
Twenty-three patients (mean age 
43.6 years) received aqueous mo­
lecular iodine, 0.07 to 0.09 mg of 
I2/k g  body weight daily. The place­
bo group (mean age 39.2 years), 
received an aqueous mixture of a 
brown vegetable dye with quinine 
added for flavour.
Results
Study 1
Iodide replacement therapy.
Clinically the improvement rate was 
70%. Side effects included changes 
in the thyroid indices in 4% of 
patients, the development of iodism 
in 3% and the occurrence of acne, 
which was unacceptable to the pa­
tients.
Iodine caseinate replacement 
therapy. A good response was 
noted in 40% of the patients (Fig. 
2). Side effects involved 9.5% of the 
patients and have been described in 
detail elsewhere.18’19
Study 2
Of the 145 patients in the cross­
over series, 108 (74.5%) showed an 
improvement, having pain-free 
breasts; the remainder still had 
some premenstrual pain and residu­
al fibrosis.
In the de novo group, the 108 
patients responded more swiftly, 
with complete disappearance of 
their microcysts within 5 months; 
98% were pain free at evaluation, 
and objective improvement was 
noted in 71.8% (Fig. 3).
A .
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FIG. 4. Effect of duration of treatment with molecular iodine evaluated subjectively. 
0 =  worse, 1 =  unchanged, 2 = improved (less pain with only premenstrual 
discomfort) and 3 =  freedom from pain and lumps. Group 1 =  4 to 6 months, group 
2 =  7 to 18 months and group 3 = more than 18 months.
FIG. 5. Effect of duration of treatment with molecular iodine assessed objectively by 
numerical scoring. 1 represents numerical score of 0, 2 represents numerical score 
less than 7, 3 represents numerical score less than pretreatment score, 4 represents 
numerical score greater than pretreatment score. Group 1 =  4 to 6 months, group 
2 = 7 to 18 months and group 3 = more than 18 months.
These results indicate the superi­
ority of molecular iodine over io­
dides when treating fibrocystic 
breast disease.
Both subjective and objective im- 
provments, according to the evalua­
tion scale, were time dependent (Ta­
ble II, Figs. 4 and 5). Sixty-five 
percent of women experienced a 
reduction in breast size as the fi­
brocystic condition was corrected 
(Fig. 6).
The side effects of treatment with 
molecular iodine were minor and 
involved 149 (10.9%) of the pa­
tients, including 78 (5.7%) who had 
a short-lived period of increased 
pain (Table III). This period of pain 
seemed to correspond to a softening 
of the breast and disappearance of 
fibrous tissue plaques on clinical 
examination.
During this period of observation 
six women failed to respond to any 
type of therapy, including aqueous 
molecular iodine (I2), tamoxifen, da- 
nazol, bromcriptine or progester­
one. These women subsequently 
underwent subcutaneous mastecto­
my. Histologic examination indicat­
ed a total disruption of the normal 
breast architecture (Fig. 7). The 
pathological review of the mamma­
ry tissue from these patients was 
remarkably similar, with dense fi­
brosis that isolated breast acini 
from the duct system. We conclude, 
therefore, that there is a “ point of 
no return’’ in fibrocystic disease. 
Once this point is crossed, surgical 
excision of the diseased tissue is the 
only method of treatment. This 
state can be suspected when a total 
white-out is observed on the mam­
mogram.
Study 3
There was a placebo effect in 11 
(33%) women of the control group, 
which is in keeping with previous 
reports on the treatment of benign 
breast disease.20
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On objective evaluation, the con­
trol group’s numerical assessment 
deteriorated by 3% during the study 
compared with a 65% improvement 
in the treated group (p < 0.001, x2 
analysis) (Table IV).
On subjective evaluation, 15
(65%) women in the treated group 
showed improvement, compared 
with 11 (33%) in the control group 
(Table IV). The laboratory results 
were unchanged, and no side effects 
were reported.
Repeat mammography failed to
show any significant change (2 to 5 
years are required for any mammo- 
graphic change to be manifest and 
the final evaluation in this study 
was at 6 months).
Despite the small size of the two 
participating groups, the results 
clearly indicate that the placebo 
effect in the control group was at 
the rate expected for studies of the 
treatment of benign breast disease. 
The objective findings worsened in 
this group in the 6 months under 
study. In contrast, the treated 
group demonstrated unequivocal 
objective results by x2 analysis (Ta­
ble IV).
Discussion
Eskin worked for many years in 
the animal laboratory on the hy­
pothesis that a low iodine or an 
iodine-deficient state rendered the 
rat breast more susceptible to dys­
plasia and carcinoma.21 His model 
consisted of Sprague-Dawley rats 
raised from birth on a Remington 
diet, which is iodine free with per­
chlorate blockade and causes an 
iodine-deficient state. His rat model 
approximated the microscopic find­
ings seen clinically with the triad of 
cystic spaces, epithelial and apo­
crine hyperplasia and interacinar fi­
brosis. Previous rat models pro­
duced by hormonal manipulation
FIG. 6. Effect of duration of treatment on breast size: percentage of women who 
reported decrease in breast size measured by brassiere size. This varied from 
one-half cup size to five cup sizes and was time dependent. Group 1 = 4 to 6 
months, group 2 = 7 to 18 months and group 3 =  more than 18 months.
FIG. 7. Histologic appearance of breast tissue refractory to treatment with 
molecular iodine. Note complete absence of normal acinar intraductular structure 
(hematoxylin-eosin stain).
T a b le  II I .  S ide E ffe c ts  o f  A queous
M o le cu la r Iod ine  T h e ra p y  in  S tu d y  2
W o m e n
S ide effect No. (% )  of w om en
Acne 1 5 (1 .1 )
Nausea 8 (0 .6 )
D iarrhea 2 ( 0 .1 )
H a ir th in n in g 1 3 (1 .0 )
H yp e rth y ro id is m 2 ( 0 .1 )
H yp o th y ro id ism 4 (0 .3 )
S k in  rash 3 ( 0 .2 )
lo d ism 2 ( 0 .1 )
H eadaches 3 (0 .2 )
Increased  pain 7 8  (5 .7 )
O ther 22  (1 .6 )
T o ta l 149  (1 0 .9 )
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resulted in excess fluid and hyper­
plasia but lacked the fibrotic ele­
ment.22'23
Eskin showed that there is a 
hierarchical response in the rat 
mammary gland to the type of io­
dine compound administered to cor­
rect the changes induced by iodine 
deprivation. Lugol’s iodine (I- ) cor­
rects the cystic spaces and partially 
corrects the epithelial hyperplasia 
and the fibrosis. The 5% free iodine 
(I2) in Lugol’s iodine could explain 
the partial resolution of the syn­
drome. Iodine caseinate (I- ) partial­
ly corrects the cysts and the hyper­
plasia but does not ameliorate the 
fibrosis. Iodine in its elemental 
form, I2, corrects the entire disease 
process. Thus, it seems that I2 is 
the preferential form of iodine for 
breast metabolism. This activity is 
localized in the terminal and in­
tralobular duct cells.24' 26
The human response to sodium 
iodide (I'), protein-bound iodide 
(I ')  or iodine (I2) paralleled Eskin’s 
findings in the experimental model. 
Our previous findings with sodium 
iodide and protein-bound iodide (I- ) 
have been reported; they showed a 
lesser response than we have ob­
tained with molecular iodine (I2).1819 
In addition, all iodides are thyro­
tropic, as Eskin has demonstrated, 
whereas I2 seems to be involved 
primarily in extrathyroidal activi­
ties. Our complication rate of ab­
normal thyroid indices was not 
above the expected incidence in the 
Great Lakes goitre region in un­
treated controls.
The exact mechanism of action of
I2 on breast tissue is not under­
stood. We do know that there is a 
differential absorption of iodides 
(I") and iodine (I2) from the gut of 
the Sprague-Dawley rat.27 It has 
been established that the only areas 
of the breast in which iodine can be 
found are in the terminal and in­
tralobular duct cells, a minuscule 
proportion of the total breast volu­
me.24-26 It is this area that is pri­
marily involved in cystic and malig­
nant changes. We theorize that the 
trace element, molecular iodine, is 
necessary for breast normality. Its 
absence renders the epithelium of 
the terminal and intralobular ducts 
more sensitive to estrogen stimula­
tion. This hypersensitivity can pro­
duce excess secretions over the 
limit of absorption, thus distending 
the acini to produce microcysts. 
The fluid in microcysts is extremely 
high in potassium,3 and this could 
act as an irritant, producing fibrosis 
and eventually cyst isolation.
Iodides are necessary for thyroi­
dal normality and are trapped by 
the thyroid. Thyroid tissues are rich 
in peroxidase, which oxidizes iodide 
(I~) to iodine (I2) on the way to the 
formation of monoiodotyrosine, di- 
iodotyrosine and finally triiodothy­
ronine and thyroxine. Breast tissue 
is peroxidase poor, and as such it 
cannot extract iodine (I2) from the 
circulating iodides. This has been 
dem onstrated by Eskin and 
others.24-28
It appears that the trace element 
I2 is essential for breast normality. 
The effect of the molecule on the 
terminal and intralobular duct cells
Table IV. R e su lts  o f  S u b je c tiv e  E va lua tion  A fte r  6  M o n th s  o f T re a tm e n t in W o m e n  in S tu d y  3  —  A 
P ro sp e c tive  D o u b le -B lin d  T r ia l o f A qu e o u s  Io d in e  T h e rapy
Evaluation
Control group 
( n  =  33)
Treated group 
( n  =  23)
No. (% ) No. (%)
S ub jec tive
W orse 0 ( 0 ) 0 (0 )
No change 2 2  (6 7 ) 8 (3 5 )
Im proved 11 (3 3 ) 1 5 (6 5 )
may be to render them less sensitive 
to circulating estrogens. As such it 
could be classed as a natural “an­
tiestrogen.” If this premise is borne 
out by further animal testing and 
larger clinical trials, it will be of 
importance for breast health, nor­
mality and longevity.
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ARTICLES ORIGINAUX
Patellectomie : resultats a long terme
Simon Cantin, MD; Claude Laroche, PhD; Pierre Lavallee, MD; Jean-Marc Lessard, MD
Les auteurs sont en disaccord avec la litterature au sujet du futur des genoux patellectomises suite a 
une fracture comminutive de la rotule. Ils ont evalue de facon retrospective 17 patients ayant subi une 
patellectomie unilateral post-traumatique entre 1955 et 1980. Une evaluation subjective et 
objective (examen clinique, radiologique et etude de force sur appareil Cibex II) a ete faite pour chaque 
patient en utilisant le genou sain controlateral comme temoin. Les resultats demontrent un haut niveau 
de satisfaction (88 %), l’absence d’instabilite ligamentaire et d’arthrose precoce, mais une diminution de 
la force de l’appareil extenseur du genou a 75 %. Les auteurs concluent que la patellectomie totale est 
une chirurgie bien toleree et moins morbide que ne le suggere la litterature.
The authors are in disagreement with the literature on the results of patellectomy after comminuted 
fracture of the patella. They assessed retrospectively 17 patients who underwent unilateral total 
patellectomy between 1955 and 1980. Subjective and objective (clinical examination, radiologic 
examination and Cibex II studies) assessment was carried out for each patient using the contralateral 
healthy knee as a control. The results demonstrated 88% patient satisfaction, no ligamentous 
instability and no early arthrosis but a decrease in extensor muscle strength to 75% of normal. The 
authors conclude that total patellectomy is better tolerated and causes less morbidity than suggested in 
the literature.
L a patellectomie est une chirur­gie ancienne. La premiere des­
cription, par Lister, remonte a 
1877. Depuis ce temps, de nom- 
breuses etudes ont decrit [’interven­
tion en bien ou en mal.
Actuellement, la patellectomie est 
consideree comme traitement de 
dernier recours lors d’une fracture.1 
On dit qu’elle est a l’origine d’insta­
bilite du genou,2 d’arthrose au ni­
veau des condyles femoraux.134 On 
dit egalement qu’elle est inestheti- 
que et qu’elle diminue la force d’ex- 
tension.1-2-4' 6
Notre experience clinique ne sem- 
ble pas corroborer cette optique. 
Nous avons decide de proceder a 
une etude clinique afin de faire le 
point sur ce sujet.
Patients et methode
L’etude porte sur un groupe de 
17 patients qui ont subi une patel­
lectomie unilateral, postfracture 
entre 1955 et 1980 au centre hospi- 
talier de l’Enfant-Jesus, Quebec, 
(Que). Le genou controlateral sain 
fut utilise comme temoin.
Le groupe comprend 6 femmes et 
11 hommes dont l’age moyen a 
l’examen etait de 49 ans. Le suivi 
moyen est de 21,5 ans. Les fractu­
res etaient en majorite a droite. 
Elies etaient toutes comminutives: 
dix etaient ouvertes. La majorite 
etait secondaire a un accident d’au- 
tomobile.
Les fractures associees au mem- 
bre inferieur ipsilateral se trou- 
vaient surtout au niveau de la partie 
distale du femur (trois fractures au 
niveau des condyles femoraux et 
une fracture du tibia).
Technique operatoire
Une incision transverse sur la 
peau et les fascias avec enucleation
de la rotule fut utilisee le plus 
souvent (16 cas sur 17). L’appareil 
extenseur fut par la suite rapproche 
pour combler la lacune laissee par 
la rotule, selon la methode de 
Brooke.
L’immobilisation postoperatoire, 
dans un cylindre platre a 0° de 
flexion, dura en moyenne 41,7 
jours. La physiotherapie a ete utili­
see chez huit patients. A court 
terme, une ankylose du genou fut 
traitee par mobilisation sous anes- 
thesie generate et, a long terme, 
une exerese de calcification sur le 
tendon extenseur fut pratiquee.
Evaluation
L’evaluation du genou fut basee 
sur un questionnaire, un examen 
clinique, des radiographies ainsi 
qu’un test sur Cibex II (Lumex 
Corp., Cyber Division, Ron Kon 
Koma, NY).
Du departement de chirurgie orthopedique, Hopital de TEnfant-Jesus, Universite Laval, Quebec (Que.)
Accepte pour publication le 10 decembre 1992
Les demandes de tires a part doivent etre adressees au O' Simon Cantin, Departement d ’orthopedie, Hopital de TEnfant-Jesus, 1401, 18e rue, 
Quebec. QCC1T 1Z4
CJS, VOL. 36, NO. 5, OCTOBER 1993 461
CANTIN ET AL
Le questionnaire est base sur le 
“ Cincinnati Rating System”7 deve- 
loppe par Noyes, McGinnis et 
Mooar.8 Celui-ci permet d’evaluer 
l’etat fonctionnel du genou lors 
d’activites.
Examen physique a ete fait par le 
meme membre de l’equipe (S.C.). 
L’examen verifiait la presence d’a- 
trophie au quadriceps, de liquide 
intra-articulaire, la stability des liga­
ments collateraux et croises, le 
deplacement de l’axe de rotation, 
l’extension, la flexion et la douleur 
a la palpation des differents compar­
tments du genou. Au meme mo­
ment, des radiographies des genoux 
furent faites en antero-posterieur, 
lateral et vue rotulienne.
Les forces des quadriceps furent 
etudiees sur Cibex II dans un mode 
isocinetique, selon la technique 
usuelle.7>9 Le travail total du quadri­
ceps fut etudie a une vitesse de 
6 0 ° /s  sur la moyenne de cinq cy­
cles pour le cote sain et patellecto- 
mise. Cette partie de l’examen fut 
faite par le physiotherapeute de 
l'equipe (C.L.).
Resultats
De fagon subjective, le genou 
patellectomise ne presente aucune 
douleur chez 59 %10 des patients, 
des douleurs a l’activite intense 
chez 35 %6 des patients et au travail 
ou sport modere chez 6 %l des 
patients, aucun patient ne presen- 
tait des douleurs a l’effort leger (p 
= 0,05).
Un seul patient decrit un gonfle- 
ment du genou patellectomise lors 
de sport ou de travail intense (p > 
0,05).
Le derobement se presente au 
niveau du genou patellectomise en 
aucun moment chez 41 % (sept) des 
patients, seulement a l’activite in­
tense chez 41 % (sept) des patients, 
a l’activite moderee chez 18 % 
(trois) des patients. Aucun patient
ne presente de derobement a l’acti­
vite legere (p < 0,001).
Quatre-vingt huit pourcent (15) 
des patients ont decrit aucune modi­
fication de leur travail, 12 % (2) des 
patients ont decrit une diminution 
de leur capacite de travail.
En ce qui a trait a la satisfaction 
subjective, 59 % des patients (10) 
decrivent avoir eu un excellent 
resultat avec absence d’handicap, 
29 % (5) un bon resultat avec un 
leger handicap qu’ils decrivent sur- 
tout comme un derobement, 6 % (1) 
des patients decrivent un resultat 
moyen et 6 % (1) un resultat mau- 
vais. Le mauvais resultat est surve-
nu chez un patient avec une frac­
ture sus et intercondylienne qui 
presente un deficit important de 
flexion et d'extension (10° et 35°).
A l'examen physique, aucune dif­
ference n’est notee quant a l’epan- 
chement intra-articulaire, aux dou­
leurs a la palpation, aux mouve- 
ments et a la stability ligamentaire 
(collateral et croisee). II existe une 
atrophie du quadriceps du cote pa­
tellectomise, de 1,2 cm (p < 0,05).
A l’examen radiologique aucune 
difference entre les deux genoux 
en ce qui a trait aux signes 
d’arthrose femoro-tibiale n’est de­
montree.
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PATELLECTOMIE
L’evaluation des forces d’exten- 
sion demontre une perte de force 
sur toute l’extension, mais surtout 
dans les 15 derniers degres de l’ex- 
tension. En moyenne, le genou pa- 
tellectomise est de 25 % moins puis­
sant. Paradoxalement, dans deux 
cas, le genou pallectomise etait plus 
puissant.
Discussion
L’evaluation a long terme nous 
demontre que 88 % des patients 
sont subjectivement satisfaits de la 
patellectomie totale (excellents et 
bons resultats) mais ceux-ci presen- 
tent un peu de derobement et des 
douleurs legeres comme principales 
plaintes. Ceci est corrobore par 
d’autres auteurs4-6’10-12
Nous n'avons pu retrouver chez 
nos patients aucune difference a 
long terme quant a l’arthrose1'3'4 et 
de l’instabilite2 telle que decrite par 
d’autres. L’examen physique n’a 
demontre aucune difference au ni­
veau de la stability ligamentaire des 
mouvements de flexion et d’exten- 
sion. Une atrophie moyenne de 1,2 
cm est observee ce qui semble etre 
moins que ce que la litterature 
decrit.212 Nous n’avons observe 
aucun «extension lag# suite aux 
patellectomies transverses.
La presence d’une fracture au 
niveau femoral et tibial, nous sem­
ble etre un facteur defavorable (dou- 
leur au travail, diminution de la 
flexion et de l’extension). D’autres 
facteurs tels que l’age au trauma, le 
cote fracture et le fait d’avoir une 
fracture ouverte n’influencent pas le 
pronostic.
L’evaluation sur Cibex II a 
demontre une diminution moyenne 
de 25 % de la force d’extension 
moyenne du genou. Cette diminu­
tion est etalee sur toute l’extension 
mais surtout au niveau des 15 der­
niers degres d’extension comme le 
confirme d’autres auteurs.9
Si nous utilisons le ((Cincinnati 
Rating System# tel que modifie par 
Saltzman dans son etude des patel­
lectomies partielles, nous retrou- 
vons les resultats suivants : 18 % 
excellent (trois patients), 53 % bon 
(neuf patients), 24 % moyen (quatre 
patients) et 6 % (un patient) mau- 
vais.
Si nous comparons nos resultats 
avec les resultats de Saltzman et 
collegues7 sur les patellectomies 
partielles, en utilisant les memes 
criteres, les genoux ayant une patel­
lectomie partielle presentent plus de 
douleurs (58 % contre 40 %) et 
d’epanchement (10 % contre 6 %). 
La patellectomie totale presente 
plus de derobement (59 % contre 
12 %) et d’atrophie du quadriceps 
(1,2 cm contre 0 cm). Au niveau 
cinetique, la patellectomie partielle 
preserve 85 % de la force d’exten­
sion par rapport a 75 % pour la 
patellectomie totale. La radiologie 
montre la presence d’arthrose patel- 
lo-femorale importante chez les pa­
tellectomies partielles (53 %). Au 
niveau des complications a long 
terme, 3 des 40 patellectomies par­
tielles ont du subir une conversion 
en patellectomie totale, comparati- 
vement a un patient ayant eu une 
exerese d’une calcification chez nos 
patellectomies totales. Au niveau du 
pointage final la patellectomie par­
tielle presente 77 % de bons et 
d’excellents resultats apres 8,4 ans 
de suivi, comparativement a 71 % 
pour les patellectomies totales apres 
21,5 ans de suivi.
Conclusions
Notre etude semble confirmer 
notre impression clinique, la patel­
lectomie totale est une chirurgie qui 
permet un etat fonctionnel adequat 
apres une fracture comminutive de 
la rotule. II nous semble clair que 
celle-ci n’amene aucune arthrose ou 
instabilite mais provoque une dimi­
nution de la force d’extension.
11 semble que la patellectomie 
partielle preserve un etat fonction­
nel plus grand du genou, mais 
celle-ci apporte plus de douleur et 
demande plus souvent une seconde 
chirurgie que la patellectomie tota­
le.
Done devant une fracture commi­
nutive de la rotule, nous pouvons 
orienter le traitement selon l’etat de 
comminution et les besoins du pa­
tient.
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Intramedullary Nailing of Femoral Shaft 
Fractures: Reoperation and Return to Work
Drew A. Bednar, MD, CM, FRCSC, FAAOS; Pervez Ali, MD
Objective: To define the functional outcome and residual disability in adults treated for isolated femoral 
shaft fractures.
Design: A retrospective case study of HMRI records. The mean follow-up was 34.5 months from the 
time of injury.
Setting: A tertiary-care teaching hospital.
Patients: One hundred and thirty adults with femoral shaft fractures. Of these, 47 were isolated and 
qualified for study.
Interventions: Primary reamed intramedullary nailing performed between April 1987 and September 
1990.
Main Outcome Measures: Reoperation and return to work.
Results: Of the 47 patients, primary healing occurred in 41 (87%) patients; 6 (13%) patients had 
delayed union or nonunion. Twenty (43%) patients had delayed implant-related pain after fracture 
healing; 85% of these had relief of pain after implant removal. Of 41 patients available for analysis of 
function based on return to work, 33 (80%) had returned to work full time in their original occupation 
at the time of follow-up, and 4 (10%) were working in other full-time employment; 3 (7%) were working 
part time. Only one (2%) patient was disabled and unable to work.
Conclusions: Primary reamed intramedullary nailing is an effective method of achieving consistent 
primary union in adults with femoral shaft fractures. However, the majority of patients will require 
secondary surgery. Most patients will be able to return to work after these injuries.
Objectif : Definir les resultats fonctionnels et l’incapacite residuelle chez des adultes traites pour une 
fracture isolee de la tige du femur.
Conception : Une etude retrospective de cas, a partir des dossiers d’hopitaux. La periode moyenne de 
surveillance des suites therapeutiques a ete de 34,5 mois, a partir du moment de la blessure.
Contexte : Un hopital universitaire de soins tertiaires.
Patients : Cent trente adultes qui avaient subi une fracture isolee de la tige du femur. Parmi ceux-ci,
47 rencontrerent les criteres d’admissibilite.
Interventions : Les enclouages medullaires primaires realises entre avril 1987 et septembre 1990. 
Principaux effets mesures: Les reoperations et la reprise du travail.
Resultats : Une guerison primaire est survenue chez 41 des 47 patients (87 %); 6 (13 %) eurent une 
fusion retardee ou une absence de fusion. Vingt patients (43 %) souffrirent de douleurs persistantes 
associees a l’implant; 85% de ceux-ci eurent un soulagement de la douleur apres le retrait de l’implant. 
Des 41 patients permettant une analyse fonctionnelle s’appuyant sur la reprise du travail, 33 (80 %) 
avaient repris leur travail anterieur a plein temps au moment du suivi et 4 (10 %) vaquaient a d’autres 
emplois a plein temps; 3 (7 %) avaient un emploi a temps partiel. Seulement un patient (2 %) avait une 
incapacity ne lui permettant pas de reprendre le travail.
Conclusions : L’enclouage medullaire primaire est une methode efficace d’obtenir regulierement une 
fusion primaire chez les adultes qui subissent une fracture de la tige du femur. Toutefois, la majority 
des patients necessitent une chirurgie secondaire. La plupart des patients sont capables de reprendre le 
travail apres de telles blessures.
From the Division o f Orthopedic Surgery, Department o f  Surgery, McMaster University, Hamilton, Ont.
Accepted fo r publication Apr. 7, 1993
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INTRAMEDULLARY NAILING
Reamed intramedullary nailing of femoral shaft fractures in 
adults is accepted as the treatment 
of choice in North America.1-4 The 
operative technique and postopera­
tive management are well defined5' 7 
and predictably lead to union in 
most cases.
The extensive literature dealing 
with this subject has generally ad­
dressed the clinical end point of 
radiographic union as the goal of 
management. Little attention has 
been paid to return to work and 
residual debility after this treat­
ment.
A retrospective study of the expe­
rience of adult patients treated for 
isolated femoral shaft fractures was 
undertaken to define functional out­
come and residual debility in this 
population.
Patients and Methods
The medical records of 130 
adults treated with primary reamed 
intramedullary nailing between 
April 1987 and September 1990 
were reviewed after retrieval from 
the Hospital Medical Records Insti­
tute (HMRI).
Patients whose injuries included 
other lesions affecting weight bear­
ing were excluded, as were those 
treated by other means. Eighty- 
three (64%) patients did not qualify 
for this review; they included 9 
patients treated primarily with 
plates, 8 patients with bilateral fem­
oral shaft fractures, 15 patients 
with floating knees, 31 patients 
suffering massive multiple injuries 
and 20 patients whose mobility was 
compromised by comorbid disease 
or prior injury. Only 47 index cases 
(39 male, 8 female) were thereby 
available for review.
After appropriate review of the 
HMRI records and radiographic 
files, the study patients were con­
tacted by telephone for current sta­
tus review and to confirm the accu­
racy of the data on file.
Results
Demographics
The mean age of the patients was 
22 years. Thirty-eight (81%) frac­
tures were closed and 9 (19%) were 
open. Three patients were known to 
be unemployed at the time of inju­
ry, and another was an unemploy­
able schizophrenic. One geriatric 
patient was retired. The mean 
length of follow-up at the time of 
review was 34.5 months from inju­
ry.
Etiology
In all patients the fractures were 
caused by blunt trauma: 35 (74%) 
were driving a motor vehicle at the 
time of injury, and 4 (9%) were 
pedestrians struck by a vehicle; 4 
(9%) were injured in falls, 3 (6%) 
were injured at sport and 1 (2%) 
was injured otherwise.
Primary Surgery
All patients underwent internal 
fixation with either primary reamed 
Grosse-Kempf or standard Russell- 
Taylor nails. Eighty-nine percent of 
primary operations were undertaken 
within 72 hours of injury. Only one 
nail was not locked; 37 (79%) were 
statically locked, and 9 (19%) were 
dynamic nailings, most of these 
from early in the series.
Secondary Surgery for Nonunion
Six patients had delayed or non­
union, defined by persisting pain 
and tenderness with open fracture 
lines radiologically 3 months or 
more after the intramedullary nail­
ing. Three of these were initially 
dynamic nailings (primary healing
in 67% of fractures [6 of 9] in this 
group) and three were initially stati­
cally locked (primary healing in 
92% of fractures [34 of 37] in this 
group).
Three patients requiring reopera­
tion to achieve union had open 
fractures (primary union in 67% [6 
of 9]), and the other three were 
initially closed (primary union in 
92% [35 of 38]).
Delayed or nonunion was ma­
naged by reoperation involving 
overreaming and static renailing. In 
these six patients, five fractures 
united and one demonstrated per­
sisting nonunion radiographically, 
but the patient refused further in­
tervention in the absence of symp­
toms.
Secondary Surgery for Pain
Twenty (43%) patients presented 
with activity-related hip (14 pa­
tients, 30%) or knee (6 patients, 
13%) pain that appeared clinically 
to be related to the implant. Remov­
al of the implant was undertaken 
electively at a mean of 20 months 
after injury.
There were no repeat fractures 
after implant removal (mean follow­
up 15 months). Seventeen (85%) of 
these patients had subsequent pain 
relief, including 12 (86%) of the 14 
patients who had hip pain and 5 
(83%) of the 6 patients who had 
knee pain.
Secondary Surgery for Implant 
Removal
In 19 patients not complaining of 
pain, elective implant removal was 
undertaken at a mean of 21 months 
after injury on the advice of the 
treating physician. Four (21%) pa­
tients in this group noted that their 
residual discomfort improved after 
implant removal. No patient had 
any increase in pain after secondary 
surgery.
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Secondary Surgery for Reinjury
One patient had a second motor­
cycle accident 6 months after the 
original injury, suffering fractures 
through the locking screws at both 
ends of his Grosse-Kempf nail (a 
displaced subcapital fracture of the 
femoral neck and a transcondylar 
fracture of the distal femur). De­
spite reoperation he did not do well 
and remains disabled.
Return to Work
The reinjured patient’s devastat­
ing injuries excluded him from this 
analysis. The unemployable schizo­
phrenic was also excluded as was 
the retiree. Of the remaining 44 
patients, 3 were unemployed at the 
time of injury, leaving 41 patients 
for analysis of return to work.
Patients returned to work on 
average 4 months after injury. At 
follow-up 33 patients (80%) had 
returned to full-time preinjury em­
ployment. Another four patients 
(10%) were working full-time in 
other jobs, and three (7%) were 
working part-time. Only one patient 
(2%) remained disabled at the time 
of follow-up.
Discussion
Extensive documentation in the 
current literature has established 
reamed intramedullary nailing of 
adult femoral shaft fractures as a 
consistent, reliable treatment.1'3' 5 
Technique in achieving optimum 
radiographic and clinical union is 
well described.2'67 Very little atten­
tion has been given to the clinically 
important issues of requirement for 
secondary operation in united frac­
tures, return to work or residual 
disability.
Our review confirms the recog­
nized high rate of primary fracture 
union with this treatment1' 4 and the
low rate of complications after im­
plant removal.2
We found that 43% of patients 
with united fractures experienced 
hip or knee pain after reamed in­
tramedullary nailing. The cause of 
this pain may be multifactorial.2'8 Of 
these patients, 85% obtained signifi­
cant relief of pain after implant 
removal.
Ninety percent of patients re­
turned to full-time employment. An­
other 7% returned to part-time 
work. Only 2% of adult patients 
treated with primary reamed in­
tramedullary nailing for isolated 
fractures of the femoral shaft will 
remain disabled 3 years after injury.
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hypertension; usually administered in association with other drugs, 
particularly thiazide diuretics. Consider the risk of angioedema (see 
WARNINGS). Normally used when a diuretic or beta-blocker was ineffective 
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agent where a diuretic and/or beta-blocker is contraindicated or could 
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Angioedema, with laryngeal edema and/or shock, have been reported 
and may be fatal. In such cases, discontinue drug promptly and observe 
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use, may be at increased risk (see CONTRAINDICATIONS).
Symptomatic hypotension has occurred, usually during initial therapy 
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volume-depleted. In patients with severe congestive heart failure, excessive 
hypotension may be associated with oliguria and/or progressive azotemia. 
For patients in whom the excessive hypotension could result in severe or 
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heart or cerebrovascular disease -  start therapy under close medical 
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H yperkalem ia : In clin ical trials, hyperkalemia (>5.7 m mol/L) was 
observed in approximately 1% of hypertensive patients, and caused 
discontinuation of therapy in 0.28% of such patients. Risk factors tor 
hyperkalemia development may include renal insufficiency, diabetes 
mellitus, and concomitant use of agents to treat hypokalemia (see 
ADVERSE REACTIONS).
Valvular Stenosis: Theoretically, patients with aortic stenosis, who do 
not develop as much afterload reduction, might be at risk of decreased 
coronary perfusion when treated with vasodilators. 
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ADVERSE REACTIONS
VASOTEC®: In controlled clinical trials involving 2314 hypertensive 
patients and 363 heart failure patients, the most severe adverse reactions 
were: angioedema (0.2%), hypotension (2.3%) and renal failure (5 cases). 
In hypertensive patients, hypotension occurred in 0.9% and syncope in
0.5%, with a discontinuation rate of 0.1%. In heart failure patients, 
hypotension occurred in 4.4% and syncope in 0.8%, with a discon­
tinuation rate of 2.5%. The most frequent clinical adverse reactions in 
controlled clinical trials were: headache (4.8%), dizziness (4.6%) and 
fatigue (2.8%). Discontinuation of therapy was required in 6.0% of the 
2677 patients.
Hypertension Heart Failure
% %
(2314 Patients) (3 6 3  P a tie n ts )
CARDIOVASCULAR
Hypotension 
Chest Pain 
Palpitations
Myocardial Infarction, Acute 
Myocardial Infarction, Recurrent 
GASTROINTESTINAL 
Nausea 
Vomiting 
Dysphagia 
Diarrhea 
Abdominal pain 
RENAL 
Renal failure 
Oliguria 
Proteinuriat 
DERMATOLOGIC 
Rash 
Pruritus
NERVOUS SYSTEM
Headache 
Dizziness 
Insomnia 
Nervousness 
Somnolence 
Paresthesia 
ALLERGIC 
Cough 
Angioedema 
HEMATOLOGIC 
Anemia 
Leukopenia 
MISCELLANEOUS 
Muscle cramps 
Dyspnea
0.9 4.4
0.9 1.7
0.6 0.3
0.2 0.6
— 0.3
1.4 1.1
0.8 1.7
0.1 —
1.4 3.0
0.7 1.4
0.1 0.6
1 case —
0.1 —
1.4 1.9
0.4 1.4
5.2 2.2
4.3 6.6
0.5 0.3
0.6 —
0.6 —
0.6 —
1.3 1.4
0.2 —
0.1 _
1 case —
0.6 0.3
0.6 1.1
MISCELLANEOUS (cont'd)
Hyperhidrosis 0.7 _
Impotence 0.4 0.3
Fatigue 3.0 1.4
Taste disturbance 0.4 0.3
t  Defined as >1g/24h or >0.5 g/12h on two consecutive measurements,
at least one month apart.
ABNORMAL LABORATORY FINDINGS
Hyperkalemia: (see PRECAUTIONS).
Creatinine, Blood Urea Nitrogen: Increases were reported in about 
20% of patients with renovascular hypertension and about 0.2% of patients 
with essential hypertension on enalapril alone. Increases, which usually 
were reversible upon discontinuation of enalapril or concomitant therapy, 
were reported in 9.7% of heart failure patients who were receiving diuretics 
and/or digitalis.
Hemoglobin and Hematocrit: Decreases (mean approximately 0.34 
g% and 1.0 vol%, respectively) occurred frequently, but were rarely of 
c lin ic a l im portance. In c lin ica l tria ls , less than 0.1% of patients 
discontinued therapy due to anemia.
Hepatic: Elevations of liver enzymes and/or serum bilirubin have occurred 
(see PRECAUTIONS).
ADVERSE REACTIONS REPORTED IN UNCONTROLLED TRIALS 
AND/OR MARKETING EXPERIENCE 
W ith  an in c id en ce  of 0 .5  to 1% : Insomnia, impotence, renal 
dysfunction, renal failure and oliguria.
W ith an incidence < 0.5% :
C ardiovascular: Myocardial infarction or cerebrovascular accident, 
possibly secondary to excessive hypotension in high risk patients (see 
WARNINGS); cardiac arrest; pulmonary embolism; rhythm disturbances; 
angina pectoris. G a s tro in te s tin a l: Anorexia; ileus; pancreatitis; 
dyspepsia; constipation. Hemopoeitic: Neutropenia; thrombocytopenia; 
bone marrow depression. Hepatic: Liver function abnormalities; hepatitis; 
jaundice (hepatocellu la r and/or cholestatic) Nervous S y s te m / 
Psychiatric: Vertigo; depression; confusion; ataxia. Respiratory: 
Bronchospasm/asthma; rhinorrhea. O ther: Erythema m ultiform e; 
exfoliative derm atitis; Stevens-Johnson syndrome; toxic epidermal 
necrosis; urticaria; photosensitivity; alopecia; flushing; tinnitus; hearing 
impairment; gloss itis; blurred vision. A symptom complex has been 
reported w hich may include fever, seros itis , vasculitis, m yalg ia, 
arthralgia/arthritis, a positive ANA, elevated erythrocyte sedimentation rate, 
e o s in o p h ilia  and leuko cytos is . Rash, photosens itiv ity  or other 
dermatologic manifestations may occur. These symptoms have disap­
peared after discontinuation of therapy.
LABORATORY TEST FINDINGS: Hyponatremia 
VASOTEC® I.V .:  Since enalapril is converted to enalaprilat, those 
adverse reactions associated w ith VASOTEC® tablets might also be 
expected to occur with VASOTEC® I.V. The incidence of symptomatic 
hypotension is 3.4% with VASOTEC® I.V. Other adverse experiences 
occurring in greater than 1% of patients were headache (2.9%) and nausea 
(1.1 %). Adverse reactions occurring in 0.5 to 1.0% of patients in controlled 
clinical trials include myocardial infarct, fatigue, dizziness, fever, rash and 
constipation.
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Lim ited human data are available. The most likely manifestation of 
overdosage would be hypotension, which can be treated by I.V. infusion of 
normal saline solution. Enalaprilat may be removed from the general 
circulation by hemodialysis.
DOSAGE AND ADMINISTRATION 
VASOTEC® FOR ORAL ADMINISTRATION ONLY
Dosage must be individualized. The absorption of enalapril maleate is not 
affected by food.
HYPERTENSION
Initiation of enalapril requires consideration of extent of blood pressure 
elevation, salt restriction and recently used anti hypertensive agents, the 
dosage of which may need to be adjusted.
The recommended initia l dose of enalapril maleate in patients not on 
diuretics is 5 mg once a day. Adjust dosage according to blood pressure 
response; the usual range is 10 to 40 mg daily, in a single dose or divided 
in two doses. Some patients on once-daily dosage may have diminished 
antihypertensive effect toward the end of dosing interval and require an 
increase in dosage, or twice daily administration. If blood pressure is not 
controlled, a diuretic may be added. Raising the daily dose above 40 mg is 
not recommended because adverse reactions may be increased. 
Occasionally symptomatic hypotension may occur following the initia l 
dose, more likely in patients currently taking a diuretic. Therefore, if 
possible, discontinue the diuretic two to three days before initia ting 
enalapril therapy (see WARNINGS). If the diuretic cannot be discontinued, 
use an initial dose of 2.5 mg.
In the absence of sufficient experience in the treatment of accelerated or 
malignant hypertension, enalapril is not recommended in such situations. 
Dosage in the Elderly (over 65 years): Start at 2.5 mg daily. Some 
elderly patients may be more responsive than younger patients.
Dosage Adjustment in Renal Impairment: (see PRECAUTIONS -  
Hemodialysis patients)
Guidelines for reducing doses in hypertensive patients:
Renal Status
Creatinine
Clearance
m L/m in(mL/s)
In itia l Dose 
mg/day
Normal renal 
function
>80 mL/min 
(>1.33 mL/s)
5 mg
Mild impairment <80 >30 mL/min 
(<1.33 >0.50 mL/s)
5 mg
Moderate to 
severe impairment
£ 30  mL/min 
(<0.50 mL/s)
2.5 mg
Dialysis patients 2.5 mg on 
dialysis days*
* Enalaprilat is dialysable. Dosage on nondialysis days should be adjusted 
depending on the blood pressure response.
CONGESTIVE HEART FAILURE
Use in conjunction with a diuretic and digitalis. Initiate therapy under close 
medical supervision, usually in a hospital. Monitor blood pressure and 
renal function before and during treatment with enalapril, because severe 
hypotension, and more rarely, consequent renal failure have been reported 
(see WARNINGS and PRECAUTIONS).
When in itia tin g  ena lapril consider the recent d iure tic therapy and 
possibility of severe salt/ volume depletion. Before beginning enalapril 
reduce diuretic therapy if possible.
The recom m ended in it ia l d a ily  dose is 2.5 mg. W hile  m anaging 
sym ptom atic hypotension, increase dose gradually, depending on 
indiv idual response, to the usual maintenance dose of 10-20 mg daily, 
given in a single dose or divided in two doses. This dose titration may be 
performed over a two- to four-week period, or more rapidly if indicated by 
residual signs and symptoms of heart failure. The maximum daily dose is 
40 mg.
VASOTEC® I.V . FOR INTRAVENOUS ADMINISTRATION ONLY
VASOTEC® I.V. vials should be inspected visually and should not be used 
if particulate matter or discoloration is observed.
VASOTEC® I.V. may be administered intravenously as supplied, or mixed 
with up to 50 mL of one of the following diluents:
5% Dextrose Injection 
0.9% Sodium Chloride Injection 
0.9% Sodium Chloride Injection in 5% Dextrose 
5% Dextrose in Lactated Ringer’s Injection 
Diluted solutions should be used within 24 hours.
The dose is 1.25 mg every 6 hours administered intravenously over at least 
5 minutes. A clinical response is usually seen within 15 minutes. Peak 
effects after the first dose may not occur for up to four hours after dosing. 
The peak effects of the second and subsequent doses may exceed those of 
the first.
No dosage regimen for VASOTEC® I.V. has been clearly demonstrated to' 
be more effective in treating hypertension than 1.25 mg every 6 hours. 
However, in controlled clinical studies in hypertension, doses as high as 5 
mg every 6 hours were well tolerated for up to 36 hours. There has been 
inadequate experience with doses greater than 20 mg per day.
In studies of patients with hypertension, VASOTEC® I.V, has not been 
administered for periods longer than 48 hours. In other studies, patients 
have received VASOTEC® I.V. for as long as 7 days.
The dose for patients being converted to VASOTEC® I.V. from oral therapy 
fo r hypertension w ith  enalapril maleate is 1.25 mg every 6 hours 
administered intravenously over at least 5 minutes. For conversion from 
intravenous to oral therapy, the recommended initial dose of VASOTEC® 
tablets is 5 mg once a day with subsequent dosage adjustm ents as 
necessary.
Patients on D iuretic Therapy
For patients on diure tic therapy, the recommended starting dose for 
hypertension is 0.625 mg administered intravenously over at least
5 minutes. A clinical response is usually seen within 15 minutes. Peak 
effects after the first dose may not occur for up to 4 hours after dosing, 
although most of the effect is usually apparent within the first hour. If after 
1 hour there is an inadequate clinical response, the 0.625 mg dose may 
be repeated. Additional doses of 1.25 mg may be administered at 6 hour 
intervals.
For conversion from intravenous to oral therapy, the recommended initia l 
dose of VASOTEC® tablets for patients who have responded to 0.625 mg of 
enalaprilat every 6 hours is 2.5 mg once a day with subsequent dosage 
adjustment as necessary.
Dosage Adjustment in Renal Impairm ent 
The usual dose of 1.25 mg of enalaprilat every 6 hours is recommended for 
patients with a creatinine clearance >30 mL/min [> 0.50 mL/s] (serum 
creatinine up to approximately 3 mg/dL [265.2 pmol/L]). For patients with 
crea tin ine  clearance <30 m L/m in [<0 .50  m L/s ] (serum  crea tin ine  
>3 mg/dL [>  265.2 |jmol/L]), the initial dose is 0.625 mg (see WARNINGS). 
If after 1 hour, there is an adequate clinical response, the 0.625 mg dose 
may be repeated. Additional doses of 1.25 mg may be administered at
6 hour intervals.
For dialysis patients, the initial dose should be 0.625 mg every 6 hours, 
(see PRECAUTIONS - Hemodialysis patients).
For conversion from intravenous to oral therapy, the recommended initia l 
dose of VASOTEC® is 5 mg once a day for patients w ith  creatinine 
clearance >30 mL/min [>0.50 mL/s] and 2.5 mg once daily for patients with 
creatinine clearance <30 mL/min [<0.50 mL/s]. Dosage should then be 
adjusted according to blood pressure response.
AVAILABILITY OF DOSAGE FORMS
Barrel-shaped, biconvex tablets, engraved with code number on one side
and VASOTEC on other.
VASOTEC® 2.5 mg - yellow, scored, engraved 14.
VASOTEC® 5 mg - white, scored, engraved 712.
VASOTEC® 10 mg - rust-red, engraved 713.
VASOTEC® 20 mg - peach, engraved 714.
All strengths available in bottles of 100 tablets.
VASOTEC® I.V. 1.25 mg per mL, is a clear, colourless solution and is 
supplied in vials containing 2 mL.
PRODUCT MONOGRAPH AVAILABLE ON REQUEST 
(490iv-a.11.92)
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Anterior and Posterior Spinal Fusion: 
Comparison of One-Stage and Two-Stage 
Procedures
G. Richard Viviani, MD, FRCSC;* Viorel Raducan, MD, FRCSC;t
Drew A. Bednar, MD, CM, FRCSC, FAAOS;* Waldemar Grandwilewski, MD*
Objective: To compare postoperative morbidity and length of hospital stay after combined anterior and 
posterior spinal fusion for patients treated by a one-stage procedure and those treated in two stages, 1 
to 2 weeks apart.
Design: Retrospective review of all cases handled by the first author between July 1989 and November 
1991. The patients had been referred for treatment of severe spinal deformity, scoliosis or kyphosis by 
combined anterior and posterior spinal fusion.
Setting: The operations were performed at McMaster University Medical Centre, Hamilton, Ont., by the 
first author, who was assisted by another specialist in spinal surgery and a fellow or resident.
Patients: Eleven operations of each type were performed. The mean age of the 22 patients was 16.6 and 
14.6 years for those who underwent the one-stage and the two-stage procedures respectively. The 
diagnoses included neuromuscular disease, neurofibromatosis, spina bifida, congenital kyphoscoliosis 
and severe idiopathic spinal curvature. The one-stage procedure was used after the surgical team 
became able to provide the care associated with this type of major surgery; selection of patients also 
involved preoperative risk assessment and the feasibility of combining two surgical procedures that 
would take a maximum of 9 hours. The preoperative plan was to spend a maximum of 9 hours in 
performing the one-stage procedure.
Interventions: Similar surgical procedures were performed in both groups. The average number of 
intervertebral levels fused during the anterior component of the operation was 4.6 in the one-stage 
procedure and 6.0 in the two-stage procedure. Thoracolaparotomy was performed in four patients who 
underwent the two-stage procedure. During the posterior component of the operation, instrumentation 
was inserted through an average of 11.6 and 12.6 intervertebral levels in the groups undergoing the 
one-stage and the two-stage procedures respectively. Total operating time averaged 7 hours and 15 
minutes for the one-stage procedure and 11 hours for the two-stage procedure. Mean blood loss was 
1830 mL for the one-stage procedure and 2270 mL for the two-stage procedure.
Main Outcome Measures: The number of days spent in the intensive care unit (ICU) and the total 
number of days spent in hospital, as well as morbidity after the operation, were determined.
Results: Postoperative morbidity included five minor complications in patients who underwent a 
one-stage procedure; all of these complications resolved well. Among those who underwent the 
two-stage procedure there were 11 complications; in two patients further surgery was required. The 
patients’ stay in the ICU averaged 2.6 and 7.7 days respectively for one-stage and two-stage 
procedures, and the total stay in hospital averaged 14 and 33 days respectively.
Conclusions: When possible, the one-stage procedure for anterior and posterior spinal fusion is 
preferred over the two-stage procedure because of a significant reduction in the length of stay in the 
ICU and in hospital, as well as reduced morbidity. However, this analysis should be interpreted 
cautiously because of the small number of cases and the variables encountered in treating this type of 
spinal deformity.
From the *Division of Orthopedic Surgery, Department o f  Surgery, McMaster University, Hamilton, Ont., and the f  Division o f Orthopedic Surgery 
Department o f  Surgery, University o f  Manitoba, Winnipeg, Man.
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Objectif: Comparer la morbidite postoperatoire et la duree de l’hospitalisation apres une fusion 
anterieure et posterieure simultanee des vertebres chez les patients traites au moyen d’une 
intervention en une etape et chez ceux qui sont traites au moyen d’une intervention en deux etapes 
espacees d’une ou 2 semaines.
Conception : Etude retrospective de tous les cas dont le premier auteur a ete responsable entre juillet 
1989 et novembre 1991. Les patients avaient ete presentes pour traitement de malformation grave de la 
colonne vertebrale, de scoliose ou de cyphose au moyen d’une fusion anterieure et posterieure 
simultanee des vertebres.
Contexte : Le premier auteur a realise les operations au Centre medical de l’Universite McMaster avec 
l’aide d’un autre specialiste en chirurgie de la colonne vertebrale et d’un associe ou d’un resident. 
Patients : On a effectue 11 operations de chaque type. En moyenne, les 22 patients qui ont subi 
l’intervention en une etape etaient ages de 16,6 ans et ceux qui ont subi 1’intervention en deux etapes 
etaient ages de 14,6 ans. Les diagnostics portaient sur des maladies neuromusculaires, la 
neurofibromatose, le spina-bifida, la cyphoscoliose congenitale et une grave courbure rachidienne 
idiopathique. Lorsque l’equipe chirurgicale a ete en mesure de fournir les soins lies a ce type de 
chirurgie lourde, on a pratique l’intervention en une etape; la selection des patients comportait aussi 
une evaluation des risques preoperatoires et de la faisabilite de combiner deux interventions 
chirurgicales d’une duree de 9 heures. La planification chirurgicale a donne lieu a un plan 
preoperatoire qui consistait a consacrer 9 heures au maximum a la realisation de l’intervention en une 
etape.
Interventions : Dans les deux groupes, on a effectue des interventions chirurgicales semblables. Au 
cours de la composante anterieure de l’operation, on a fusionne un nombre moyen de 4,6 etages 
intervertebraux dans le cadre de l’intervention en une etape et de 6,0 etages intervertebraux dans le 
cadre de l’intervention en deux etapes. Chez quatre patients qui ont subi l’intervention en deux etapes, 
on a pratique une thoracolaparotomie. Au cours de la composante posterieure de l’operation, on a 
introduit des instruments dans 11,6 et 12,6 etages intervertebraux en moyenne pour les groupes qui 
ont subi respectivement les interventions en une etape et en deux etapes. La duree totale de l’operation 
etait de 7 heures et 15 minutes en moyenne pour l’intervention en une etape et de 11 heures pour 
l’intervention en deux etapes. La perte sanguine moyenne etait de 1 830 mL pour l’intervention en une 
etape et de 2 270 mL pour l’intervention en deux etapes.
Principales mesures des resultats : On a determine le nombre de jours passes a l’unite des soins 
intensifs (USI) et le nombre total de jours d’hospitalisation, de meme que la morbidite apres 
l’operation.
Resultats : La morbidite postoperatoire regroupait cinq complications legeres chez des patients qui ont 
subi l’intervention en une etape; toutes ces complications ont eu une issue positive. Chez ceux qui ont 
subi l’intervention en deux etapes, 11 complications sont survenues ; deux patients ont eu besoin de 
chirurgie supplemental. Le sejour des patients a l’USI a dure en moyenne 2,6 et 7,7 jours 
respectivement pour les interventions en une etape et en deux etapes, et la duree respective 
l’hospitalisation etait de 14 et 33 jours au total.
Conclusions : Dans la mesure du possible, il faut preferer l’intervention en une etape pour la fusion 
anterieure et posterieure des vertebres a 1’intervention en deux etapes etant donne une reduction 
significative de la duree du sejour a l’USI et de l’hospitalisation, de meme qu’une morbidite reduite. 
Cependant, cette analyse devrait etre interpretee prudemment en raison du petit nombre de cas et des 
variables rencontrees dans le traitement de ce type de malformation de la colonne vertebrale.
The treatment of severe spinal deformity represents a major 
challenge, one that often requires 
both anterior and posterior ap­
proaches to spinal fusion to achieve 
optimal realignment and consistent 
arthrodesis. The advantages of this 
aggressive approach are well docu­
mented.1-10 Such major reconstruc­
tive surgery has traditionally been 
performed in stages because of con­
cerns about the length of the proce­
dure and surgeon fatigue. However, 
it has recently been recognized that 
appropriately trained and prepared 
surgical teams can perform such 
operations in one stage. The major 
potential advantages include de­
creased morbidity and diminished 
length and cost of the stay in 
hospital.11
Staged procedures have been the
routine at our centre, but recent 
recruitment of staff presented the 
opportunity for a team of two quali­
fied surgeons to undertake such 
procedures in one stage. A protocol 
was devised to allow for the com­
parison of a series of patients treat­
ed by the one-stage procedure with 
a previous series of the same num­
ber of patients who had been treat­
ed in two stages. This study was
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not randomized or blinded, as such 
a design was not possible for treat­
ing patients with these abnormali­
ties. Consequently, the results of' 
the comparison should be interpret­
ed cautiously.
Planning for the one-stage proce­
dure was complex, because such 
surgery necessitates multidiscipli­
nary support both during and after 
the operation. Contributions from 
the departments of anesthesia and 
critical care were of particular im­
portance.
Patients and Methods
Between July 1989 and Novem­
ber 1991, 22 consecutively referred 
patients underwent combined ante­
rior and posterior spinal fusion for 
severe spinal deformity. Eleven pa­
tients underwent the operation in 
two stages separated by 1 to 2 
weeks, and 11 underwent the one- 
stage procedure, in which one of 
the authors (G.R.V.) was supported 
by another trained spinal surgeon 
and a senior resident.
Preoperative evaluation for the 
patients scheduled to undergo the 
one-stage procedure included con­
sultations with the anesthetist and a 
critical care physician. Several pa­
tients made preoperative autolo­
gous blood donations, but no in­
traoperative blood salvage was pos­
sible. During preoperative planning 
an arbitrary goal of a maximum of 
9 hours operating time was estab­
lished in consideration of the pa­
tients’ well-being, the availability of 
time in the operating room and the 
availability of an anesthetist.
After surgery, every patient was 
admitted to the intensive care unit 
(ICU), where his or her condition 
was monitored routinely until it was 
stable enough for the patient to be 
moved to the ward. Patients who 
underwent the two-stage procedure 
were admitted to the ICU twice.
The surgical technique included 
rigid internal fixation to allow rapid 
primary mobilization without or- 
thotic support or restriction.
Results
Demographics
The three females and eight 
males who underwent the one-stage 
procedure ranged in age from 7 to 
40 years (mean 16.6 years); six 
were between the ages of 7 and 13 
years.
The eight females and three 
males who underwent the two-stage 
procedure ranged in age from 7 to 
30 years (mean 14.6 years). Seven 
of the patients in this group were 
between the ages of 7 and 13 years.
Diagnoses
The patients in both groups ex­
hibited a wide variety of conditions 
producing major spinal deformity 
(Table I). These conditions included 
neuromuscular disease, neurofi­
bromatosis, dysraphism, congenital 
scoliosis and kyphosis, as well as 
high-grade idiopathic curvature 
(Fig. 1).
Surg ical Procedure
The surgical undertaking was of 
a similar magnitude in the two 
groups, the major difference being 
the anatomic extent of the anterior 
surgery. Thoracolaparotomy was 
not performed in the one-stage 
group but was performed four times 
in the two-stage group. This differ­
ence may have led to the greater 
postoperative morbidity observed in 
the latter group.
The anterior component involved 
fusion of a mean of 4.6 interverte­
bral levels in the one-stage group 
and 6.0 levels in the two-stage 
group. Instrumentation was used
for a mean of 2.2 levels in the 
one-stage group and 4.7 levels in 
the two-stage group.
Fusion and instrumentation dur­
ing the posterior component were 
of similar extent in the two groups 
(Table II).
Duration  o f  the Operation
For patients who underwent the 
one-stage procedure the mean dura­
tion of the anterior component was 
3 hours (range from 2 to 4 hours) 
and of the posterior component 4 
hours (range from 3.5 to 6.0 
hours); the mean total operating 
time was 7 hours.
For patients who underwent the 
two-stage procedure the mean dura­
tion of the anterior component was
6.5 hours (range from 4 to 7 
hours); the mean total operating 
time was 11 hours. The mean dura­
tion of the posterior component was
5.5 hours (range from 3.5 to 8 
hours); the mean total operating 
time was also 11 hours.
B lood  Loss
The mean blood loss was 1830 
mL (range from 500 to 5400 mL) 
among patients who underwent the 
one-stage procedure and 2270 mL 
(range from 650 to 2850 mL) 
among those who underwent the
T a b le  1. D ia g n o se s  fo r  P a tie n ts  W ho  
U n d e rw e n t O ne -S tage  o r T w o -S ta g e  
A n te r io r and P o s te r io r S p in a l Fus ion  at 
M cM a s te r U n iv e rs ity  M ed ica l C entre 
B etw een J u ly  1 9 8 9  and N o ve m b e r 1991
D ia g n o s is
T y p e  o f p ro c e d u re ;  
n o . o f p a t ie n ts
O n e -s ta g e  T w o -s ta g e
N e u ro m u scu la r
a b n o rm a lity 3 3
N e u ro fib ro m a to s is 2 0
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a b n o rm a lity 1 4
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two-stage procedure. In spite of the 
similar amounts of blood lost, the 
latter group received substantially 
more blood product replacement 
(mean of 4.9 and 12.5 units for the 
one-stage and the two-stage groups 
respectively). Most blood product 
replacement occurred after the op­
eration, in the ICU; the higher 
amount of blood product replace­
ment among the patients who un­
derwent the two-stage procedure 
may relate to attempts to optimize 
the hemodynamic variables before 
the second stage.
Length o f Stay
Patients who underwent the one-
stage procedure spent an average 
of 2.6 days (ranging from 1 to 5 
days) in the ICU, whereas those 
who underwent the two-stage pro­
cedure spent an average total of 
7.7 days in the ICU. This included 
a mean of 4.9 days (ranging from 
1 to 12 days) after the first stage 
and a mean of 2.9 days (ranging 
from 1 to 6 days) after the second 
stage.
The total number of days spent in 
hospital averaged 14 (range from 
10 to 20) for the patients who 
underwent the one-stage procedure. 
The mean length of stay in the 
other group was more than twice as 
long: 33 days (range from 20 to 73 
days).
Complications
Major complications, all of a 
medical nature (Table III), occurred 
in only five of the patients who 
underwent the one-stage procedure. 
These complications included one 
case of sepsis and one of respiratory 
failure secondary to crystalloid 
overload; both patients recovered 
well. There were no neurologic in­
juries or failures of instrumentation 
in these patients, nor were there 
any thrombotic episodes.
Eight of the 11 patients in the 
group that underwent the two-stage 
procedure suffered serious compli­
cations, including three episodes of 
infection and two of pulmonary
FIG. 1. (Left) Spinal curvature of 85° and 55° in 23-year-old man with sequela of meningitis and hemiparesis. He was 
treated by one-stage spinal fusion, which included thoracotomy of fourth rib, diskectomy of third to ninth thoracic vertebrae (T3 
to T9) and insertion of Dwyer instrumentation through T4 to T8, and Cotrel-Dubousset instrumentation through T2 to T12. 
Operation took 9 hours, and patient received 4 units of blood. (Right) Six months later spinal curvature has been reduced to 30° 
and 25°.
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complications. One patient experi­
enced foot drop, which resolved 
after revision surgery, and one ex­
perienced deep vein thrombosis, 
which necessitated placement of a 
Greenfield filter.
Cost
We were unable to arrange a 
case-specific cost analysis before 
this study was undertaken, and at­
tempts to perform a retrospective
analysis yielded inconsistent infor­
mation.
However, a good approximation 
of costs can be drawn from the data 
concerning length of stay. Per diem 
costs at McMaster University Medi­
cal Centre average $625, so the 
mean reduction in duration of hos­
pital stay (17 days) in the patients 
who underwent the one-stage pro­
cedure could represent a net cost 
saving of $10 625 per patient. This 
analysis almost certainly represents 
an underestimate of the savings, 
since time spent in the operating 
room and the ICU is even more 
expensive.
Discussion
The combined anterior and poste­
rior approach with fusion and in­
strumentation for the treatment of 
severe spinal deformities is increas­
ingly well accepted. Numerous au­
thors from around the world have 
documented the advantages of this 
approach in various settings.3-5-12
Leatherman and Dickson12 and 
Winter, Moe and Lonstein13 advo­
cated a two-stage approach in deal­
ing with congenital spinal deformi­
ties. Swank, Cohen and Brown10 
and O’Brien9 arrived at the same 
conclusion in treating neuromuscu­
lar scoliosis, and Banta14 proved the 
same point in treating spinal defor­
mities in dysraphic patients.
These authors unanimously 
stressed the benefits of two-stage 
surgery in achieving optimal correc­
tion of deformity and consistent 
arthrodesis. This principle holds 
even when the results for lesser 
curves treated by more traditional 
single-stage posterior surgery are 
compared with those for severe 
curves treated in two stages.10-13
The reported complication rates 
for two-stage spinal fusion range 
from as low as 10%12 to as high as 
42%14 and 50%.2 The potential for
T a b le  II. S urgica l P ro ce d u re s  fo r  P a tien ts  W h o  U n d e rw e n t O ne -S tage  o r  T w o -S ta g e  A n te rio r and
P o s te r io r S p in a l Fus ion
Type of procedure;
no. of patien ts
P ro c e d u re O ne-s tag e Tw o -s tage
A n te r io r  app ro ach *
T ra n s th o ra c ic 5 4
T h o ra c o a b d o m in a l 0 4
T y p e  o f in s tru m e n ta tio n
D w ye r 5 5
T e x a s  S co ttish  R ite  (TS R H ) 1 0
O th e r 1 1
N o n e 4 5
In s tru m e n ta t io n  fo r p o s te r io r
a p p ro a c h f
C o tre l-D u b o u s s e t 2 5
H a rr i-L u q u e 4 1
L u q u e -G a lv e s to n 3 3
L u q u e 1 0
T S R H 1 0
O th e r 0 2
*A  m e a n  o f 4 .6  and 6 .0  in te rv e rte b ra l le ve ls  w e re  fu s e d  in th e  o n e -s ta g e  and th e  tw o -s ta g e
g ro u p s  re sp e c tive ly . In s tru m e n ta tio n  w a s  in s e rte d  th ro u g h  a m ea n  o f 2 .2  and 4 .7  leve ls  re-
s p e c tiv e ly .
t A  m e a n  o f 11.6 and 12 .6 leve ls  w e re  fu s e d  in th e  o n e -s ta g e and th e  tw o -s ta q e
g ro u p s  re sp e c tive ly . In s tru m e n ta tio n  w a s  in s e rte d  th ro u g h  a m ean  o f 11 .6  and 1 2 .6  leve ls  re -
s p e c tiv e ly .
T a b le  I I I .  C o m p lic a tio n s  E xpe rienced  b y  P a tie n ts  W h o  U n d e rw e n t O ne -S tage  o r T w o -S tage  
A n te r io r and P o s te r io r S p in a l Fusion
C o m p lic a tio n N o. of patien ts
T re a tm e n t 
and outcom e
O n e -s ta g e  p rocedure
Ile u s 2 R eso lved
IA D H S 1 R eso lved
B a c te re m ia 1 R eso lved
R e s p ira to ry  fa ilu re 1 R eso lved
T w o -s ta g e  p rocedure  
A fte r  f i r s t  stage
R e s id u a l p leura l e ffu s io n 1 R epeat d ra inage
U r in a ry  tra c t in fe c tio n 1 C y s to s to m y
U n ila te ra l pneum on ia 1 R eso lved
B ila te ra l pne um o n ia 1 R eso lved
R e s id u a l p n e u m o th o ra x 1 R eso lved
D eep  v e in  th ro m b o s is 1 P la ce m e n t o f
G reen fie ld  f ilte r
A fte r  s e c o n d  stage
A c u te  p e ric a rd itis  (v ira l) 1 R eso lved
F u ll ra d ic u lo p a th y  a t fo u r th  
and  f i f th  lum bar ve rte b ra e
( le f t  fo o t d ro p ) 1 R evised
IA D H S  =  inadequate  a n tid iu re tic  h o rm o n e  se c re tio n
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frequent major complications in 
such operations is considerable, 
particularly during the interval be­
tween stages when the patient may 
undergo enforced bed rest. Most 
complications do not necessitate 
surgery or are of a medical na­
ture;2’14 they often involve respira­
tory, urinary, cardiac, thrombotic or 
coagulopathic conditions. The com­
promised metabolic status in pa­
tients approaching the second stage 
of surgery may also be an adverse 
factor.8
Another potential difficulty is the 
loss of benefit from anterior release 
in patients who become too ill to 
undergo the second stage of the 
procedure at an appropriate time.
The concept of one-stage com­
bined surgery is not new; it was 
first discussed more than 15 years 
ago.11 In 1991 Schufflebarger and 
colleagues15 published a retrospec­
tive analysis of 75 patients. They 
compared staged and same-day sur­
gery and defined benefits similar to 
those that we found in a similarly 
heterogeneous group of patients.
Mendelbaum and colleagues8 
stressed the potential for nutritional 
and immunologic compromise in 
patients who underwent a two-stage 
operation and found a high frequen­
cy of compromise after both the 
first and especially the second 
stages. There was a statistically 
significant association between 
staged surgery and the occurrence 
of infection. Similar conclusions, 
recently presented to the American 
Academy of Orthopaedic Surgeons, 
were reached by Dick, Boachie- 
Adjei and Wilson.1 The lesson that 
orthopedic trauma is better ma­
naged in one stage than in multiple 
stages seems to be reinforced by 
these findings.
Our data suggest that there are 
significant benefits to performing 
anterior and posterior spinal fusion 
in one stage; these benefits include 
decreased length of stay in hospital
and the associated cost savings, as 
well as a possible reduction in mor­
bidity. These conclusions must be 
judged cautiously, as the patients 
were not prospectively randomized, 
and differences in the diagnoses and 
the patients’ conditions may explain 
some of the results. Nevertheless, 
this experience represents a trend 
that is now occurring and reflects 
how we have changed the treatment 
of most such patients at our centre. 
The one-stage treatment is current­
ly preferred for resolving these diffi­
cult spinal deformities, although 
each case must be carefully as­
sessed to determine whether this 
option is the most appropriate. The 
principal surgeon involved in this 
review acknowledges that several of 
the patients who were treated with 
the two-stage procedure would be 
treated with the one-stage proce­
dure if they presented today.
The main consideration in not 
choosing the one-stage operation is 
the existence of spinal deformities 
involving the thoracic and lumbar 
spine, for which thoracolaparotomy 
is required. We still consider this 
procedure to be excessive if com­
bined with an extensive posterior 
surgical approach during the same 
session. As the surgeons gain more 
experience, this belief may change. 
For ethical reasons and because of 
the nature of the diagnoses and the 
low number of patients, it does not 
appear feasible to perform a pro­
spectively randomized trial.
Conclusions
The one-stage combined anterior 
and posterior procedure for fusion 
in cases of severe spinal deformity 
is a valid, safe and perhaps optimal 
approach to these difficult clinical 
problems. It allows for a significant­
ly decreased length of hospital stay 
and corresponding cost savings, as 
well as possible decreased morbidity.
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IM ORAL IM ORAL
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testinal bleeding. These reactions can occur a t any time during the treatment. If peptic ulcer­
ation is suspected or confirmed, or if gastrointestinal bleeding occurs, ketorolac tromethamine 
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Renal Effects: As w ith o ther drugs th a t inh ib it p rostag land in  biosynthesis, elevations 
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by the kidney, the following precautions are indicated for patients with: Severely impaired 
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associated with less risk (see DRUG INTERACTIONS), In patients receiving anticoagulants, the risk 
of intramuscular haematoma formation from Toradol IM injections may be increased. In post­
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not recommended as a pre-operative or intra-operative medication because of the risk of 
excessive bleeding. Blood d ysc ra sia s associated w ith the use of NSAIDs are rare, 
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infection: In common with other non-stero idal anti-inflam m atory drugs, ketorolac 
tromethamine may mask the usual signs of infection.
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tromethamine induces or inhibits the hepatic enzymes capable of metabolizing itself or other 
drugs. Hence, it would not be expected to alter the pharmacokinetics of other drugs due to 
enzyme induction or inhibition mechanisms.
Probenecid: Concomitant administration of ketorolac tromethamine and probenecid 
results in the decreased clearance of ketorolac and a significant increase in ketorolac plasma 
levels (approximately three-fold increase) and terminal half-life (approximately two-fold 
increase).
Furosemide: Ketorolac trom etham ine reduces the diuretic response to furosemide 
by approximately 20% in normovolemic subjects.
Lithium: Some NSAIDs have been reported to inhibit renal lithium clearance, leading to 
an increase in plasma lithium concentrations and potential lithium toxicity, The effect of 
ketorolac tromethamine on lithium plasma levels has not been studied.
Methotrexate: The concomitant administration of methotrexate and some NSAIDs has 
been reported to reduce the clearance of methotrexate, thus enhancing its toxicity, The 
effect of ketorolac tromethamine on methotrexate clearance has not been studied.
Morphine: Intramuscular Toradol has been administered concurrently with morphine 
in several clinical trials of postoperative pain without evidence of adverse interactions.
ADVERSE EVENTS: .
TORADOL TABLETS: Short-Term Patient Studies - The incidence of adverse reactions in 371 
patients receiving multiple 10 mg doses of Toradol (ketorolac tromethamine) for pain resulting 
from surgery or dental extraction during the post-operative period (less than 2 weeks) is listed 
below. These reactions may or may not be drug related. Incidence between 4 and 9%: 
Nervous system - somnolence, insomnia: Digestive system - nausea, Incidence between 2 and 
3%: Nervous system - nervousness, headache, dizziness: Digestive system - diarrhea, dyspep­
sia, gastrointestinal pain, constipation. Body as a whole - fever. Incidence 1% or Less: Nervous 
system - abnormal dreams, anxiety, dry mouth, hyperkinesia paresthesia, increased sweating, 
euphoria, hallucinations; Digestive system - anorexia, flatulence, vomiting, stomatitis, gastritis, 
gastrointestinal disorder, sore throat; Body as a whole - asthenia, pain, back pain; 
Cardiovascular system: vasodilatation, palpitation, migraine, hypertension; Respiratory system - 
cough increased, rhinitis, dry nose; Musculo-skeletal system - myalgia, arthralgia; Skin and 
appendages - rash, urticaria; Special senses - blurred vision, ear pain; Urogenital system: 
dysuria.
Long-Term Patient Study - The adverse reactions listed below were reported to be probably 
related to study drug in 553 patients receiving long-term oral therapy (approximately 1 year) 
with Toradol. Incidence between 10 and 12%: Digestive system - dyspepsia gastrointestinal 
pain.
Incidence Between 4 and 9%: Digestive system - nausea, constipation; Nervous system - 
headache. Incidence Between 2 and 3%: Digestive system - diarrhea, flatulence, gastrointesti­
nal fullness, peptic ulcers; Nervous system - Dizziness, somnolence; Metabolic/Nutritional disor­
der - edema Incidence 1% or Less: Digestive system - eructation, stomatitis, vomiting, anorex­
ia, duodenal ulcer, gastritis, gastrointestinal haemorrhage, increased appetite, melena, mouth 
ulceration, rectal bleeding, sore mouth; Nervous system - abnormal dreams, anxiety, depres­
sion, dry mouth, insomnia nervousness, paresthesia; Special senses - tinnitus, taste perversion, 
abnormal vision, blurred vision, deafness, iacrimation disorder; Metabolic/Nutritional disorder - 
Weight gain, alkaline phosphatase increase, BUN increased, excessive thirst, generalized 
edema, hyperuricemia; Skin and appendages - pruritus, rash, burning sensation skin; Body as 
a whole - asthenia, pain, back pain, face edema, hernia; Musculo-skeletal system - arthral­
gia, myalgia, joint disorder: Cardiovascular system: chest pain, chest pain substernal, 
migraine; Respiratory system - dyspnea, asthma epistaxis; Urogenital system - hematuria, 
increased urinary frequency, oliguria, polyuria; Hemic and lymphatic - Anemia purpura. 
TORADOL IM: The adverse reactions listed below were reported in Toradol IM clinical effica­
cy trials. In these trials patients (n=660) received either single 30 mg doses (n=151) or multiple 
30 mg doses (n=509) over a time period of 5 days or less for pain resulting from surgery.
These reactions may or may not be drug related. Incidence Between 10 and 13%: Nervous 
System - somnolence; Digestive system - Nausea. Incidence Between 4 and 9%: Nervous sys­
tem - headache; Digestive system - vomiting; Injection site - injection site pain Incidence 
Between 2 and 3%: Nervous System - sweating, dizziness: Cardiovascular system - vasodilata­
tion. Incidence 1% or Less: Nervous system - insomnia, increased dry mouth, abnormal 
dreams, anxiety, depression, paraesthesia, nervousness, paranoid reaction, speech disorder, 
euphoria, libido increased, excessive thirst, inability to concentrate, stimulation; Digestive sys­
tem - flatulence, anorexia, constipation, diarrhea, dyspepsia, gastrointestinal fullness, gastroin­
testinal haemorrhage, gastrointestinal pain, melena, sore throat, liver function abnormalities, 
rectal bleeding, stomatitis; Cardiovascular system - hypertension, chest pain, tachycardia, 
haemorrhage, palpitation, pulmonary embolus, syncope, ventricular tachycardia, pallor, flush­
ing; Injection site - injection site reaction; Body as a whole - asthenia, fever, back pain, chills, 
pain, neck pain; Special senses - taste perversion, tinnitus, blurred vision, diplopia, retinal 
haemorrhage; Musco-skeletal system - myalgia, twitching; Respiratory system - asthma, 
cough increased, dyspnea, epistaxis, hiccup, rhinitis; Skin and appendages - pruritus, rash, sub­
cutaneous hematoma, skin disorder; Urogenital system - dysuria, urinary retention, oliguria, 
increased urinary frequency, vaginitis, Metabolic/nutritional disorders - edema, hypokalemia, 
hypovolemia Hemic and lymphatic system - anemia, coagulation disorder, purpura. 
Post-Marketing Experience: The following post-marketing adverse experiences, although 
rare (1 % or less), have been reported for patients who have received either formulation of Toradol.
Renal events - acute renal failure, flank pain with or without haematuria and/or azotemia; 
Hypersensitivity reactions: bronchospasm, laryngeal edema, hypotension, flushing, rash, and 
anaphylactoid reactions, such reactions have occurred in patients with no prior history of 
hypersensitivity. Gastrointestinal events - gastrointestinal hemorrhage, peptic ulceration, gas­
trointestinal perforation; Hematologic events - postoperative wound haemorrhage, rarely 
requiring blood transfusion (see PRECAUTIONS), thrombocytopenia; C entra l n e rv o u s syste m -  
convulsions, abnormal dreams, hallucinations, hyperkinesia, hearing loss; C ard iovascu lar- 
pulmonary edema; Dermatology - Lyell's syndrome, Stevens - Johnson syndrome, exfoliative 
dermatitis, maculopapular rash.
OVERDOSAGE: The absence of experience with acute overdosage precludes characteriza­
tion of sequelae and assessment of antidotal efficacy at this time. In a gastroscopic study of 
healthy subjects, daily doses of 360 mg given over an 8-hour interval for each of five consecu­
tive days (3 times the highest recommended dose) caused pain and peptic ulcers which 
resolved after discontinuation of dosing,
DOSAGE AND ADMINISTRATION:
Adults: Dosage should be adjusted according to the severity of the pain and the response 
of the patient. Oral; The usual oral dose of Toradol (ketorolac tromethamine) is 10 mg every
4 to 6 hours for pain as required. Doses exceeding 40 mg per day are not recommended. 
Toradol is recommended for short-term use only, i.e„ for a maximum of a few weeks.
Parenteral: The recommended usual initial dose is 30 mg. Subsequent dosing may be 10 mg 
to 30 mg every 4-6 hours as needed to control pain. It is recommended that the administration 
of Toradol IM be limited to short-term therapy (not over 5 days) and the total daily dose should 
not exceed 120 mg.
This is because the risk of toxicity appears to increase with longer use at recommended doses 
(see WARNINGS and PRECAUTIONS). The administration of continuous multiple daily doses of 
Toradol IM has not been extensively studied. There has been limited experience with intramus­
cular dosing for more than 3 days since the vast majority of patients have transferred to oral 
medication or no longer required analgesic therapy after this time, In the initial post-operative 
period, more frequent dosing (e.g, every 2 hours) may be employed but the total daily dosing 
should not exceed 120 mg/day. If supplementary analgesia is required, a concomitant low 
dose of opiate can be used.
Patients under 50 kg, over age 65 years, or with less severe pain at baseline: the lower end 
of the dosage range (10-15 mg 4 times a day) is recommended.
Im paired Renal Function - M oderate - In patients with impaired renal function (serum 
creatinine values ranging from 1.9 to 5.0 mg/dL or 168 to 442 pmol/L), the total daily dose of 
Toradol should be reduced by half;
Severe - In patients with severely impaired renal function (serum creatinine values greater than
5 mg/dL or 442 pmol/L) Toradol is not recommended.
Conversion from Parenteral to Oral Therapy: Toradol tablets may be used either as monothera­
py or as foliow-on therapy to parenteral ketorolac. Toradol IM should be replaced by an oral 
analgesic as soon as feasible. When Toradol tablets are used as a follow-on therapy to par­
enteral ketorolac, the total combined daily dose of ketorolac (oral + parenteral) should not 
exceed 120 mg on the day the change of formulation is made. Subsequent oral dosing should 
not exceed the recommended daily maximum of 40 mg.
Directions for Use of the Prefilled Syringes: Insert the plunger into the syringe barrel and thread 
it onto the screw. WITHOUT REMOVING THE NEEDLE GUARD, apply quick, firm pressure to the 
plunger to break the inner seal. (You will feel it let go). Pull back on the plunger slightly to 
relieve pressure. Remove the needle guard by twisting as you pull. Use the unit as you would a 
normal syringe. Dispose of properly. Single use only. Discard Unused Portions, Parenteral drug 
products should be inspected visually for particulate material and discoloration prior to use. 
Toradol (ketorolac tromethamine) is a Schedule F drug.
Stability and Storage Recommendations:
Toradol Tablets: Store at room temperature with protection from light.
Toradol IM: Store at room temperature with protection from light.
Availability ot Dosage Forms: Toradol (ketorolac tromethamine) is available as 10 mg white 
round film coated tablets containing ketorolac tromethamine, microcrystalline cellulose, lac­
tose and magnesium stearate with one side printed in red with TORADOL inside bold T and 
other side with Syntex. Toradol (ketorolac tromethamine) 10 mg tablets are available in bottles 
of 100 and 500 tablets.
Toradol IM is available in 1 mL ampoules (trays of 10) containing 10 or 30 mg/mL,
Toradol IM is also available in 1 mL syringes (1 /box) containing 15 or 30 mg/mL.
Product Monograph available on request.
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Bochdalek Hernia With Hemorrhage in an 
Adult
Brian J. Miller, MD, FRCSC, FRACS;* Ian J.G. Martin, MB, BSf
Life-threatening herniation of intra-abdominal viscera through a patent Bochdalek foramen is well 
recognized in neonates. Persistent foramina, leading to clinical problems in adult life, are very 
rare. In the case of the 17-year-old girl described in this paper, two-thirds of the stomach had inverted 
and passed into the left side of the chest as had the splenic flexure of the colon and most of the greater 
omentum. There was 500 mL of blood free in the peritoneal cavity and 1200 mL in the left pleural 
cavity, with no hernial sac. The defect measured 5 cm in diameter. It was repaired primarily after 
reduction of the viscera. Prompt operative intervention is recommended in such cases to prevent 
strangulation and bleeding from engorged viscera.
Une hernie d un viscere abdominal a travers un foramen de Bochdalek permeable, hernie capable de 
mettre en peril la vie du malade, est un phenomene bien connu chez le nouveau ne. La persistance d’un 
foramen pouvant causer des problemes cliniques a Page adulte est tres rare. Dans le cas d’une jeune 
fille de 17 ans faisant l’objet de cette communication, les deux tiers de l’estomac se sont retournes dans 
la cavite thoracique gauche, avec l’angle gauche du colon et la plus grande partie du grand epiploon. 
On a retrouve 500 mL de sang dans la cavite peritoneale et 1200 mL dans la cavite pleurale gauche; il 
n y avait pas trace de sac herniaire. L’orifice mesurait 5 cm de diametre. On proceda a une reparation 
primaire apres reduction des visceres. Une intervention chirurgicale immediate est recommandee dans 
de tels cas afin de prevenir l’etranglement et l’hemorragie des visceres engorges.
P ersistence of the pleuroperito­neal canal of embryonic life can 
permit life-threatening extrusion 
of abdominal viscera into the chest 
in neonates. It is very unusual 
for this canal to persist and cause 
trouble in adults. However, when 
this does happen there is the poten­
tial for strangulation of viscera in 
the left upper quadrant of the abdo­
men. The purpose of our report is 
to draw attention to this entity in 
adults and to recommend prompt 
operative correction to avoid viscer­
al hemorrhage and ischemia.
Case Report
A 17-year-old girl was seen in the 
emergency department of the Prin­
cess Alexandra Hospital, Brisbane, 
with a history of dry retching and 
severe upper abdominal pain in­
creasing over 48 hours after an 
episode of laughing. She told of 
four shorter episodes over the pre­
ceding 6 weeks, each apparently 
triggered by physical exertion such 
as swimming. Previously, the pain 
had been relieved by gaseous eruc­
tation and vomiting of dark fluid,
but she had been unable to do that 
on this occasion. Otherwise, she 
was entirely fit and had no signifi­
cant personal or family history.
On examination, she was pale, 
sweating and tachycardic, with a 
pulse rate of 120 beats/min. Her 
body temperature was normal. 
There was dullness on percussion 
and diminished air entry at the left 
lung base. Examination of the abdo­
men revealed marked tenderness 
and involuntary guarding in the 
upper half of the abdomen. There 
was no distension. Bowel sounds
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were present. Results of rectal ex­
amination were normal. The leuko­
cyte count was 15.0 X 109/I>, but 
otherwise the results of all laborato­
ry investigations were normal. An 
upright chest film (Fig. 1) showed 
left basal atelectasis and a massive 
air fluid level in the lower part of 
the left side of the chest.
A nasogastric tube was inserted 
without difficulty, and 1500 mL of 
coffee-grounds material was re­
moved. This resulted in some reduc­
tion in the patient’s symptoms and 
signs. However, she remained 
tachycardic, and repeated physical 
examination still revealed considera­
ble tenderness in the left upper 
quadrant of the abdomen.
Radiologic study of the upper 
gastrointestinal tract with Gastro- 
grafin (Fig. 2) demonstrated inver­
sion of the stomach into the left 
side of the chest through a post­
erolateral diaphragmatic defect, 
with the gastroesophageal junction 
in the normal position. There was 
no flow of Gastrografin into the 
duodenum. Ultrasonography of the 
upper and lower abdomen showed 
evidence of free fluid but no other 
abnormalities.
Because of the patient’s continu­
ing tachycardia and upper abdomi­
nal tenderness, she was taken to 
the operating room immediately. 
The peritoneal cavity, opened
FIG. 1. Preoperative upright chest film 
shows gastric dilatation in left hemi- 
thorax.
through a left subcostal incision, 
contained 500 mL of free blood. 
The greater curvature of the stom­
ach, including about two-thirds of 
the total volume of the stomach, 
the splenic flexure of the colon and 
most of the greater omentum had 
passed into the left side of the chest 
through a patent Bochdalek fora­
men in the posterolateral aspect of 
the left hemidiaphragm, measuring 
5 cm in diameter. The peritoneum 
and pleura were continuous, and 
there was no hernial sac. The 
spleen had remained in the abdo­
men. Reduction of the stomach and 
the splenic flexure of the colon into 
the abdomen produced further flow 
of 1200 mL of non-clotted blood 
from the left pleural cavity through 
the foramen. The greater omentum 
was adherent to the medial aspect 
of the left pleural cavity. After this 
had been reduced it was noted that 
the lesser omentum of the stomach 
was edematous, but all viscera were 
viable. A discrete bleeding site was 
not discovered although the portion 
of omentum from the left pleural 
cavity was engorged. This portion 
of the omentum was removed, and a
FIG. 2. Gastrografin introduced 
through nasogastric tube demonstrates 
acutely inverted and obstructed stom­
ach, which is above left hemidia­
phragm.
size 28 chest tube was placed per- 
cutaneously into the left pleural 
cavity. The Bochdalek foramen was 
then closed primarily with heavy (0 
gauge) interrupted nylon sutures.
There were no complications, and 
the patient left hospital on the 7th 
postoperative day. One month later 
she was well and her chest x-ray 
film appeared normal.
Discussion
The Bochdalek foramen, or pa­
tent pleuroperitoneal canal, can lead 
to life-threatening herniation of vis­
cera into the left side of the chest 
as a neonate draws its first breath.1 
It is the most common congenital 
hernia of the diaphragm in infants, 
with an incidence of about 1 in 
4000 live births. A death rate of 
50% in infants has been reported.2 
However, it is extremely uncommon 
for Bochdalek hernia to present in 
adult life as a surgical emergency.3 
Fewer than 200 cases have been 
reported in the world literature,4 
including only 51 during the last 25 
years.2
At the end of the 4th embryonic 
week, the stomach is a fusiform 
dilatation of the foregut in the 
median plane, connected to the 
body wall by a short dorsal mesen­
tery owing to the presence of the 
pleural and peritoneal canals lateral­
ly.1 The formation of the diaphragm 
is usually complete by the 8th week 
of embryonic life. The developing 
pleural membrane separates the 
inner layer of muscle from the tho­
racic wall to form the lateral mus­
cular part of the diaphragm. This 
results in only two layers of inter­
costal muscles with the homologue 
of the transversus abdominis mus­
cle becoming the muscle of the 
diaphragm. The central tendon de­
velops from the original septum 
transversum and the dorsal portion 
of the diaphragm develops from the
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esophageal mesentery. The dorsal 
paired pleuroperitoneal membranes 
close the pleuroperitoneal canals. 
The congenital posterolateral dia­
phragmatic defect, well described by 
Bochdalek in 18485 is caused by 
failure of the septum transversum 
and the pleuroperitoneal mem­
branes to fuse. No sac is present in 
70% of cases, and 30% have incom­
plete muscularization of the pleu­
roperitoneal membrane leaving a 
filmy layer that separates the ab­
dominal cavity from the chest. Ap­
proximately 80% of these hernias 
are on the left side.6
An episode of increased intra­
abdominal pressure appears to be 
important in the etiology of adult 
herniation, and six patients with 
acutely symptomatic Bochdalek 
hernias during pregnancy have been 
reported.7 The incidence of strangu­
lation is 34% in patients who have 
an acute condition, and this empha­
sizes the need for early diagnosis 
and prompt operative management.2 
Gastric volvulus has been reported 
with Bochdalek hernia, the rotation 
occurring around the gastric mes­
enteric axis in the sagittal plane.8 
Severe bleeding, causing hemo­
thorax and hemoperitoneum with 
loss of 1700 mL of blood, has not 
been reported before. Without early 
operation the patient’s blood loss 
would likely have been greater.
A plain x-ray film of the chest 
and contrast studies of the gastroin­
testinal tract are necessary to con­
firm the diagnosis. A previously 
normal chest x-ray film does not 
rule out a diaphragmatic hernia, as 
the defect may be occluded by the
spleen or by the presence of a 
confining sac. Up to 20% of patients 
have no symptoms at presentation, 
and this condition has been diag­
nosed incidentally on magnetic res­
onance imaging.9 Computed tomog­
raphy has been recommended for 
making the diagnosis, but in our 
case the need for operation was 
quickly established by a contrast 
study with Gastrografin.10
The principle of reduction of the 
viscera from the left side of the 
chest and repair of the defect with 
strong non-absorbable suture mate­
rial is well established. Direct clo­
sure of the diaphragmatic defect 
has been reported as possible in 
92% of patients.2 The posterior rim 
of the diaphragm was easy to define 
in our patient, and it was not 
necessary to dissect up the muscle 
of the posterior leaf of the dia­
phragm from the superior aspect of 
the left kidney. Most groups favour 
thoracotomy to approach right­
sided defects, and there are advo­
cates of laparotomy and thoracoto­
my, or a combined approach, for 
left-sided defects.5 We had no diffi­
culty with exposure and repair of 
the defect through a left subcostal 
incision. Postoperative gastric 
atony has been thought clinically 
significant in over 50% of patients 
but was not a problem in our 
patient.11
In summary, a patent Bochdalek 
foramen cannot be dismissed even 
in adult life as a cause of acute 
gastric outlet obstruction. The diag­
nosis should be suspected whenever 
symptoms occur after physical exer­
tion and are associated with signs in
the left lung base and a nondistend- 
ed abdomen. Prompt operative in­
tervention is necessary to prevent 
the complications of visceral isch­
emia and hemorrhage into the pleu­
ral and peritoneal cavities.
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IONS AND CLINICAL PHARMACOLOGY
> ‘Mobiflex’ (tenoxicam) is a non-steroidal anti-inflammatory agent with analgesic and 
i yretic properties. Its mechanism of action, as with other non-steroidal anti-inflammatory 
agents, is not yet completely known. Tenoxicam is an inhibitor of prostaglandin biosynthesis 
both in vitro and in vivo (protects mice against arachidonic acid induced toxicity). In vitro tests 
of leucocyte peroxidase also suggest that tenoxicam may act as a scavenger for active oxygen at 
the site of inflammation. These effects probably explain in part, the activity of Mobiflex' in the 
treatment of painful inflammatory and degenerative diseases of the musculoskeletal system.
^ ^ ^ ^ ^ ‘Mobiflex’ does not act by pituitary-adrenal stimulation.
After 4 ,7 ,10  or 14 days of culture with tenoxicam (2.4,12,48 pg/mL), there was no significant 
effect on the amount of cartilage proteoglycans synthesized and released into the culture medium 
of human chondrocytes, as compared to untreated cultures.
In vitro studies have also shown that tenoxican inhibits the activity of both proteoglycanase and collage- 
nase enzymes obtained from human osteoarthritic cartilage. These in vitro results suggest a positive effect 
of tenoxicam on the joint cartilage under experimental conditions by slowing down the enhanced catabolism 
of the osteoarthritic cartilage matrix. The clinical significance of these findings is not yet known and is being 
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ORIGINAL ARTICLES
Aortoesophageal Fistula Secondary 
to Benign Barrett’s Ulcer: a Rare Cause 
of Massive Gastrointestinal Hemorrhage
Deepak Katyal, MD;* Laurence D. Jewell, MD, FRCPC;t Walter W. Yakimets, MD, FRCSC*
Aortointestinal fistula is a rare cause of massive upper gastrointestinal bleeding. The authors report 
on an 82-year-old man who had an aortoesophageal fistula due to a benign Barrett’s ulcer. The patient 
presented with a sentinel hemorrhage followed by fatal exsanguination despite vigorous attempts at 
resuscitation. Management of the entity requires awareness, appropriate radiologic and endoscopic 
investigation and early surgery. Even with appropriate management, the mortality remains high.
Une fistule aorto-oesophagienne est une cause rare d’hemorragie massive des voies digestives 
superieures. Les auteurs decrivent le cas d’un homme de 82 ans qui presenta une fistule 
aorto-oesophagienne due a un ulcere benin de Barrett. A son arrivee, le patient souffrait d’une 
hemorragie sentinelle qui degenera en une exsanguination fatale, malgre de vigoureux efforts de 
reanimation. Le traitement de cette affection exige de l’experience, des examens radiologiques et 
endoscopiques appropries et une intervention chirurgicale precoce. Meme avec un traitement adequat, 
la mortality demeure elevee.
Massive upper gastrointestinal bleeding is most often caused 
by gastroduodenal ulcers or esopha­
geal varices. Rarely, aortointestinal 
fistulae become a source of bleed­
ing. In a review by Kane, Meyer and 
Kozoll1 they accounted for 6.1% of 
deaths due to gastrointestinal he­
morrhage. The duodenum is in­
volved with aortointestinal fistulae 
in the majority of cases, usually 
after surgery for aortic aneurysms. 
However, 20% involve the esopha­
gus.
The cause of aortoesophageal fis­
tula (AEF) in 75% of cases is a 
ruptured thoracic aneurysm.2 Less 
commonly, esophageal foreign bo­
dies, malignant tumours of the 
esophagus or bronchus and instru­
mental perforation of the esopha­
gus may lead to fistula formation. 
Chronic ulcerative esophagitis is an 
extremely rare cause of AEF, repre­
senting less than 0.5% of reported 
cases.3 We report a rare case of a 
benign perforated ulcer in Barrett’s 
esophagus, resulting in a fatal 
upper gastrointestinal hemorrhage.
Case Report
An 82-year-old man was admitted 
to a peripheral hospital after col­
lapsing at home. He had been tak­
ing cimetidine for 3 years because 
of vague symptoms of dyspepsia 
but was otherwise well. No cause 
for the collapse was found, and
aside from one episode of epigastric 
pain that was relieved by antacids 
his initial hospital course was sta­
ble. Six days after admission he 
collapsed again, had a transient 
hypotensive episode and passed a 
melena stool. The following morn­
ing he vomited bright red blood, 
and his hemoglobin level was 41 
g/L .
Arrangements were made for ur­
gent transfer to the Walter C. Mac­
kenzie Health Sciences Centre. On 
arrival, the patient was conscious 
with a systolic blood pressure of 
80 mm Hg. He was vigorously re­
suscitated with intravenous fluids 
and blood. Urgent upper gastroin­
testinal endoscopy revealed a large 
hiatus hernia with bright red blood
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oozing from the gastroesophageal 
junction. Closer examination re­
vealed a large ulcer in the hiatus 
hernia with what was thought-to be 
a visible vessel at its base. Scleroth­
erapy was attempted but this in­
creased the bleeding. Consequently, 
the patient aspirated blood and re­
quired intubation.
Brisk bleeding and refractory hy­
potension necessitated immediate 
transfer to the operating room. 
Through a midline laparotomy inci­
sion, a gastrotomy was performed, 
and large amounts of fresh blood 
and clots were evacuated. Blood 
was noted to be coming from above 
the gastroesophageal junction. 
Manual compression was attempted 
while a left thoracoabdominal ex­
tension of the original midline inci­
sion was made. Entrance into the 
thorax revealed extensive scarring 
in the region of the aorta and distal 
esophagus with the two structures 
closely adherent to each other. At­
tempt at proximal control of the 
aorta was difficult. As a result, the 
patient continued his downward spi­
ral and sustained a cardiac arrest
secondary to exsanguination. Re­
suscitation was unsuccessful.
At autopsy, the lower two-thirds 
of the tubular esophagus exhibited 
glandular metaplasia. The epitheli­
um was architecturally disorganized 
with patchy intestinal metaplasia 
characteristic of Barrett’s ulcer. No 
dysplasia or carcinoma was identi­
fied. A perforation 3.5 cm in diame­
ter was apparent on the posterior 
wall at the junction of lower and 
middle thirds and had eroded into 
the aorta (Fig. 1). The aorta, al­
though atherosclerotic, was not 
aneurysmal. The degree of athero­
sclerosis was surprisingly mild in all 
major vessels, including the thorac­
ic aorta. No other significant find­
ings were noted.
Discussion
AEF is a rare cause of upper 
gastrointestinal hemorrhage that is 
frequently diagnosed only at autop­
sy. It was first described by Du- 
brueil in 1818,4 but there have been 
few reported survivors despite ad­
vances in cardiovascular surgery. 
The key to survival in these pa­
tients is maintaining awareness of 
the condition to allow early diagno­
sis and operative management of 
this treatable lesion.
Clinically, AEF presents in two 
ways. If the fistula forms abruptly, 
rapid exsanguination results. How­
ever, in 80% of cases, the presenta­
tion is Chiari’s classic triad of mid- 
thoracic pain, “sentinel” hemorrh­
age and exsanguination following a 
symptom-free interval.5 Possible 
reasons for this latent period in­
clude spasm of the arterial wall 
closing the orifice, hypotension 
from the initial hemorrhage and 
occlusion of the fistula by clot, 
which is later digested by infection 
or gastrointestinal contents.6
To institute prompt and proper 
therapy, the diagnosis must be 
made shortly after the sentinel he­
morrhage has occurred. As only 
25% of patients will rebleed within 
6 hours,7 there is ample time for 
radiologic investigation. Plain chest 
radiographs may suggest the pres­
ence of a thoracic aneurysm, which 
can be confirmed by aortography or 
computed tomography. However, 
aortography will only delineate the 
fistulous tract if the rate of bleeding 
is 0.5 to 1 mL/min,3 and computed 
tomography with oral water-soluble 
contrast has demonstrated the fistu­
la only occasionally.8-9 Air-contrast 
barium esophography has been re­
ported as the most sensitive method 
for demonstrating the fistula,1011 
but there still remains a high rate of 
false-negative or inconclusive re­
sults. Endoscopy is useful in diag­
nosing mass lesions, esophagitis, 
ulcerations or foreign bodies. On 
rare occasions, as in this case, the 
fistula site may be seen. Biopsy of a 
mass lesion, injection of a bleeding 
esophageal ulcer and sclerotherapy 
of a “visible vessel” are to be 
avoided in any patient suspected of 
having an AEF in order to prevent
FIG. 1. Aortoesophageal fistula (identified by string passing from esophagus into 
aorta [A]) is viewed from esophageal aspect. Arrows mark squamocolumnar 
junction, which is junction of upper and middle thirds of tubular esophagus.
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disastrous consequences.
Frequently, bleeding is so rapid 
as to preclude endoscopy and other 
diagnostic tests. In this setting, 
insertion of a Sengstaken-Blake- 
more tube has been used as a useful 
temporizing measure to prevent ex- 
sanguination and to allow stabiliza­
tion of the patient for surgery.1213 A 
case of embolization of an AEF 
under radiologic guidance in an 
unstable patient has also been re­
ported.14
The surgical approach to AEF is 
through a left thoracotomy. After 
the aorta has been controlled, treat­
ment options include simple clo­
sure, resection with insertion of a 
prosthetic graft, or bypass grafting 
from aortic arch to distal thoracic 
aorta. Management of the esopha­
gus depends on the size of the 
perforation and the cause of the 
fistula. Small perforations due to 
aneurysmal erosion can usually be 
closed primarily after debridement 
and then reinforced with pericardial 
fat.2 When the esophagus contains 
the primary pathologic process, as 
in reflux esophagitis, it will usually 
be too friable to close primarily. In 
this situation, thoracic esophageal
resection, end cervical esophagosto- 
my and gastrostomy are indicated. 
Gastrointestinal continuity can be 
restored by gastric “pull-up” or 
colonic interposition. Interposition 
of a pericardial or pleural flap or 
vascularized intercostal muscle flap 
between the aorta and reconstruct­
ed gastrointestinal tract is recom­
mended to prevent repeat fistuliza- 
tion.12 Although all untreated cases 
of AEF are fatal, prompt recogni­
tion and early surgery still result in 
a death rate of 55% to 75%.1516
We thank Colleen Gardner and Rose­
marie Henley for preparation of this 
manuscript.
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SESAP VII Critique /  Critique SESAP VII
Item 256
Patients with aortic stenosis typically present with congestive heart failure, angina pectoris, and syncope. 
Systemic embolization may occur. This patient’s systolic murmur corroborates an aortic valve problem. The 
importance of prompt and correct diagnosis cannot be overemphasized, especially in a patient who requires 
operation for unrelated disease. The left ventricle hypertrophies, which then results in changes in ventricular 
compliance. These patients are sensitive to increased volume and can develop pulmonary edema and cardiogenic 
shock with induction of anesthesia. Significant aortic stenosis must be diagnosed and treated prior to any 
elective surgical procedure.
D
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Action
In vitro studies indicate that the bacterial action of Claforan (cefotaxime sodium) a semi-synthetic cephalosporin 
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible 
strains of the designated micro organisms in the diseases listed below.
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(formerly Diplococcus pneumoniae), other streptococci (excluding enterococci, e.g. S. faecalis), Staphylococcus 
aureus (penicillinase and non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including 
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract in fec tions : caused by Escherichia coli, unspecified Klebsiella species (including K  pneumoniae), 
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated 
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
Bacteremia / Septicem ia: caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens. 
Skin in fec tions : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), S. epidermidis, 
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdominal in fec tions : caused by Escherichia coli, and unspecified Klebsiella species.
Gynecological in fec tions : including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by 
E. coli, Group A streptococci and Staphylococcus epidermidis: anaerobic bacteria including unspecified Peptococcus 
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures 
were achieved, bacteriological follow-up was not available.
Central nervous system in fec tions : meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria 
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active 
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in 
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci.
Claforan has been shown to be active against some strains of Pseudomonas.
’ In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis.
I  Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative
l |  organisms and to determine their susceptibilities to Claforan, Therapy may be instituted before results of susceptibility
"  studies are known; antibiotic treatment should be re-evaluated once these results become available.
» Prophylactic U se: The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively)
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal 
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or 
potentially contaminated.
t In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain 
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as 
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism 
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin 
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous 
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with 
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be 
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an 
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents 
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudomembranous co litis  has been reported w ith  the use of cephalosporins (and other broad spectrum 
antib iotics); therefore, it is im portant to consider its  diagnosis in patients who develop diarrhea during 
the administration of Claforan. This colitis  can range from  mild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit 
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium 
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic. 
Moderate to severe cases should be managed with fluid, electrolyte and protein supplementation as indicated 
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic 
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy 
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions). 
Precautions
Claforan (cefotaxime sodium) should be prescribed with caution in individuals with a history of lower gastro­
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women 
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the 
possible risks.
|  Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is
l  administered to nursing mothers.
v Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the
!j patient’s condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures
l  taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended, 
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended 
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and 
prolonged serum antibiotic concentrations.
; Positive direct Coombs' test is known to develop in individuals during treatment with the cephalosporin group of
antibiotics, including cefotaxime sodium.
: In laboratory tests a false positive reaction to glucose may occur with reducing substances but not with the use
of specific glucose oxidase methods.
As with other beta-lactam antibiotics, granulocytopenia and, more rarely, agranulocytosis may develop during 
treatment with Claforan, particularly if given over long periods. For courses of treatment lasting longer than 10 
days, blood counts should therefore be monitored.
Adverse Reactions
► The most frequent adverse reactions with their frequency of occurrence are
Hypersensitivity (1.8%): Rash, pruritus, fever. Local (5% ); Injection site inflammation with intravenous 
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%); Colitis, 
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan 
treatment. Hematologic System ( <  1%): Neutropenia, transient leukopenia, eosinophilia, thrombocytopenia and 
agranulocytosis have been reported. Some individuals have developed positive direct Coombs’ test during
treatment with Claforan and other cephalosporin antibiotics. Rare cases of hemolytic anemia have been reported. 
Genitourinary System ( <  1%): Moniliasis, vaginitis. Liver ( <  1%): Transient elevations in SGOT, SGFT, serum 
LDH and serum alkaline phosphatase levels have been reported. Kidney ( <  1%); Increased serum creatinine and 
BUN have occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or 
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table 
with recommended mode of reconstitution according to route of administration).
Dosage
Adults : The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the 
infection and condition of the patient.
Guidelines for Dosage or Claforan (cefotaxime sodium)
Type of Infection
Daily Dose
(g) Frequency and Route
Uncomplicated Gonorrhea 1 1 g IM (single dose)
Uncomplicated infections 2 1 g every 12 hours IM or IV
Moderately severe to severe infections 3-6 1-2g every 8 hours IM or IV
Very severe infections (e.g. septicemia, CNS) 6-8 2g every 6-8 hours IV
Life-threatening infections up to 12 2g every 4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are 
as follows;
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate 
antibiotic levels are present in the serum and tissues at the start of surgery;
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional 
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery;
(c) 1 g IM or IV administered within 2 hours following completion of surgery.
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses 
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates: 0-1 week of age 50 mg / kg IV q 12 h
1-4 weeks of age 50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is 
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe 
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or 
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for 
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or 
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary 
tract infections and may be required for several months after therapy has been completed; persistent infections may 
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 the dose of Claforan should be 
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient) 
may be used to convert these values into creatinine clearance.
Males: Weight (kg) x  (140 -  age)
72 x  serum creatinine 
Females: 0.85 x  above value
Administration
In tram uscu la r: Claforan should be injected well within the body of a relatively large muscle such as the upper 
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a 
blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia, bacterial septicemia, or other severe 
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from 
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if 
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes. 
Using an infusion system, it may also be given over a longer period of time through the tubing system by which 
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this 
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue 
temporarily the administration of other solutions at the same site.
Stability
Claforan reconstituted in the original vial as described under RECONSTITUTION maintains satisfactory potency for 
24 hours at room temperature (25°C) and for 48 hours under refrigeration (0-5°C).
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a 
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or 
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP 
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium 
(expressed as acid on a dry basis).
Storage: Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
*Reg’d TM of Abbott Laboratories.
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ORIGINAL ARTICLES
T h e Anatomical Basis for Laparoscopic 
Splenectomy
Eric C. Poulin, MD, FRCSC; Claude Thibault, MD
The anatomy of the splenic blood supply is extremely variable. Two principal patterns, the distributed 
and the magistral types, include the majority of variations. These two types differ with respect to the 
length of the splenic trunk, the number of arterial branches and the proportion of the medial surface of 
the spleen occupied by the branches as they enter the organ. The suspensory ligaments of the spleen, 
including the sustentaculum lienis, are usually avascular except for the gastrocolic and lienorenal 
ligaments on the medial side. The tail of the pancreas touches the spleen in 30% of cases and lies 
within 1 cm of the spleen in 73%. Knowledge of these basic anatomic facts and the variations should 
contribute to the safety of laparoscopic splenectomy.
L anatomie de la vascularisation de la rate est extremement variable. II existe deux principaux types 
d’architecture vasculaire, le type distribue et le type magistral, qui incluent la majorite des variations. 
Ces deux types different de par la longueur du tronc de l’artere splenique, de par le nombre des 
branches arterielles et de par la proportion de la surface interne de la rate traversee par les vaisseaux. 
Les ligaments suspenseurs de la rate, incluant le sustentaculum lienis, sont habituellement 
avasculaires sauf pour les ligaments gastro-splenique et lieno-renal a la face interne. La queue du 
pancreas touche la rate dans 30 % des cas et se situe en defa de 1 cm dans 73 %. La connaissance de ces 
donnees anatomiques de base et de leur variations devrait contribuer a la realisation securitaire de la 
splenectomie par voie laparoscopique.
L aparoscopic surgery and video­imaging technology have al­
lowed the observation of magnified 
anatomic detail in the performance 
of many surgical procedures. It has 
also become increasingly clear that 
minimal access surgery requires 
maximal knowledge of anatomy to 
ensure optimal hemostatic control 
and preservation of anatomic integ­
rity.
The knowledge of anatomy re­
quired for safe performance of lapa­
roscopic splenectomy is crucial be­
cause the spleen is a fragile, highly 
vascularized, solid viscus.1 Al­
though most anatomy texts imply 
that the splenic artery is constant in
its course and branches, Michels in 
his classical essay in 19422 called 
attention to the fact that each 
spleen has its own peculiar pattern 
of terminal splenic artery branches.
In this paper we summarize the 
anatomic facts pertinent to the per­
formance of laparoscopic splenecto­
my with emphasis on the splenic 
artery, its branches, the suspensory 
ligaments of the spleen and the 
pancreas.
History
Julius Caesar Arantius of Vienna 
(1571) was the first to emphasize
the tortuous course of the splenic 
artery. Lipshutz3 in a study of 83 
cadavers described the terminal 
branches of the splenic arteries out­
side the parenchyma. Melnikoff4 
(1923) dealt primarily with the divi­
sions of the splenic artery within 
the spleen, even claiming the exis­
tence of a well-developed system of 
collaterals. However, in the same 
year (1923) Volkmann5 denied the 
existence of any important collater­
als in the spleen. Ssoson-Jaros- 
chewitsch6 classified the highly 
variable vascular anatomy of the 
spleen in two main patterns: the 
magistral type and the distributed 
type. Henschen7 drew attention to
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the fact that the distributed type of 
anatomy was more often encoun­
tered in lobulated and unevenly 
contoured spleens as opposed to 
spleens that had a more even inner 
surface.
The Splenic Artery
The celiac axis is the largest and 
the shortest branch (15 to 20 mm) 
of the abdominal aorta. It arises 
above the body of the pancreas and 
in 82% of specimens divides into 
three primary branches, the left 
gastric artery being given off as the 
first branch and the hepatic and 
splenic arteries coming from a com­
mon stem. Rarely, the splenic artery 
takes its origin directly from the 
aorta and even less often, a second 
splenic artery is seen arising from 
the celiac axis. Other variations 
exist. They include origin from the 
superior mesenteric artery, the mid­
dle colic artery, the left gastric 
artery, the left hepatic artery and 
the accessory right hepatic artery. 
As a rule, the splenic artery starts 
from the celiac axis to the right of 
the midline, thus necessitating a 
crossing of the aorta to reach the 
spleen. Its course can be very tortu­
ous. Its tortuosity increases with 
age and with a longer artery.
In his study of 100 cadaver 
spleens, Michels2 reported that the 
distributed type was found in 70% 
of dissections. By definition, the 
splenic trunk is then short, and 
numerous long branches (6 to 12) 
enter over 75% of the medial sur­
face of the spleen. The branches 
originate between 3 and 13 cm from 
the hilus (Fig. 1). The magistral 
type was present in the remaining 
30% of the specimens. It is charac­
terized by the presence of a long 
main splenic artery dividing into 
short terminal branches near the 
hilus. The splenic branches enter 
over only 25% to 33% of the medial
surface of the spleen. They are 
large and few (three to four). They 
originate 3.5 cm on average from 
the spleen and reach the centre of 
the organ as a compact bundle 
(Fig. 2).
Branches of the Splenic Artery
The splenic branches exhibit 
such marked variations in length, 
size and origin that no two spleens 
have the same anatomy. Outside the 
spleen, the arteries also present 
frequent transverse anastomoses 
with each other which, according to 
Testut,8 arise at a 90° angle be­
tween the involved arteries, as with 
most collaterals (Fig. 1). Before it 
divides, the splenic trunk usually 
gives off a few slender branches to 
the tail of the pancreas. Then, the 
splenic artery divides into first and 
second terminal branches (two to 
six branches), after which there are 
two other levels of division — the
penultimate and ultimate branches 
(2 to 12 branches). The level of 
segmental and subsegmental divi­
sion is variable and can occur out­
side or inside the spleen. The num­
ber of arteries entering the spleen 
varies from 6 to 36; the size of the 
spleen does not determine the num­
ber of entering arteries, but the 
presence of notches and tubercules 
usually correlates well with a great­
er number of entering arteries.
The general scheme of splenic 
artery branches may include up to 
seven principal branches at various 
division levels and in various ana­
tomic arrangements. They include 
the following: the superior terminal 
artery, the inferior terminal artery, 
the medial terminal artery, the su­
perior polar artery, the inferior 
polar artery, the left gastroepiploic 
artery and the short gastric arteries 
(Fig. 3). Veins are usually posterior 
to the arteries except at the ulti­
mate division level where they may 
be anterior or posterior.
FIG. 1. Distributed type of vascularization. LG =  left gastric artery, H =  hepatic 
artery, DP =  dorsal pancreatic artery, SG =  short gastric arteries, ANAS =  
anastomosis, SP =  superior polar artery, ST = superior terminal artery, IT =  
inferior terminal artery, IP =  inferior polar arteries, LGE =  left gastroepiploic 
artery, PU =  penultimate branch, U =  ultimate branch.
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First Terminal Division 
Branches
In Lipshutz’s study,3 72% of 
specimens had three terminal 
branches (superior polar, and supe­
rior and inferior terminal), whereas 
28% had two terminal branches. 
The medial terminal artery was ob­
served in only 20% of cases.3 When 
the superior terminal branch is ex­
cessively large, the inferior terminal 
branch is rudimentary, an added
blood supply often coming from the 
left gastroepiploic and polar vessels.
The Short Gastric Arteries
There may be up to six short 
gastric arteries arising from the 
fundus of the stomach, but usually 
only the ones opening into the 
superior polar artery of the spleen 
need to be ligated during laparo­
scopic splenectomy (Fig. 1).
The Left Gastroepiploic 
Artery(ies)
This artery is the most varied of 
the splenic branches and courses 
along the left side of the greater 
curvature in the anterior layer of 
the greater omentum. In about 72% 
of the cases, it arises from the 
splenic trunk several centimetres 
from its primary terminal division. 
In 22% of cases, it originates from 
the inferior terminal artery or its 
branches. It may also originate 
from the middle of the splenic trunk 
or from the superior terminal ar­
tery.
Characteristically this artery 
gives off inferior polar branches, 
which vary in number (from one to 
five), size and length.
The Inferior Polar Artery
This artery is present in 82% of 
cases. There may be up to five 
collateral branches, which may arise 
from the splenic trunk, the inferior 
terminal artery or, as already men­
tioned, from the left gastroepiploic 
artery. Inferior polar branches may 
have multiple origins and, usually, 
the calibre of the artery is smaller 
than that of the superior polar 
branch.
The Superior Polar Artery
The superior polar artery is pres­
ent 65% of the time and arises from 
the main splenic trunk in 75% of 
cases, from the superior terminal 
artery in 20% of cases and occasion­
ally from the inferior terminal ar­
tery or separately from the celiac 
axis, thus providing the spleen with 
a double splenic artery. In the ma­
jority of cases, it gives origin to one 
or two short gastric branches and 
rarely to the left inferior phrenic 
artery and pancreatic rami. The
FIG. 2. Magistral type of vascularization. LG =  left gastric artery, H =  hepatic 
artery, DP =  dorsal pancreatic artery, SG =  short gastric arteries, SP = superior 
polar artery, ST = superior terminal artery, IT = inferior terminal artery, IP =  
inferior polar artery, PU = penultimate branch, U = ultimate branch.
FIRST TERMINAL SECOND TERMINAL II COLLATERALS ! THIRD TERMINAL FOURTH TERMINAL
DIVISION DIVISION 1 DIVISION DIVISION
S u p e r io r — ► 4. S u p e rio r — ►  7. S h o r t  — — ►
te rm in a l p o la r g a s t r ic
a r te ry a rte ry a r te r ie s
( 1 - 2 )
In fe r io r — ► 5. In fe rio r ------------------------------------------ ►  P e n u lt im a te — ► U lt im a te
te rm in a l p o la r b ra n c h e s b ra n c h e s
a rte ry a rte ry (2  t o  1 2 ) (w ith in  s p le e n )
G a s tro -
(2  to  12)
M e d ia l ’
6.
e p ip lo ic
a r te r y
te r m in a l
a r te r y
FIG. 3. General scheme of splenic artery branches.* = Present in only 20% of cases.
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incidence and calibre of this artery 
appears to be correlated with tuber­
cle formation, for it is more promi­
nent in spleens having large tuber­
cles. Frequently this artery is very 
long and slender and may be torn 
during splenectomy. This fact 
prompted Henshen to suggest, in 
1928, that ligation of splenic 
branches should be started from the 
inferior pole of the spleen.7
The Suspensory Ligaments of 
the Spleen
Duplications of the peritoneum 
form the suspensory ligaments of 
the spleen. The phrenocolic liga­
ment courses from the diaphragm 
to the splenic flexure of the colon; 
its superior end is referred to as the 
phrenosplenic ligament.9 The at­
tachment of the lower pole on the 
internal side is called the splenocol- 
ic ligament. Between these two, a 
horizontal shelf is formed on which 
rests the inferior pole of the spleen. 
It is often moulded into a sac that 
opens cranially and is called the 
sustentaculum lienis, acting as a 
brassiere to the inferior pole of the 
spleen. There are two ligaments on 
the hilar side: anteriorly, the gas- 
trosplenic ligament containing the 
short gastric and the gastroepiploic 
vessels and posteriorly, the lienore- 
nal ligament with the splenic ves­
sels and the tail of the pancreas 
(Fig. 4).
The Pancreas
Michels2 stated that Ssoson- 
Jaroschewitsch found the tail of the 
pancreas in direct contact with the 
spleen in 30% of cadavers. Baro- 
nofsky and associates10 confirmed 
this finding and added that the 
distance from the pancreas to the 
splenic hilus was not more than 1 
cm in 73% of their patients.
Surgical Considerations
Precise knowledge of splenic 
anatomy is required before its re­
moval is attempted laparoscopically. 
The surgeon should appreciate the 
infinite variability of splenic vascu­
lar anatomy. However, on seeing 
the spleen and its hilus, the sur­
geon can usually predict its type of 
vascularization. A notched spleen 
with a wide hilus will have a more 
complicated type of vascularization. 
The distributed type will have more 
variations and more vessels, but 
dissection will probably be easier 
because of the greater space be­
tween vascular structures. The 
spleen with even borders and a 
compact hilus (magistral type) will 
have fewer variations and fewer 
vessels. The dissection, however, is 
more tedious and more risky be­
cause of the narrow, compact na­
ture of the hilus where vessels are 
very close to one another and more 
prone to injury.
In patients who undergo preoper­
ative arteriography or splenic artery 
embolization, the radiologist must 
be familiar with the variability of 
access to the splenic artery so as to 
successfully cannulate the arterial 
tree for proximal and distal emboli­
zation.
Laparoscopic splenectomy is 
started at the lower pole of the 
spleen. When many branches of the 
left gastroepiploic artery have to be 
taken, it should be recognized that 
the blood supply coming from the 
left gastroepiploic artery through 
its splenic branches may approxi­
mate that reaching the spleen 
through its primary lienal branches, 
complicating the effectiveness of 
preoperative embolization in some 
cases.
Surgical control of the splenic 
vessels is subsequently obtained dis­
tal to the often-seen transverse col­
laterals and proximal to the en­
trance of vessels in the spleen, 
resulting in 8 to 18 ligatures (arter-
FIG. 4. Suspensory ligaments of spleen, lig. =  ligament, a =  artery.
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ies and veins). The segmental distri­
bution of arteries within the spleen 
makes observation of parenchymal 
colour changes very useful during 
the procedure. Devascularized seg­
ments (ligature or embolization) ap­
pear charcoal gray, and viable seg­
ments retain a pinkish hue. A char­
acteristic phenomenon useful in la­
paroscopic splenectomy is the ob­
servation of selective distribution of 
inferior polar arteries to notched 
areas of the spleen, the arteries 
being numerically proportional to 
the notches.
When preoperative splenic artery 
embolization is performed, place­
ment of the proximal coils should 
spare arterial branches of the sple­
nic trunk to the tail of the pancreas 
to avoid pancreatitis. During the 
operation, pancreatic injury should 
be avoided and the relationship of 
the tail of the pancreas to the 
splenic hilus borne in mind during 
laparoscopic dissection. Therefore, 
safe laparoscopic splenectomy re­
quires careful dissection of the tail 
of the pancreas from the splenic 
hilus. Dissection should be very 
close to the splenic hilus to avoid 
pancreatic injury with instruments 
like the cautery.
Knowledge of the structures
found in the gastrosplenic and lie- 
norenal ligaments of the spleen 
should also prevent injury. One 
should appreciate that the other 
suspensory ligaments of the spleen 
are avascular except in cases of 
portal hypertension and myelo­
proliferative disorders.11 The sus­
tentaculum lienis, seldom noticed in 
open surgery, is readily seen 
through the laparoscope. It is avas­
cular most of the time and is easily 
sectioned with the cautery, close to 
the spleen, with care taken of the 
tail of the pancreas on the medial 
side. Gentle downward traction on 
the splenic flexure of the colon 
helps the initial phase of the opera­
tion when the phrenocolic, the sple- 
nocolic and the sustentaculum lie­
nis ligaments are taken with the 
cautery. After the gastroepiploic 
vascular branches to the lower pole 
have been ligated, the splenic flex­
ure of the colon effectively drops 
away from the operating field for 
the remainder of the operation. 
Care should also be taken to avoid 
cautery burns to the splenic flexure 
during lower-pole manipulations.
We believe that the appreciation 
of these significant anatomical land­
marks should contribute to the 
safety of laparoscopic splenectomy.
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SPONSORS’ NEWS 
NOUVELLES DES PARRAINS
The Canadian Association of General 
Surgeons
1993 Annual Meeting
At the annual meeting of the Canadian Association of 
General Surgeons (CAGS), held in Vancouver from 
Sept. 9-13, 1993, a new executive was elected. The 
new president is Dr. Fred Inglis. The president-elect 
is Dr. Chris Heughan from St. John’s, Nfld. The 
past-president is Dr. Marvin Wexler and the secretary 
and treasurer remain Drs. Keith and Huntington 
respectively.
At the annual meeting the postgraduate courses 
on laparoscopic surgery and malignant diseases of 
the large intestine were very successful; registrants 
were delighted with the content of the two programs.
A new event was held this year. Dr. Wexler 
initiated an annual dinner featuring presentations to 
all of the past-presidents. The dinner was attended by 
200 members and will become an annual event. The 
presidential address was delivered before the annual 
business meeting on Friday, Sept. 10. Dr. Wexler 
reflected on the profile of general surgery in his 
presentation entitled “The General Surgeon Through 
the Looking Glass — Bright Reflections From a 
Tarnished Image.”
The annual program featured guest lecturer by Dr. 
Alfred Cuschieri from Dundee, Scotland, and Dr. E. 
Moore from Denver, Colo., who delivered the W.R. 
Ghent Lecture. The CAGS Lecture was presented by
Professor R.J. Heald from England, whose presenta­
tion was entitled “Carcinoma of the Rectum — 
Surgery, Radiotherapy and Chemotherapy: Are Cur­
rent Priorities Correct?”
Annually, the CAGS honours two of its senior 
members who have made major contributions to 
general surgery in Canada. This year honorary 
memberships were given to Dr. Tait McPhedran of 
Calgary and Dr. Wally Chung of Vancouver.
During the annual business meeting, general sur­
gical residents from the 16 Canadian departments of 
surgery were presented with the CAGS/Merck 
Frosst Resident Award for Teaching. This award is 
sponsored by the association and Merck Frosst 
Canada. Residents are recognized for the excellence 
of their teaching contribution in their respective 
medical schools during their senior year of residency.
Coat of Arms
The CAGS coat of arms was officially presented by 
the Chief Herald of Canada to the Royal College of 
Physicians and Surgeons of Canada on behalf of the 
CAGS. This mounted and inscripted coat of arms will 
be placed in the Royal College offices in Ottawa. The 
presentation was conducted during the opening cere­
monies of the Royal College annual meeting. The 
association owes a debt of gratitude to Dr. Robert 
Thorlakson for his major contribution in the develop­
ment of this outstanding work of art.B
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CIPROFLOXACIN HYDROCHLORIDE 
.V- CIPROFLOXACIN INJECTION
THERAPEUTIC CLASSIFICATION 
THERAPEUTIC CLASSIFICATION
ANTIBACTERIAL AGENT 
ANTIBACTERIAL AGENT
ACTIONS
Ciprofloxacin, a synthetic fluoroquinolone, has a bactericidal mode of action. This action is achieved through inhibition of DNA 
gyrase, an essential component of the bacterial DNA replication system. Inhibition of the alpha subunit of the DNA gyrase blocks 
the resealing of the nicks on the DNA strands induced by this alpha subunit, leading to  the degradation of the DNA by 
exonucleases. This bactericidal activity persists not only during the multiplication phase, but also during the resting phase of the 
bacterium.
Ciprofloxacin retained some of its bactericidal activity after inhibition of RNA and protein synthesis by rifampin and 
chloramphenicol, respectively. These observations suggest ciprofloxacin may possess two bactericidal mechanisms, one 
mechanism resulting from the inhibition of DNA gyrase and a second mechanism which may be independent of RNA and protein 
synthesis.
INDICATIONS AND CLINICAL USES 
A) Oral Administration
CIPRO (Ciprofloxacin hydrochloride tablets) may be indicated for the treatment of patients with the following infections caused 
by susceptible strains of the indicated microorganisms:
Respiratory Tract Infections: Acute bronchitis and acute pneumonia caused by: £  cloacae, £  coli, H. influenzae, K. pneumoniae,
P. mirabilis, P. aeruginosa, S. aureus, S. pneumoniae
Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas infections of the respiratory 
tract, bacterial eradications may not be achieved in patients who display clinical improvement despite evidence of in vitro 
sensitivity. In patients requiring subsequent courses of therapy, CIPRO® should be used alternately with other antipseudomonal 
agents. Some strains of Pseudomonas aeruginosa may develop resistance during treatment. Therefore, susceptibility testing 
should be performed periodically during therapy to detect the emergence of bacterial resistance.
Urinary Tract Infections: Upper and lower urinary tract infections, such as complicated and uncomplicated cystitis, pyelonephritis, 
and pyelitis, caused by: C. diversus, C. freundii, E. cloacae, E. coli, K. pneumoniae, K. oxytoca, M. morganii, P  mirabilis,
P. aeruginosa, S. marcescens, S. aureus, S. epidermidis, S. faecalis
Skin and Soft Tissue Infections: caused by: £. cloacae, E  coli, K. pneumoniae, P  vulgaris, P  mirabilis, S. pyogenes, P  aeruginosa, 
S. aureus, S. epidermidis
Bone and Joint Infections: caused by: S. marcescens, P. aeruginosa, S. aureus, E cloacae
Infectious Diarrhea: (When antibacterial therapy is indicated) caused by: £  coli (enterotoxigenic strains), C. jejuni, S. flexneri,
S. sonnei
B) Intravenous Administration
CIPRO® I.V. (Ciprofloxacin injection) may be indicated for the treatment of patients with the following infections caused by 
susceptible strains of the indicated microorganisms:
Respiratory Tract Infections: acute pneumonia caused by: £  coli, K. pneumoniae, £  cloacae, P  mirabilis, P  aeruginosa,
H. influenzae, H. parainfluenzae, S. pneumoniae
Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas infections of the respiratory 
tract, bacterial eradications may not be achieved in patients who display clinical improvement despite evidence of in vitro 
sensitivity. In patients requiring subsequent courses of therapy, CIPRO® should be used alternately with other antipseudomonal 
agents. Some strains of Pseudomonas aeruginosa may develop resistance during treatment. Therefore, susceptibility testing 
should be performed periodically during therapy to detect the emergence of bacterial resistance.
Urinary Tract Infections: Upper and lower complicated urinary tract infections including pyelonephritis caused by: C. diversus,
£  coli, K. pneumoniae, P. mirabilis, P  aeruginosa
Skin or Skin Structure Infections: caused by: £  cloacae, £  coli, K. pneumoniae, M. morganii, P  vulgaris, P  mirabilis,
P  aeruginosa, S. aureus, S. pyogenes 
Septicemia: caused by: £  coli, S. typhi 
Bone: caused by: £  cloacae, P. aeruginosa
Appropriate culture and susceptibility tests should be performed prior to  initiating treatment in order to isolate and identify 
organisms causing the infection and to determine their susceptibilities to ciprofloxacin. Therapy with CIPRO® and CIPRO® I.V. 
may be initiated before results of these tests are known. However, modification of this treatment may be required once results 
become available or if there is no clinical improvement. Culture and susceptibility testing performed periodically during therapy 
will provide information on the possible emergence of bacterial resistance. If anerobic organisms are suspected to be contibuting 
to the infection, appropriate therapy should be administered.
CONTRAINDICATIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection] are contraindicated in patients who have 
shown hypersensitivity to ciprofloxacin or other quinolone antibacterial agents.
WARNINGS
Children The safety of CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection) in children has not 
yet been established. Damage to juvenile weight-bearing joints and lameness were observed both in rat and dog studies but not 
in weaned piglets (see TOXICOLOGY in Product Monograph). Histopathological examination of the weight-bearing joints in 
immature dogs revealed permanent lesions of the cartilage. Consequently, CIPRO® and CIPRO® I.V. should not be used in 
prepubertal patients. Experience in pubertal patients below 18 years of age is limited.
Pregnancy The safety of CIPRO® and CIPRO® I.V. in the treatment of infections in pregnant women has not yet been established 
(see PRECAUTIONS).
PRECAUTIONS
General Anaphylactic reactions including cardiovascular collapse have occurred rarely in patients receiving therapy with CIPRO® 
and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection). These reactions may occur within the first 30 
minutes following the first dose and may require epinephrine and other emergency measures.
CIPRO® and CIPRO® I.V. may cause central nervous system (CNS) stimulation which may lead to tremor, restlessness, light­
headedness, confusion, and very rarely to hallucinations or convulsive seizures. Therefore, CIPRO® and CIPRO® I.V. should be 
used with caution in patients with CNS disorders, such as severe cerebral arteriosclerosis or epilepsy. Patients with known 
convulsive seizure disorders should only be treated with CIPRO® and CIPRO® I.V. if anticonvulsant therapy has been initiated. 
SERIOUS AND FATAL REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING CONCURRENT ADMINISTRATION OF 
CIPRO® I.V. AND THEOPHYLLINE. These reactions include cardiac arrest, seizure, status epilepticus and respiratory failure. 
Similar serious adverse events have been noted with administration of theophylline alone, however, the possibility that 
ciprofloxacin may potentiate these reactions cannot be eliminated. If concomitant use cannot be avoided, the plasma levels of 
theophylline should be monitored and appropriate dosage adjustments should be made.
Severe hypersensitivity reactions characterized by rash, fever, eosinophilia, jaundice, and hepatic necrosis with fatal outcome 
have also been reported to occur very rarely in patients receiving ciprofloxacin in combination with other drugs. The possibility 
that these reactions were related to ciprofloxacin cannot be excluded. Ciprofloxacin should be withdrawn at the firs t appearance 
of a skin rash or other signs of hypersensitivity.
Crystalluria related to ciprofloxacin has been reported only rarely in man because human urine is usually acidic. Crystals have 
been observed in the urine of laboratory animals, usually from alkaline urine. Patients receiving ciprofloxacin should be well
hydrated and alkalinity of the urine should be avoided. The recommended daily dose should not be exceeded.
Pseudomembranous colitis has been reported with virtually all antibacterial agents, including ciprofloxacin, and may range in 
severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients with diarrhoea subsequent 
to the administration of antibacterial agents.
Subsequent to diagnosis of pseudomembranous colitis, therapeutic measures should be initiated. Mild cases will usually respond 
to discontinuation of drug alone. In moderate to severe cases, consideration should be given to the management with fluids, 
electrolytes, protein supplementation and treatment with an antibacterial drug effective against C. difficile.
Prolonged use of CIPRO® and CIPRO® I.V. may result in the overgrowth of nonsusceptible organisms. Careful observation of the 
patient is therefore essential, and if superinfection should occur during therapy, appropriate measures should be taken. 
Pregnancy The safety of CIPRO® and CIPRO® I.V. in pregnancy has not yet been established. CIPRO® and CIPRO® I.V. should not 
be used in pregnant women unless the likely benefits outweigh the possible risk to  the fetus. CIPRO® and CIPRO® I.V. has been 
shown to  be non-embryotoxic and non-teratogenic in animal studies.
Nursing Mothers Ciprofloxacin is excreted in human milk. A decision should be made to discontinue nursing or to discontinue the 
administration of CIPRO® and CIPRO® I.V., taking into account the importance of the drug to the mother and the possible risk to 
the infant.
Drug Interactions Concurrent administration of ciprofloxacin with theophylline may lead to an elevated plasma concentration and 
prolongation of elimination half-life of theophylline. This may result in increased risk of theophylline-related adverse reactions. If 
concomitant use cannot be avoided, plasma concentrations of theophylline should be monitored and dosage adjustments made as 
appropriate.
Ciprofloxacin has been shown to interfere with the metabolism and pharmacokinetics of caffeine. Excessive caffeine intake should 
be avoided.
Some quinolones, including ciprofloxacin, have been associated with transient increases in serum creatinine levels in patients who 
are concomitantly receiving cyclosporine.
Quinolones have been reported to increase the effects of the oral anticoagulant warfarin and its derivatives. During concomitant 
administration of these drugs, the prothrombin time or other appropriate coagulation tests should be closely monitored. 
Probenecid blocks renal tubular secretion of ciprofloxacin and has been shown to produce an increase in the level of ciprofloxacin 
in the serum.
Concomitant administration of a nonsteroidal anti-inflammatory drug (fenbufen) with a quinolone (enoxacin) has been reported to 
increase the risk of CNS stimulation and convulsive seizures.
Antacids containing aluminum or magnesium hydroxide have been shown to reduce the absorption of ciprofloxacin. Concurrent 
administration with these agents should be avoided.
Administration of sucralfate prior to CIPRO® resulted in a 30% reduction in absorption of ciprofloxacin. Concurrent 
administration with ciprofloxacin should be avoided.
Oral ferrous sulfate at therapeutic doses decreases the bioavailability of oral ciprofloxacin, therefore concomitant therapy is not 
advised.
The use of calcium supplement reduces the absorption of ciprofloxacin. Concurrent administration should be avoided. In particular 
cases, concurrent administration of ciprofloxacin and glyburide can intensify the action of glyburide (hypoglycemia).
Renal Impairment Since ciprofloxacin is eliminated primarily by the kidney, CIPRO® and CIPRO® I.V. should be used with caution 
and a t a reduced dosage in patients with impaired renal function. (See DOSAGE AND ADMINISTRATION).
Hepatic Impairment In preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin 
pharmacokinetics were observed. The kinetics of ciprofloxacin in patients with acute hepatic insufficiency, however, have not been 
fully elucidated. An increased incidence of nausea, vomiting, headache and diarrhea were observed in this patient population. 
ADVERSE REACTIONS
CIPRO® (ciprofloxacin hydrochloride tablets) and CIPRO® I.V. (ciprofloxacin injection) are generally well tolerated. During 
worldwide clinical investigation, 16,580 courses of ciprofloxacin treatment were evaluated for drug safety.
Adverse events, possibly, probably or highly probably related to ciprofloxacin occurred in 1395 (8.8%) of patients. The adverse 
reactions according to treatment (oral, iv, and sequential therapy) show that the incidence of adverse reactions was 8.0% for the 
group treated orally, 17% for the group treated with CIPRO® I.V. and 15.3% for the group treated sequentially. The difference 
between the oral and iv group relates to adverse vascular reactions which are known to be associated with iv administration.
In orally treated patients enroled in clinical trials, the most frequently reported events, possibly,probably drug-related were: 
nausea (1.3%) and diarrhea (1.0%).
In patients treated with CIPRO® I.V., the most frequently reported events, possibly, probably drug-related were: rash (1.8%), 
diarrhea (1.0%), and injection site pain (1.0%).
Events possibly, probably drug-related occurring a t a frequency of less than 1% with ciprofloxacin oral and i.v. treatment during 
clinical tria ls and subsequent post-marketing surveillance are as follows:
Gastro-lntestinal: vomiting, dyspepsia, abdominal pain, flatulence, dysphagia, enlarged abdomen, dry mouth, stomatitis, 
gastrointestinal moniliasis, anorexia, jaundice. The following have been reported very rarely: constipation, tooth discoloration, 
ulcerative stomatitis, pseudomembranous colitis, intestinal perforation, esophagitis, increased appetite, gastro-intestinal 
hemorrhage, melena, liver damage, tenesmus, ileus, toxic megacolon, hepatomegaly, glossitis.
Cardiovascular system: palpitation, tachycardia, phlebitis, The following have been reported very rarely: hypertension, hot flashes, 
cerebrovascular disorder, syncope, kidney vasculitis, vasodilation, atrial fibrillation, cardiac arrest, angina pectoris, 
electrocardiogram abnormality, myocardial infarct, substemal chest pain, pulmonary embolus, pericarditis, hypotension.
Nervous System: increased sweating, dizziness, agitation, tremor, somnolence, insomnia, confusion, hallucinations, convulsion, 
headache. The following have been reported very rarely: anxiety, depression, nervousness, apathy, depersonalization, abnormal 
dreams, hemiplegia, sleep disorder, neuritis, paresthesia, polyneuritis, diplopia, meningism, migraine, increase of intracranial 
pressure. In some instances these reactions occurred after the first administration of CIPRO®. In these instances, CIPRO® has 
to be discontinued and the doctor should be informed immediately.
Respiratory System: dyspnea. The following have been reported very rarely: hiccup, increased cough, stridor, larynx edema, voice 
alteration, lung edema, pharyngitis, hyperventilation, lung hemorrhage.
Skin and Appendages: rash, pruritus. The following have been reported very rarely: urticaria, photosensitive dermatitis, 
angioedema, alopecia.
Special Senses: tinnitus, abnormal vision, taste perversion. The following have been reported very rarely: conjunctivitis, comeal 
opacity, eye pain, colour blindness, chromatopsia, diplopia, ear pain.
Urogenital System: albuminuria, hematuria. The following have been reported rarely: leukorrhea, dysuria, urinary retention, acute 
kidney failure, abnormal kidney function, nephritis, vaginitis.
Hypersensitivity: rash. The following have been reported rarely: pruritus, drug fever, anaphylactic/ anaphylactoid reactions 
including facial, vascular and laryngeal edema, serum sickness, petechiae, haemorrhagic bullae and small nodules (papules) with 
crust formation showing vascular involvement (vasculitis), Stevens-Johnson-syndrome, interstitial nephritis, hepatitis; very rarely, 
major liver disorders including hepatic necrosis, joint pain, Lyell Syndrome.
Blood and Blood constituents: eosinophilia, leukocytopenia, leukocytosis, anaemia, granulocytopenia. Very rarely: haemolytic 
anaemia, thrombocytopenia, thrombocytosis, altered prothrombin levels.
Laboratory values: increased alkaline phosphatase, Gamma - GT, transaminases, cholestatic parameters, lactic dehydrogenase, 
BUN, NPN, AST, ALT, decreased creatinine clearance, hypercholesteremia, albuminuria, bilirubinemia, hyperuricemia, increased 
sedimentation rate. The following have been reported rarely: electrolyte abnormality, hypercalcemia, hypocalcemia, acidosis, 
crystalluria and haematuria.
Other thrombophlebitis. Very rarely, asthenia, death.
Most of the adverse events reported were described as only mild or moderate in severity .There have been 54 reports of 
arthropathies with CIPRO®. Ten of these reports involved children. Arthralgia was usually the firs t symptom which led to  rapid 
assessment and withdrawal of the drug. No irreversible arthropathies have been observed.
SYMPTOMS AND TREATMENT OF OVERDOSE
Overdose has not yet been reported with CIPRO® and CIPRO® I.V. (ciprofloxacin hydrochloride tablets and ciprofloxacin injection). 
In the event of acute overdosage, the stomach should be emptied by inducing vomiting or by gastric lavage. The patient should be 
carefully observed and given supportive treatment.
D0SA6E AND ADMINISTRATION
The determination of dosage for any particular patient must take into consideration the severity and nature of the infection, the 
susceptibility of the causative organism, the integrity of the patient’s host-defense mechanisms, and the status of renal function.
Oral Administration
CIPRO® (Ciprofloxacin hydrochloride tablets) may be taken before or after meals. Absorption is faster on an empty stomach. 
Patients should be advised to drink fluids liberally and not take antacids containing magnesium or aluminum.
Adult The recommended dosages of oral CIPRO® are:____________________________________________________________
location of Infection Type/Severity Unit Dose Frequency Daily Dose
Urinary Tract Mild/Moderate 250 mg 
Severe/Complicated 500 mg
q 12h 
q 12h
500 mg 
1000 mg
Lower Respiratory Tract 
Bone £ Joint 
Skin £ Soft Tissue
Mild/Moderate 500 mg 
Severe/Complicated'5 750 mg
q 12h 
q 12h
1000 mg 
1500 mg
Infectious Diarrhea Mild/Moderate/Severe 500 mg q 12h 1000 mg
1 e.g. hospital-acquired pneumonia, osteomyelitis
Depending on the severity of the infections, as well as the clinical and bacteriological responses, the average treatment period 
should be approximately 7 to 14 days. Generally, treatment should last 3 days beyond the disappearance of clinical symptoms or 
until cultures are sterile. Patients with osteomyelitis may require treatment for a minimum of 6 to  8 weeks and up to 3 months. 
With acute cystitis, a five-day treatment may be sufficient.
Intravenous Administration
Adult The recommended adult dosages of CIPRO® I.V. (ciprofloxacin injection) are:
Location of Infection Type/Severity Unit Dose Frequency Daily Dose
Urinary Tract Moderate/Severe/ 200 mg to 
Complicated 400 mg
q 12h 400 mg to 
800 mg
Lower Respiratory Tract 
Skin or Skin Structure 
Blood 
Bone
Moderate 400 mg q 12h 800 mg
Definitive clinical studies have not been completed in severe respiratory tract and other infections.
The duration of treatment depends upon the severity of infection. Generally ciprofloxacin should be continued for a t least 3 days 
after the signs and symptoms of infection have disappeared. The usual duration is 7 to 14 days. However, for severe and 
complicated infections more prolonged therapy may be required. Bone and joint infections may require treatment for 4  to 6 
weeks or longer.
Sequential IV/PO Therapy
In patients receiving intravenous ciprofloxacin, oral ciprofloxacin may be substituted when clinically indicated a t the discretion of 
the physician. Clinical studies evaluating the use of sequential IV/PO therapy in septicemia have not yet been completed. 
Impaired Renal Function
Ciprofloxacin is eliminated primarily by renal excretion. However, the drug is also metabolized and partially cleared through the 
biliary system of the liver and through the intestine. This alternate pathway of drug elimination appears to compensate for the 
reduced renal excretion of patients with renal impairment. Nonetheless, some modification of dosage is recommended,
particularly for patients with severe renal dysfunction. The following table provides a guideline for dosage adjustment. However, 
monitoring of serum drug levels provides the most reliable basis for dosage adjustments. Only a small amount of ciprofloxacin 
(<10%) is removed from the body after haemodialysis or peritoneal dialysis.____________________________________________
Creatinine Clearance Dose
m l/s (mL/min)
> 0 .5  (30) No Dose adjustment
<  0.5 (30)
and patients on haemodialysis or 
peritoneal dialysis
Use recommended dose once daily or 
half usual dose twice daily
When only the serum creatinine concentration is available, the following formula (based on sex, weight and age of the patient) 
may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal
function:
Creatinine Clearance mL/sec In traditional units mL/min
Males: Weight (kg) x (140 - age)
49 x serum creatinine (^mol/L)
Males: Weight (kg) x (140 - age)
72 x serum creatinine mg/100 mL
Females: 0.85 x the above value Females: 0.85 x the above value
Children
The safety and efficacy of CIPRO® and CIPRO® I.V. in children have not been established. 
CIPRO® and CIPRO® I.V. should not be used in prepubertal patients (see WARNINGS).
Tablets: 
Cipro *  250
Cipro *  500
Cipro '75 0
AVAILABILITY OF D0SA6E FORMS
Each tablet is engraved MILES on one side and 512 on the other and contains ciprofloxacin hydrochloride 
equivalent to 250 mg ciprofloxacin. Bottles of 100.
Each tablet is engraved MILES on one side and 513 on the other and contains ciprofloxacin hydrochloride 
equivalent to  500 mg ciprofloxacin. Bottles of 100 and unit dose packages of 100. v
Each tablet is engraved MILES on one side and 514 on the other and contains ciprofloxacin hydrochloride 
equivalent to  750 mg ciprofloxacin. Bottles of 50 and unit dose packages of 100.
Injection:
Ciprow I.V. Each mL contains 10 mg of ciprofloxacin, in vials of 20 mL and 40  mL.
Product Monograph available upon request.
©  MILES CANADA INC., 1993
®  Registered Trademark. MILES CANADA INC., is the Registered User of the Trademark CIPRO®, the original brand of 
ciprofloxacin hydrochloride.
™ The trademark of the Cipro tablet, consisting of it's  colour, shape and size, is a trademark of MILES CANADA INC.
References: 1. Cipro /  Cipro I.V. Canadian Product Monograph, MILES CANADA INC., September 1991 
2. Current manufacturers' prices as of Jan., 1993.
CI042-0693E
MILES CANADA INC. 
Pharmaceutical Division 
77 Belfield Road,
Etobicoke, Ontario M 9 W  1G6
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INTRODUCTION TO VASCULAR 
ULTRASONOGRAPHY. 3rd edition. 
Edited by William J. Zwiebel. 423 pp. 
Illust. W.B. Saunders Company/Har- 
court Brace Jovanovich, Inc., Philadel­
phia, 1992. $95. ISBN 0-7216-3551-2
The nature of vascular imaging has 
changed profoundly in the past 2 dec­
ades, largely as a result of ultrasound 
technology. During the last 5 years 
colour-duplex sonography has emerged 
as a common examination tool.
This book is a welcome update of a 
standard reference text. Virtually any 
radiologist, cardiovascular surgeon or 
ultrasound technologist involved in vas­
cular sonography will find this an indis­
pensable and comprehensive guide.
The major addition to this third 
edition is the discussion of colour- 
duplex technology and imaging. The 
book is divided into five sections. The 
first section is devoted to the basic 
principles of hemodynamics, Doppler 
physics and instrumentation, spectrum 
analysis and colour-duplex sonography. 
These chapters are easily understand­
able and well illustrated by both Dopp­
ler and gray-scale images, as well as line 
diagrams. In subsequent sections cere­
brovascular disease, extremity arterial 
and venous examinations and abdomi­
nal vascular imaging are discussed. In 
each of these sections there is a thor­
ough discussion of normal anatomy, 
technical considerations, pathologic fea­
tures and pitfalls. Included in the ex­
tremity arterial section is a chapter on 
nonimaging physiologic tests for as­
sessment of arterial disease, such as 
plethysmography and arterial pressure 
measurement. Echocardiography is not 
dealt with in this text.
There are only two significant short­
comings. First, most of the illustrations 
are black and white. The relatively few 
colour plates are grouped centrally 
within the volume, making the reader 
flip back and forth between text and 
illustrations. However, as the author 
points out, this results in a significant 
cost saving — an important feature 
when a substantial proportion of pur­
chasers will be technologists. Second, 
as a radiologist involved predominantly 
in abdominal imaging, I would have 
liked more detailed treatment of Dopp­
ler abnormalities associated with renal 
and hepatic transplantation.
On the whole, the deficiencies of this 
text are relatively minor. It is a compre­
hensive and valuable book. It certainly 
meets and surpasses its goal as an 
introductory text of vascular ul­
trasonography and should probably be 
found in the library of every vascular 
laboratory.
Joan P. Campbell, MD, FRCPC
Department of Diagnostic Imaging 
St. Michael’s Hospital 
30 Bond St.
Toronto, ON 
M5B 1W8
ELECTRICAL TRAUMA: THE PA­
THOPHYSIOLOGY, MANIFESTA­
TION AND CLINICAL MANAGE­
MENT. Edited by R.C. Lee, E.G. Cra- 
valho and J.F. Burke. 440 pp. Illust. 
Cambridge University Press, New 
York. 1992. $120. (US). ISBN
0-521-38345-5
This is the first comprehensive text to 
be published on electrical trauma. Elec­
trical injury accounts for only 4% of 
admissions to burn centres, but many of 
these injuries can be devastating. There 
has been no significant improvement in 
survival following electrical injury dur­
ing the past 20 years. This book was 
motivated by a need to consolidate 
information on the clinical and basic 
science aspects of electrical injury so as 
to facilitate understanding and integra­
tion. Contributors to this multiauthored 
book include world authorities in clini­
cal practice, physics, engineering and 
biology.
The book is well organized and well 
illustrated. The bibliography is thor­
ough, with current references. The text 
is divided into four parts: the first two 
deal with the clinical aspects of burn 
injury and the last two present the basic 
science aspects of electrical trauma. 
Part I provides an introduction to elec­
trical trauma, beginning with Edison’s 
development of the electric lamp in 
1879 and the design of the first legal
electrocution chair in New York in 
1890. There are good descriptions of 
electrical terminology. This is followed 
by chapters on industrial accidents and 
the pathophysiology of burn injury. 
The latter is particularly strong.
Part II deals with the clinical mani­
festations and management of electrical 
injury. This section is excellent. There 
are chapters on soft-tissue patterns of 
injury, the spectrum of injuries, patho­
physiology, neurologic sequelae, pediat­
ric injuries and surgical salvage tech­
niques.
Parts III and IV, the basic science 
sections of the book, are comprehensive 
and current. Many of the concepts are 
quite technical and are probably more 
helpful to basic scientists than to clini­
cians. Part III describes the various 
tissue responses to burn injury. There 
are chapters on the role of arachidonic 
acid metabolism, patterns of injury, 
electrical impedance, impedance spec­
troscopy and the presentation of an 
upper extremity model. Part IV deals 
with membrane rupture, cell membrane 
permeability and the specific mecha­
nisms involved in the injuries to various 
tissues, including heart and skeletal 
muscles.
This comprehensive text will be a 
valuable library reference book for both 
clinical practitioners and basic scientists 
interested in electrical trauma.
W alter Peters, PhD, MD, FRCSC
Associate professor of surgery 
University of Toronto.
Chief, Division of Plastic Surgery 
The Wellesley Hospital 
160 Wellesley St. E 
Toronto, ON 
M4Y 1J3
THE KNEE: FORM, FUNCTION, PA­
THOLOGY & TREATMENT. Edited 
by Robert L. Larson and William A. 
Grana. 640 pp. Illust. W.B. Saunders 
Co., Philadelphia. 1992. $125. (US). 
ISBN 0-7216-3495-8
This text is intended to be a review of 
all aspects of knee function, diagnosis
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and treatment. The editors are sports 
medicine surgeons, and the book is 
primarily directed to their own areas of 
interest. The editors invited colleagues 
to review their own areas of expertise 
and have included virtually all aspects 
of knee disorders, including not only 
ligamentous and meniscal problems, but 
also arthritis, tumours and fractures.
Because of the scope of the text’s 
mandate, a number of subjects are 
covered superficially. However, some 
sections of the book are excellent, with 
good references to complement the ma­
terial.
This text is aimed at the general 
orthopedist or resident in orthopedics 
as a basic outline of diagnosis and 
treatment, with references provided for 
further in-depth reading.
The sections on rehabilitation and 
biomechanics are excellent, with up-to- 
date information on present methods of 
physiotherapy.
The sections on diagnosis and man­
agement of knee ligament instability 
present the authors’ methods of assess­
ment and surgical management. These 
provide a reasonable grounding but do 
not provide the detail needed for some­
one with a subspecialty interest. The 
difficulties regarding reproducible eval­
uation of knee ligament instabilities are 
noted, and references are given to an 
international classification. Unfortu­
nately, this classification is so compli­
cated that it is not in widespread use.
The sections on tumour, fractures 
and arthroplasty do not go into suffi­
cient depth to be of great value to the 
arthroplasty or fracture surgeon, but 
they do provide a skeleton of manage­
ment methods. These sections should 
be regarded as a general overview only. 
The sections on infections are also 
primarily of interest for general assess­
ment and management.
The chapter on arthroscopy provides 
excellent information on the conditions 
encountered and the present methods of 
management of both meniscal and joint- 
surface problems. The chapter on allo­
graft surgery provides some insight into 
the methods now being used in some 
centres for the treatment of certain 
pathologic entities such as osteochon­
dritis dissecans and localized post- 
traumatic arthritis.
No mention is made of an assessment 
of underlying ligamentous problems as­
sociated with osteoarthritis, nor of the 
management of malalignment problems 
with underlying osteochondritis.
At least three radiographs of knees 
are upside down.
In summary, this text is of good 
value for the general orthopedic sur­
geon or orthopedic resident but in gen­
eral does not provide sufficient depth 
for the surgeon with a subspecialty 
interest. However, there is a great deal 
of basic information that is well pre­
sented and provides a good overview of 
knee problems for the orthopedic resi­
dent who requires a summary of the 
present methods of assessment and 
treatment of knee disorders.
John C. Cameron, MD, FRCSC
Surgical Consultant,
Sports Medicine Programme 
University of Toronto.
Staff surgeon
Orthopaedic & Arthritic Hospital 
43 Wellesley St. E 
Toronto, ON 
M4Y 1H1
ADVANCES IN CARDIOVASCULAR 
ENGINEERING, SERIES A: LIFE 
SCIENCES, VOLUME 235. Edited by 
Ned H.C. Hwang, Vincent T. Turitto 
and Michael R.T. Yen. 443 pp. Illust. 
Plenum Press, New York. 1992. $115. 
(US). ISBN 0-306-44313-9
This text comprises the proceedings of 
a meeting held in Malaga, Spain, from 
Dec. 4 to 14, 1991. The purpose of the 
meeting was to deal with advances in 
cardiovascular engineering and how en­
gineering principles might be adapted 
to advances in clinical care. The topics 
covered are well written and have great 
depth in their respective areas. In par­
ticular the chapters on microcirculation, 
fluid dynamics and thrombosis are of 
considerable interest and have a direct 
application to advances in patient care. 
Unfortunately, clinicians may find that 
the mathematical concepts expressed by 
the engineers and physicists involved in
this course are beyond the comprehen­
sion of the non-mathematician.
Engineers, physicists and basic scien­
tists involved in this field of medicine 
will find this text of benefit. Physicians 
may have trouble understanding some 
of the mathematical concepts but may 
find it useful as a reference text.
This book is an example of the 
increasing number of meetings proceed­
ings that are published some time after 
the meeting and are designed primarily 
for the benefit of those who could not 
attend. As such, the material in the text 
is usually topical but often not subject 
to rigorous peer review before publica­
tion. The role of education and the 
advance of knowledge remains to be 
seen; as reference texts for subsequent 
work and publications their value re­
mains uncertain.
Tomas A. Salerno, MD, FRCSC
Professor of surgery 
University of Toronto.
Division of Cardiovascular 
and Thoracic Surgery 
St. Michael’s Hospital 
30 Bond St.
Toronto, ON 
M5B 1W8
SURGERY OF THE EAR AND TEM­
PORAL BONE. Joseph B. Nadol, Jr. 
and Harold F. Schuknecht. 494 pp. 
Illust. Raven Press Ltd., New York. 
1992. $165. (US). ISBN 0-88167- 
803-1
Harold Schuknecht is a towering figure 
in the field of clinical otology and 
research related to the histopathology 
of the temporal bone. This book, writ­
ten with Joseph Nadol and their pupils, 
is a clinical accompaniment to Schuk- 
necht’s monumental Pathology o f  the 
Ear. It is lavishly illustrated, with nu­
merous temporal bone sections that are 
well produced in black and white, good 
radiographic reproduction and superb 
drawings relating to clinical examina­
tion and surgical technique. Where col­
our is needed, it is used. Robert J. Galla 
has produced all the drawings, leading
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to a wonderfully uniform appearance.
This book is much more than an atlas. 
It has the style and content of older, 
classical otologic texts. It deals at 
length with otologic examination, soft- 
tissue and bony approaches to the ear, 
and later, surgery of the external ear 
and tympanic membrane, the middle 
ear, mastoid and skull base. It contains 
chapters on functional surgery after 
conductive hearing loss, vertigo and 
sensorineural hearing loss, and it ends 
with surgery for trauma and tumours 
and reconstruction of the auricle. A 
chapter on photographic documentation 
is unusual and contains excellent ad­
vice. The section on imaging and the 
section on evaluation of the vestibular 
system, both from Chicago, are first 
rate and give good clinical guidance.
The surgical sections are lucid, al­
though some may quibble with the use 
of large-diameter pistons for stapedecto­
my. This exemplifies one of the prob­
lems of the book — some of the 
techniques and many of the references 
are outdated — not a major problem in 
the current era of easily accessible 
computerized databases. The book’s 
strengths are its excellent coverage of 
the clinical aspects and abnormalities of 
the temporal bone. Its weakness is a 
lack of coverage of auditory physiology.
The book is expensive, although of 
good value. A reviewer should attempt 
to answer the question: Will I use it? As 
a middle-aged otologist brought up in 
the same school, I can answer affirma­
tively. This text contains good practical 
advice. It shows the reader how to do it 
as no other text has done since the 
earlier editions of Shambaugh’s stan­
dard text, and its clear illustrations will 
be used for teaching for years to come. 
The text is generally of good quality, 
well written and full of common sense.
There are some things the book does 
not do: it does not deal with the 
physiology of hearing or of the middle 
ear; it is a book that tells how to rather 
than why; and it does not tell the reader 
what results to expect. It does, howev­
er, describe what troubles may occur 
and how to deal with them. The book is 
true to its title. It is a text of surgery of 
the ear and temporal bone and does not 
pretend to be a text of otology. I 
recommend it to both practitioners and 
trainees. It has a prominent place on my 
library shelf within easy reach because I 
believe it will be consulted frequently.
Peter W. Alberti, MD
Otolaryngology Associates 
The Toronto Hospital 
EN7-229 
200 Elizabeth St.
Toronto, ON 
M5G 2C4
Like any other six-year-old. 
Almost.
Hundreds of Canadian children are sick 
with a disease that's turning their skin yellow, 
and slowly but surely turning their bodies 
against them.
Liver Disease. It’s now the fourth highest 
killer disease in Canada — and it's on the rise. 
Transplants have saved the lives of many 
Canadians young and old, but we can't do 
nearly enough of them.
We need your help to find cures. Please 
give to the Canadian Liver Foundation. And 
help us give little girls and boys back their lives.
CANADIAN 
LIVER
FOUNDATION
1320 Yonge Street, Toronto, Ontario M4T 1X2 1-800- 563-5483
Charitable Registration No. 0367-151-13
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M O U N T  H O P F
ERIC WILLIAMS MEDICAL SCIENCES COMPLEX AUTHORITY
Republic of Trinidad & Tobago Telephone: (809) 645-HOPE
CONSULTANT
ANAESTHETIST
The Eric Williams Medical Sciences 
Complex authority is a five hundred (500) 
bed teaching Hospital to the University of 
the West Indies. It is situated in the island 
of Trinidad, West Indies, and is a major 
referral centre for a population of 
approximately 1.2 million. The Hospital is 
in the process of being commissioned.
Applications are being invited for the 
position of Consultant Anaesthetist.
Apply with Curriculum Vitae and 
names of two referees to:
Chief Executive Officer
Eric Williams Medical Sciences
Complex Authority
Uriah Butler Highway
Trinidad
WEST INDIES S93-168
northeastern
British
Columbia
offering a
variety of
cultural
and
sporting 
activities 
and daily 
air service 
to
Vancouver
and
Edmonton.
General
Surgeon
A full-time permanent General Surgeon 
with F.R.C.P.C. qualification is required to 
provide general surgical and m inor 
orthopedicservices in our 64 bed accredited 
acute care Hospital located in the City of 
Fort St. John serving a population of 
approximately 25,000. This is a private 
practice position (fee for service). Gross 
annual earnings are approxim ately 
$200,000 to $250,000. There are two 
qualified General Surgeons in Dawson 
Creek, a community 50 miles away, which 
would allow a call schedule for weekend 
and vacation relief. There is an Obstetrician/ 
Gynecologist, Radiologist and Pathologist 
on staff with excellent family physician 
support. (Recruiting to replace the Medical 
Internist is underway.)
P lease con tact: 
Administrator.
M rs. M. A s lin g ,
S93-167
Fort St. John General Hospital
9636 - 100th Ave., Fort St. John, B.C. V1J 1Y3 
Tel: (604) 785-6611 Local 260 Fax: (604) 785-4060
CLASSIFIED ADVERTISING Unlike a tabloid or newspaper that is read today and discarded tomorrow, an adver­
tisement in the Classified Advertising section of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons. No other Canadian surgical publication reaches over 6000 
subscribers every 2 months, giving wide coverage for your advertising dollar.
Average issue readership of CJS (81%) is among the highest of any medical journal in Canada, the latest reader- 
ship studies confirm the best and most cost efficient way to reach Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU —CJS-1
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CARDIOVASCULAR AND THORACIC 
SURGEON: AB -  Required to join a well- 
established private practice group in mid- 
western Canada. FRCSC required. Respond 
with CV to: Cardiovascular and Thoracic 
Surgical Associates, PO Box 75030, Cam­
brian Post O ffice, Calgary, AB, Canada 
T2K 6J8. -S93-165
SURGEON: BC — Required for 44-bed hospi­
tal with cooperative medical community serv­
ing a large retirement population in scenic 
mountain valley in British Columbia close to 
the Idaho border. Hospital equipped for Gl 
endoscopy and laparoscopic surgery. Moder­
ate workload would permit enjoyment of the 
area recreational facilities which include golf, 
fishing, hiking, skiing, etc. Contact: Dr. H.G. 
Harding, PO Box 130, Creston. BC VOB 
1G0; tel (604) 428-7021, fax (604) 
428-3581. -S93-154
DIRECTOR, BURN UNIT: ON -  Ross Tilley 
Burn Centre, University of Toronto invites 
applications from qualified academic plastic 
surgeons for the position of Director of the 
Ross Tilley Burn Centre. This appointment will 
be at the rank of assistant or associate 
professor, depending upon qualifications and 
experience. The centre is currently a six-bed 
fully contained surgical and nursing unit with 
complete facilities for the management of 
every aspect of burn patient care. The suc­
cessful candidate will have a strong academic 
background, demonstrated research ability 
and administrative experience. A Royal Col­
lege of Physicians and Surgeons of Canada 
fellowship or equivalent is also required. The 
University of Toronto encourages applica­
tions from qualified men and women, mem­
bers of visible minorities, aboriginal peoples 
and persons with disabilities. In accordance 
with Canadian Immigration requirements, this 
advertisement is directed firstly to Canadian 
citizens and permanent residents. Please sub­
mit by Oct. 31, 1993 a letter of application, a 
complete curriculum vitae and the names of 
three referees, to: Dr. R.T. Manktelow, 
Chair, Division of Plastic Surgery, Univer­
sity of Toronto, c/o EN10-236, The Toron­
to Hospital - General Division, 200 Eliza­
beth St., Toronto, ON M5G 2C4.
-S93-164
GENERAL SURGEON: ON -  Well-estab­
lished group practice is looking to replace a 
retiring partner/surgeon to serve a communi­
ty of 30 000 + located 25 minutes west of 
London. Town population 10 0 0 0 + . Fully 
computerized, modern clinic adjacent to a 
fully accredited, well-equipped hospital using 
116 acute care beds. Busy emergency de­
partment. Preference will be given to or- 
thopedics/gynecology. Essentials include la­
paroscopy skills and fellowship status. One- 
in-three on-call schedule for this pleasant 
community. Large referral base guaranteed. 
Associate to full partnership attainable. 
Please contact or send CV to: Steven Wong, 
c/o Strathroy Medical Clinic, 376 Carrie 
St., Strathroy, ON N7G 3E3: tel (519) 
245-0430. -S92-128
FELLOWSHIP IN 
ENDOUROLOGY AND ESWL
This 1-year postgraduate fellowship offers a 
wide range of clinical experience in en~ 
dourology including percutaneous surgery, 
ureteroscopy, ESWL and laparoscopic sur­
gery in urology. Approximately 50% of the 
fellow's time will be spent in the laboratory 
participating in projects related to en- 
dourologic and shock wave lithotripsy re­
search. Salary will commensurate with the 
level of training.
Please reply with curriculum vitae to:
Dr. John Denstedt 
Chief of Urology 
St. Joseph's Health Centre 
268 Grosvenor St.
London, ON N6A 4V2 -S93-163
GENERAL SURGEON: SK -  Associate re­
quired in a busy referral private practice. 
Laparoscopic surgery forms a significant and 
increasing portion of the practice. Moving to 
new facility within 12 months. University city 
of 180 000+ with many amenities. FRCS 
required. Contact and send CV to: Dr. Len F. 
Rivers, 406-750 Spadina Cres. E, Saska­
toon, SK S7K 3H3: tel (306) 652-4754, 
fax (306) 244-6001. -S93-157
ORTHOPEDIC SURGEON
Cambridge Memorial Hospital is seeking a 
C anadian ce rtifie d , O ntario  licensed, 
recent graduate in orthopedic surgery to 
join the existing complement of two other 
orthopedic surgeons. The candidate must 
have a broad interest in orthopedics (no 
subspecialty needed) and a willingness 
to assum e regu la r on-call duties in a 
353-bed accreditated hospital.
Cambridge is in the heart of southwestern 
Ontario and provides a high standard of 
living, including excellent social, recre­
ational and educational facilities.
For more information, contact: Dr. J.K. 
Stapleton, Chief, Department of Surgery, 
tel (519) 623-7200; or send a resume to:
Secretary, Orthopaedic 
Surgeon Search Committee 
Cambridge Memorial Hospital 
700 Coronation Blvd. 
Cambridge, ON
N1R3G2
S93-166
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T h e  Illustrated History 
of Medicine
J  rom paleomedicine to contempo­
rary laboratory medicine, from 
Mesopotamia to Greece and Europe, 
through China, India and the Ameri­
cas, this history of medicine, or rather 
the history of different kinds of 
medicine, is found here in illustrated 
form — a rigorous and elegant syn­
thesis and chronology in 13 chapters.
Professor Jean-Charles Sournia 
explores medicine’s theories, diag­
noses and therapies, public health 
and hygiene. But he also contrasts 
themes such as the continuity and 
breakdown of medical practices, or 
different forms of medicine based in 
belief and reason.
This history of medicine is also 
the history of physicians through the 
ages, of their philosophies, living 
conditions, social status, tensions 
and differences, from the unknown 
healers of prehistory to modern
by Jean-Charles Sournia
medical masters, from ethnomed- 
icine to technomedicine, from Sum­
erian concepts linking illness with 
sin to today’s Hippocratic tradition. 
The volume charts the distances and 
differences in more than 50 chrono­
logical tables, a glossary of terms, an 
index of names and a bibliography.
But it is the beautifully repro­
duced paintings and photographs
that truly bring this new study to life; 
The Illustrated History of Medicine 
gives pride of place to pictures and 
their commentaries. More than 700 
paintings and photographs from 
around the world enrich the history; 
300 of these fascinating images are in 
colour.
The Canadian Medical Associa­
tion is proud to be the exclusive 
agent in Canada for Harold Starke 
Publishers’ 'The Illustrated History of 
Medicine. Distinctively different 
from other published histories, this 
beautiful volume will be a treasured 
addition to your library.
The Illustrated History o f Medicine 
Professor Jean-Charles Sournia 
ISBN 1-872457-05-3
© Harold Starke Publishers Limited, 1992 
Size: 246mm x 326mm, 
hardbound and jacketed
' es. please send m e_______copies of The Illustrated History of Medicine today!
CM A  members: $199 (includes shipping by Priority Post and handling). O thers: $220 plus $24 shipping and 
handling. Please add 7% GST to total. All orders must be prepaid.
□  Cheque or money order enclosed {payable to the Canadian Medical Association)
O Credit card O  VISA O  MasterCard O  American Express
Card number____
Name (pleaseprint)
Address_________
City____________
Postal code_____
Signature_______
Expiry date
Province__________________
Telephone! ) ___________
Total amount (including GST)
Mail to: Membership Services
Canadian Medical Association 
1867 Alta Vista Drive 
Ottawa, ON K1G3Y6
Credit card payments may be made by
phone: 731-9331, ext. 2307 (Ottawa and area)
toll free: 1-800-267-9703, ext. 2307 (outside Ottawa area)
fax: 1-613-523-0937
GST registration #121 765 705
The benefits continue 
long after Valtrac 
has disappeared.
Introducing the Valtrac* 
biofragmentable anastomosis ring, 
a major breakthrough in bowel 
anastomosis technology that’s both 
surgeon friendly and patient friendly.
Already surgeons have proved Valtrac’s 
procedural superiority over sutures and 
staples in thousands of patients. Valtrac 
provides uniform application 
regardless of location and 
disparate bowel end sizes. It 
also performs consistently in 
end-to-end, end-to-side and 
VALTRAC side-to-side procedures.
And, finally, Valtrac closes under direct 
visualization. So you know it’s closed.
Valtrac is patient friendly because it 
biofragments and passes harmlessly and 
painlessly out of the body, leaving no foreign 
matter to hinder postoperative imaging. It 
provides the added benefit during healing 
of supplying intraluminal support, which 
reduces the incidence of stricture, stenosis 
or obstruction1.
To attend a Valtrac clinic and get the full 
Valtrac story, please call: (416)470-3600 
and ask for the Valtrac line.
DAVIS+GECK
Cyanamid Canada Inc.
♦Trademark of American Cyanamid Company 1 Data on file with Davis + Geek {
r
